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Abstract
The E2-ubiquitin conjugate is a key regulator of ubiquitination and is therefore an
important component of cellular homeostasis. Disruptions to proper E2-ubiquitin
functioning have implications in diseases such as shigellosis and Parkinson’s disease
discussed here. E2-ubiquitin conjugates like UbcH7-ubiquitin are extremely dynamic
and can adopt multiple conformations in solution or bound to target proteins. However,
the conformational arrangements that UbcH7-ubiquitin adopts while free in solution,
bound to the shigellosis-associated kinase OspG or to the Parkinson’s disease-related E3
ligase parkin are unknown. Also unknown, is a mechanistic explanation for how UbcH7ubiquitin interactions with OspG and parkin are associated with disease. Here, we
determined the crystal structure of OspG bound to UbcH7-ubiquitin, the crystal structure
of autoinhibited full-length human parkin with and without a phosphorylation-mimetic,
the crystal and NMR structures of activated full-length human parkin bound to a
phosphorylated-ubiquitin molecule, and an NMR structure of activated human parkin
bound to both phosphorylated-ubiquitin and UbcH7-ubiquitin. This work determined
that UbcH7-ubiquitin predominantly occupies closed states in solution but binds to OspG
and parkin in open conformations. Further key findings include showing that UbcH7ubiquitin is a biological target of OspG and that OspG involvement in shigellosis is to
halt host ubiquitination by competitively binding to UbcH7-ubiquitin in a way that
mimics host HECT E3 binding. We showed that parkin is autoinhibited through
interdomain interactions. Phosphorylation of autoinhibited parkin primes
phosphorylated-ubiquitin binding and this binding relieves autoinhibition by inducing
allosteric rearrangements in parkin to allow subsequent UbcH7-ubiquitin engagement.
Finally, we showed that certain hereditary variants in parkin are likely associated with
autosomal recessive juvenile parkinsonism due to a loss in the ability to interact with
UbcH7-ubiquitin. Research here has significant implications for understanding the basis
of shigellosis and hereditary forms of Parkinson’s disease, and has contributed significant
molecular understandings for the use in developing therapeutics.
Keywords: Parkinson’s disease, shigellosis, ubiquitination, nuclear factor-κappaB,
parkin, PINK1, OspG, UbcH7-ubiquitin, structural biology, NMR, crystallography
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Preface
This thesis closely examines an element common to both shigellosis and
Parkinson’s disease: the E2-ubiquitin conjugate. The E2-ubiquitin conjugate is a key
regulator of ubiquitination with implications in both diseases. Because ubiquitination
aids in managing cellular homeostasis to a great extent, it’s no surprise that disease
occurs when disruptions to this pathway develop. This thesis focuses on the underlying
structural and atomic-level mechanisms that lead to these two very different diseases by
specifically examining two sets of interactions with UbcH7-ubiquitin. The first part of
Chapter 1 is an introduction to shigellosis and the bacterial effector kinase OspG, while
the second part of Chapter 1 is an introduction to Parkinson’s disease and the E3-ligase
parkin. Chapter 2 focuses on the shigellosis-inducing bacterial pathogen OspG
interaction with UbcH7-ubiquitin while Chapters 3 and 4 focus on the Parkinson’s
disease-associated E3 ligase parkin interaction with UbcH7-ubiquitin. Chapter 5 will
summarize results while bringing to-light the significance of findings and discussing
future directions.
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Chapter 1
INTRODUCTION
1.1 Shigellosis
1.1.1 Shigellosis
Shigellosis is characterised by inflammation and destruction of the intestinal
epithelium caused by mucosal penetration of the gram-negative bacteria Shigella (Labrec
et al., 1964). Infection is often accompanied by chronic diarrhea, dehydration and
abdominal discomfort (Speelman et al., 1984). This contagious disease is transmitted by
the faecal-oral route or by contaminated food and water (Wharton et al., 1990).
Shigellosis continues to be a problem in developing countries, as it contributes to 164,000
deaths each year (Kotloff et al., 2017). Shigella are highly infectious (DuPont et al.,
1989) and are showing emerging signs of antibiotic resistance (Nüesch-Inderbinen et al.,
2016). There is currently no cure for shigellosis and the only preventative measures
include improved sanitation (Kotloff et al., 1999).
1.1.2 Shigella mode of infection
Once ingested, the bacterial pathogen Shigella travels through the gastrointestinal
tract to the colon and rectum. Shigella bypass the protective intestinal epithelium by
targeting M cells using a type 3 secretion system (T3SS) that acts as a needle to inject
approximately 30 virulent effector proteins into the host gut epithelial cell cytoplasm
(Galán and Wolf-Watz, 2006; Parsot, 2009). The proteins that comprise the T3SS and a
majority of the injected effector proteins are encoded on a large virulence plasmid
(Buchrieser et al., 2000). T3SSs are relatively well-conserved across bacterial pathogens
and are composed of a base that scaffolds to the bacterial membrane, a needle that
extends away from the bacterial surface and a cap that regulates effector secretion (Galán
et al., 2014). When the cap contacts a host plasma membrane, T3SSs form a translocon
pore for effector protein delivery to the host cell cytoplasm (Veenendaal et al., 2007).
Shigella effector proteins (Table 1.1) are distinct from other bacterial pathogens
and are used at early, middle or late stages of invasion to evade the host defence system
and manipulate cellular functions (Ogawa et al., 2008; Phalipon and Sansonetti, 2007).
At the earliest stage, Shigella contact host cells and secrete effectors like IpaA-D and
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IpgD involved in T3SS translocon pore formation and the protrusion of membrane ruffles
around the bacteria that result in bacterial entry into host cells by macropinocytosis
(Ménard et al., 1996). Upon invasion, Toll-like and Nod-like receptors recognise
common bacterial lipopolysaccharides and peptidoglycans released by the cytoplasmlocalised Shigella which leads to activation of a host immune and inflammatory defense
response (Fritz et al., 2006). Host immune polymorphonuclear leukocytes then migrate
to the invaded epithelium and paradoxically disrupt the cell lining allowing rapid Shigella
invasion of epithelial cells while leading to severe inflammatory destruction characteristic
of shigellosis (Sansonetti, 2001). Once bacteria invade host cells, the middle and late
stages of Shigella invasion involve proteins that circumvent the host innate immune
response in order to colonize and replicate. Effectors OspF, OspG and OspI as well as
the IpaH family of proteins dampen this initially useful host inflammatory response by
inhibiting the NF-κB and MAPK signaling pathways to allow bacterial intracellular
survival, replication and cell-to-cell movement (Sansonetti and Di Santo, 2007).
1.1.3 Host immune inflammatory response NF-κB pathway
To counter Shigella pathogenic infection, host intestinal epithelial cells induce an
innate immune response by undergoing activation of pro-inflammatory pathways such as
the nuclear factor-κappaB (NF-κB) pathway (Figure 1.1A) (Sansonetti, 2004). Under
non-infected conditions, transcription factor NF-κB is retained in the cytoplasm, bound to
inhibitor IκBs like IκBα. Upon bacterial infection and consequent stimulation by proinflammatory cytokines, IκBα is phosphorylated by IκB kinases (IκK), leading to
phosphorylated-IκBα dissociation from NF-κB. The ubiquitination pathway (section
1.2.4) and NF-κB pathway now intersect as phosphorylated-IκBα is targeted for
ubiquitination by the E3 SCFβ-TrCP ligase complex for consequent degradation by the 26S
proteasome. Nuclear dissociation signals locate dissociated NF-κB to the nucleus for the
activation of target genes and an inflammatory response reflected in destruction of the
intestinal epithelium seen in shigellosis (Liang et al., 2004; Karin and Ben-Neriah, 2000).
Eventually, polymorphonuclear leukocytes such as neutrophils from the host adaptive
immune response eliminate Shigella and the infection within 5-7 days (Mandic-Mulec et
al., 1997).

Table 1.1 Selected Shigella effector proteins with known functions.
Effector Onset
Targets
Biochemical Activity
IpaB
Early
Caspase, α5β1, CD44
T3SS translocon
and Mad2L2

Role in infection
Translocon pore formation,
macrophage apoptosis and host
cell-cycle arrest
Translocon pore formation,
actin polymerization, docking
and effector induction

IpaC

Early

Vimentin and keratin
intermediate filaments

T3SS translocon

IpgD

Early

Phosphatidylinositol 4,5bisphosphate

Phosphatase of phosphatidylinositol 4,5bisphosphate

Bacterial invasion and host-cell
survival

VirA

Middle

Rab1

GTPase-activating protein of Rab1

Bacterial escape from host
autophagy

OspF

Middle

MAP kinases

Phosphothreonine lyase of MAPK

Innate host immune response
suppressor

OspI

Middle

Ubc13

Deaminase of the E2 Ubc13

OspG

Late

E2-ubiquitin conjugates

Kinase (unknown target) and
competitively binds to E2-ubiquitin

Innate host immune response
suppressor
Innate host immune response
suppressor

IpaH7.8

Late

Glomulin

E3 ubiquitin ligase of glomulin

Ipa9.8

Late

U2AF35 and
NEMO/IKKγ

E3 ubiquitin ligase of U2AF35 and
NEMO/IKKγ

Activates host immune response
inflammasomes for macrophage
cell death
Innate immune response
suppressor

References
(Page et al., 1999)
(Skoudy et al., 2000)
(Lafont et al., 2002)
(Terry et al., 2008)
(Mounier et al., 2009)
(Du et al., 2016)
(Russo et al., 2016)
(Niebuhr et al., 2000)
(Mayo and Donner, 2001)
(Mellouk et al., 2014)
(Garza-Mayers et al., 2015)
(Germane et al., 2008)
(Dong et al., 2012)
(Campbell-Valois et al., 2015)
(Arbibe et al., 2007)
(Li et al., 2007)
(Zhu et al., 2007)
(Sanada et al., 2012)
(Nishide et al., 2013)
(Kim et al., 2005)
(Zhou et al., 2013)
(Grishin et al., 2014)
(Pruneda et al., 2014)
(Suzuki et al., 2014)
(Okuda et al., 2005)
(Ashida et al., 2010)
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1.1.4 OspG and E2-ubiquitin
In the year 2000, six new Shigella virulence plasmid genes were discovered and
identified as the osp (outer Shigella protein) genes (Buchrieser et al., 2000). OspG is one
of the approximately 30 virulent effector proteins secreted by Shigella and is encoded by
the ospG gene. OspG is a serine/threonine kinase that lacks a typical kinase activation
loop suggesting that it may require the binding of a host factor for activation (Zhou et al.,
2013). OspG has been shown to dampen host inflammatory responses in order to
facilitate colonization and invasion. This dampening is done by preventing the NF-κB
pathway degradation of inhibitor IκBα (Kim et al., 2005; Zhou et al., 2013), however the
mechanism used by OspG to inhibit NF-κB-directed ubiquitination of IκBα is currently
unknown. The ubiquitination system is frequently hijacked by bacterial pathogens (Jiang
and Chen, 2011; Rytkönen and Holden, 2007) and studies on OspG suggest that it plays a
role in this manipulation. Studies have shown that the presence of OspG still results in
the accumulation of phosphorylated- IκBα and the formation of E2-ubiquitin (E2-Ub)
conjugates (Kim et al., 2005) suggesting that OspG acts to prevent IκBα degradation
during the ubiquitination steps involving E2-Ub conjugate binding to the E3, or ubiquitin
(Ub) transfer to substrate. OspG has been shown to bind to free Ub and polyubiquitin
chains (Zhou et al., 2013), as well as to E2s and E2-Ub conjugates (Kim et al., 2005),
however the preferred biological target has not yet been confirmed. The ability of OspG
to bind to different E2-Ub conjugates suggests that it may interfere with the functioning
of a large number of host E3s.
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1.2 Parkinson’s Disease
1.2.1 Parkinson’s disease
The first cases of Parkinson’s disease (PD) were documented in 1817 by Dr.
James Parkinson who termed the disease as a type of “shaking palsy” accompanied with
extremely slow-progressing symptoms of involuntary tremor and a propensity to “bend
the trunk forwards” (Parkinson, 1817). Dr. Parkinson noted the belief that it was a
disease of the nervous system and an injury of the medulla spinalis, extending to the
medulla oblongata. The study of Parkinson’s disease clinical features, pathophysiology,
genetics and biochemical pathways involved has come a long way since then. Today, we
know Parkinson’s disease to be the second most common neurodegenerative disease
estimated to affect 1% of the population over 60 years of age (Tysnes and Storstein,
2017). It is diagnosed by having tremor at rest, rigidity, bradykinesia and postural
instability which are symptoms that collectively describe parkinsonism (Jankovic, 2008).
Parkinson’s disease is slow-progressing having a late onset of 65-70 years of age and
long-term effects on emotional and mental well-being of sufferers (Huber et al., 1988),
(Schrag et al., 2000). The pathophysiology of Parkinson’s disease in patients is
characterised by the neurodegeneration of dopaminergic neurons in the substantia nigra
of the midbrain (Hornykiewicz, 1966; Riederer and Wuketich, 1976) often accompanied
by the presence of Lewy bodies composed of protein aggregates such as α-synuclein in
the brainstem (Lewy, 1912; Lewy, 1923).
1.2.2 Familial PD and autosomal recessive juvenile Parkinsonism
Familial Parkinson’s disease has a hereditary component attributable to mutations
in over 10 genes discovered to-date (Table 1.2). The first gene discovered with mutations
predisposing familial Parkinson’s disease was PARK1 which encodes for the functionally
unknown protein α-synuclein (Polymeropoulos et al., 1997), which is a hallmark protein
found aggregated in Lewy bodies (Spillantini et al., 1997). Interestingly, mutations in the
genes encoding for α-synuclein and another familial Parkinson’s disease -associated gene
that encodes the serine/threonine kinase LRRK2 (Funayama et al., 2002) are showing
emerging links to the more common sporadic form of Parkinson’s disease (Gilks et al.,
2005; Mueller et al., 2005; Lesage and Brice, 2012) suggesting that there may be a more
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prevalent genetic component to sporadic cases than previously assumed. Autosomal
recessive juvenile Parkinsonism (ARJP) is a specific hereditary form of Parkinson’s
disease and accounts for approximately 10% of all Parkinson’s disease cases. ARJP
differs from common iodiopathic forms by having an earlier onset, an even slower
progression, occasional dystonia and a long-lasting response to levodopa medicines.
50% of all ARJP cases are attributable to mutations in the PARK2 gene, encoding for the
E3 ubiquitin-ligase parkin (Kitada et al., 1998), which will be a main focus of this thesis.
1.2.3 Molecular pathology underlying PD
Parkinson’s disease is believed to be caused by a combination of genetic
predispositions described above as well as environmental factors (Corrigan et al., 1998)
that lead to oxidative damage of mitochondrial proteins (Alam et al., 1997), consequent
mitochondrial dysfunction (Schapira et al., 1990) and neuronal cell death in the substantia
nigra of the midbrain. Damaged mitochondrial turnover is typically regulated by
mitophagy (mitochondrial autophagy) and in part by the ubiquitin-proteasome system,
however these pathway activities are found to malfunction in Parkinson’s disease cases
(McNaught et al., 2003). PINK1 and parkin are mitochondrial proteins that play a vital
role in regulating mitophagy and the ubiquitination-proteosome system. However,
mutations found in the genes encoding for them lead to a loss of function of these
systems and consequent associations with ARJP (Kitada et al., 1998; Valente et al.,
2004). A decrease in proteasome activity often leads to an increase in cytotoxic
misfolded proteins and cell death. For instance, large components of Lewy bodies
present in Parkinson’s disease patients are misfolded α-synuclein aggregates (Spillantini
et al., 1997), further suggesting evidence of impaired protein degradation associated with
Parkinson’s disease.

Table 1.2 Genes implicated in familial Parkinson’s disease. Mutations in just over 10 genes have been discovered for association with familial forms of
Parkinson’s disease. The most commonly mutated and well-studied genes with their respective encoded proteins are listed below.
Gene
Protein
Protein Function Inheritance Pathophysiology
Clinical symptoms
References
PARK1
α-synuclein
Unknown,
Autosomal
Loss of dopaminergic Fast progression, parkinsonism,
(Polymeropoulos et al., 1997)
and
flexible and
dominant
neurons, Lewy bodies initially levodopa responsive,
(Spillantini et al., 1997)
PARK4
unstructured
and sporadic (contain α-synuclein
cognitive decline, dementia, age of
(Ohtake et al., 2004)
synaptic protein
aggregates)
onset <50
(Nemani et al., 2010)
PARK2
Parkin
E3 ubiquitin
Autosomal
Loss of dopaminergic Slow progression, parkinsonism,
(Kitada et al., 1998)
ligase
recessive
neurons, absence of
dystonia, levodopa responsive, age
(Khan et al., 2003)
Lewy bodies
of onset <40 years
(Mori et al., 2003)
PARK5
UCHL1
Ubiquitin
Autosomal
Broad
Slow progression, parkinsonism,
(Leroy et al., 1998)
hydrolase
dominant
neurodegeneration,
levodopa responsive, age of onset
(Bilguvar et al., 2013)
Lewy bodies (contain >50 years
UCHL1 aggregates)
PARK6
PINK1
Ser/Thr kinase
Autosomal
Loss of dopaminergic Slow progression, parkinsonism,
(Valente et al., 2004)
recessive
neurons, Lewy bodies dystonia, levodopa responsive, age
(Ibáñez et al., 2006)
of onset <40 years
(Samaranch et al., 2010)
PARK7
DJ-1
Molecular
Autosomal
Unknown
Slow progression, dystonia,
(Bonifati et al., 2003)
chaperone
recessive
levodopa responsive, age of onset
(Shendelman et al., 2004)
<40 years
(Zhou et al., 2006)
PARK8
LRRK2
Ser/Thr kinase
Autosomal
Loss of dopaminergic Slow progression, parkinsonism,
(Funayama et al., 2002)
dominant
neurons, Lewy bodies levodopa responsive, age of onset
(Haugarvoll and Wszolek, 2009)
and sporadic
>50 years
(Greggio et al., 2009)
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1.2.4 Ubiquitination pathway
The ubiquitin-proteasome pathway is a major protein degradation system in
eukaryotic cells. Many regulatory protein levels involved in cellular pathways are
controlled by ubiquitin-proteasome-mediated degradation such as the NF-κB pathway
transcriptional regulator NF-κB and its inhibitor IκBα (Palombella et al., 1994), (Chen et
al., 1995), as well as mitochondrial proteins like α-synuclein (Bennett et al., 1999).
Ubiquitination is a post-translational modification involving a series of sequential steps
that requires a ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitin-ligase
(E3) enzyme (Hershko et al., 1983). The C-terminal of ubiquitin (Ub) is first ATPdependently activated by an E1 and is subsequently transferred to an active site cysteine
on an E2 to form a thioester-bonded E2-Ub conjugate. This conjugate then binds to an
E3 ligase, whereby Ub is either transferred directly to a substrate lysine ɛ-amino group
for formation of an amide isopeptide linkage, or alternatively to the E3 catalytic cysteine
for formation of another thioester-bonded complex prior to the final covalent transfer to
substrate (Figure 1.1B). The nature of the Ub linkage to substrate confers the substrate
cellular fate. For instance, the linkage of a single Ub molecule to a substrate in a monoubiquitinated manner is a signal for that substrate to undergo specific protein interactions
or to confer cellular localisation. Moreover, Ub molecules can be attached to any one of
the seven lysine residues on the first Ub molecule in a sequential manner to create a polyubiquitin chain. Substrates are targeted for proteasomal degradation by the 26S
proteasome with K48- and K11-linked chains, while K63-linked chains signal the
substrate for either NF-κB pathway activation, DNA repair or lysosomal targeting. Other
possible Ub chain linkage types exist with little known function (Ciechanover and
Brundin, 2003).
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Figure 1.1 NF-κB and ubiquitination pathways. (A) An excerpt from the NF-κB pathway shows phosphorylation of inhibitor IκBα by IκB kinase (IκK)
leading to IκBα dissociation from NF-κB. The dissociated NF-κB is now targeted for nuclear localisation while phosphorylated-IκBα is targeted for
ubiquitination and consequent degradation by the 26S proteasome. (B) The ubiquitination pathway showing Ub first ATP-dependently activated by an E1activating enzyme. Ub is then transferred to an E2-conjugating enzyme, forming an E2-Ub conjugate that adopts either open, backbent or closed conformations.
The E2-Ub conjugate binds to an E3-ligase and Ub is then transferred to substrate (using RING E3-ligases) or is first transferred to the E3 catalytic cysteine
(using HECT and RBR E3 ligases) and then to substrate. K48- and K11-linked poly-ubiquitinated substrates are targeted for degradation by the 26S proteasome.
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1.2.5 E3 Ub-ligases
Eukaryotic cells have evolved hundreds of E3 Ub-ligases (E3s) equipped with a
variety of regulatory elements, catalytic functions and substrate-recruiting modules in
order to facilitate efficient ubiquitination of a substrate protein. E3s from eukaryotic cells
are grouped into three classes based on structure and the mechanism employed to
facilitate Ub transfer to a substrate. These classes include: RING (really interesting new
gene), HECT (homologous to the E6AP carboxyl terminus) and the recently discovered
RBR (RING-IBR-RING, where IBR stands for in-between-RING) (Figure 1.2).
RING E3 ligases comprise the largest family of E3s with more than 600 predicted
members in the human genome. All RING E3 ligases contain a RING domain that acts
as a scaffold to properly bind and orient the E2-Ub conjugate (Zheng et al., 2000) in
closed conformations (Soss et al., 2013; Pruneda et al., 2012) for enhanced reactivity of
Ub and direct transfer from E2 to substrate lysine residues. RING E3s use a canonical
surface for interaction with the E2 that includes the RING loop Zn2+-loop L1, RING helix
H1 and RING Zn2+-loop L2 (Budhidarmo et al., 2012), while the RING Zn 2+-loop L1
makes contacts with Ub (Figure 1.3A). RING E3s contain a highly conserved basic
“linchpin” residue located in the RING Zn2+-loop L2 that acts to stabilize E2-Ub
conjugates in a closed conformation through a hydrogen bond network to the E2 loop 7
and Ub C-terminal tail (Pruneda et al., 2012) likely to optimise positioning of the E2-Ub
thioester for nucleophilic attack by the substrate lysine and for a consequent thioester
aminolysis reaction. This binding mechanism and closed E2-Ub orientation has been
observed in many RING E3:E2-Ub crystal structures such as the RNF4 RING E3:E2-Ub
structure (PDB ID 4AP4) (Plechanovova et al., 2012) structure, the BIRC7 RING E3:E2Ub structure (PDB ID 4AUQ) (Dou et al., 2012) and the RNF165 RING E3:E2-Ub
structure (PDB ID 5D0M) (Wright et al., 2016), suggesting that the mechanism is
universal to many RING E3:E2-Ub pairings (Figure 1.6). The E2s play an important role
in determining the final substrate polyubiquitination linkage type, however it is the
coordination between both E2 and the RING E3 that confers final specificity (Stewart et
al., 2016).
HECT E3 ligases make up a smaller group of E3s with approximately 30
members in the human genome. HECT E3s contain a bilobal HECT domain composed
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of an N-lobe and C-lobe that are connected by a flexible short hinge. Distinct from
RING E3s, HECT E3s recruit the E2 within the E2-Ub conjugate to the HECT N-lobe
while the C-lobe makes contacts with Ub so that the conjugate takes on an open
conformation as seen in a NEDD4L HECT E3:E2-Ub structure (PDB ID 3JW0)
(Kamadurai et al., 2009). Also distinct from RING E3s, HECT E3s undergo a
transthiolation reaction to form an E3-Ub intermediate prior to engaging in a thioester
aminolysis reaction to attach Ub to a substrate (Rotin and Kumar, 2009). Upon binding
of the E2-Ub conjugate, crystal structures reveal the presence of a large distance,
upwards of 50 Å, between the E3 and E2 catalytic cysteines such as in the E6AP HECT
E3:E2 structure (PDB ID 1C4Z) (Huang et al., 1999). However, structures have also
shown that HECT domains have the ability to undergo conformational rearrangement in
which the C-lobe is brought into closer proximity to the E2 catalytic site through
flexibility of the HECT bilobal hinge as seen in the WWP1 HECT E3 structure (PDB ID
1ND7) (Verdecia et al., 2003). Upon loading of Ub to the HECT E3 catalytic cysteine,
the Ub tail takes on an extended conformation for substrate lysine nucleophilic attack
(Maspero et al., 2013). Unlike RING E3s, substrate polyubiquitination linkage
specificity is enforced primarily by the HECT E3 rather than the E2 (Kim and
Huibregtse, 2009).
RBR E3 ligases are the newest discovered class of E3 ligases with over 10
members in the human genome. RBR E3 ligases contain a conserved RING1-IBRRING2 motif. RBR E3 ligases use a RING/HECT hybrid mechanism for conferring
ubiquitination (Wenzel et al., 2011) whereby the E2 within the E2-Ub conjugate is
recruited to the RING1 domain (similar to RING E3 mechanisms), and Ub is transferred
to a conserved catalytic cysteine in RING2 by a transthiolation reaction prior to thioester
aminolysis transfer to a substrate lysine (similar to HECT E3 mechanisms). RBR E3
ligases are uniquely regulated through autoinhibition and activation. For instance, the
RBR E3 ligase HOIP autoinhibition is mediated by its ubiquitin-associated (UBA)
domain and requires binding to other regulatory proteins for activation (Stieglitz et al.,
2013; Lechtenberg et al., 2016). As well, the RBR E3 ligase HHARI autoinhibition is
regulated through its Ariadne domain as it is seen occluding the catalytic cysteine on
RING2 and requires binding to another regulatory protein for activation (Duda et al.,
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2013; Yuan et al., 2017). Structures of autoinhibitied HHARI also show that the RING2
and a bound E2 would require large conformational rearrangements in order to bring the
two catalytic sites into close proximity much like the mechanism used by HECT E3s.
RBR E3 RING1 domains are structurally similar to RING E3 domains, but RBR E3
RING1 have an additional elongated RING1 Zn2+-loop L2 (Spratt et al., 2014) and they
lack the typical basic “linchpin” residue that RING E3 RING domains use to position the
E2-Ub conjugate in a closed conformation (Pruneda et al., 2012) (Figure 1.3B). Despite
these differences, RBRs are expected to use a similar RING1 Zn 2+-Loop L1, RING1
helix H1 and RING1 Zn2+-loop L2 for interaction with the E2 within the E2-Ub
conjugate (Figure 1.3A), however there is still uncertainty for what conformational
arrangement the whole E2-Ub conjugate uses for recruitment. The unique RING1
domain features of RBR E3 ligases mentioned above are proposed to direct this E2-Ub
conformational arrangement (Dove et al., 2017) and disfavour closed E2-Ub binding
(Dove et al., 2016) suggesting that more open E2-Ub conformations are favoured upon
RBR E3 ligase binding. Three crystal structures of RBR E3 ligases bound to E2-Ub
conjugates have recently been published with various open orientations of Ub within the
E2-Ub conjugate. A HOIP:E2-Ub structure (PDB ID 5EDV) shows Ub in an open
conformation oriented towards the E2 backside while making secure interactions with the
RING1 and IBR (Lechtenberg et al., 2016). In this structure, an allosteric Ub molecule is
found activating HOIP so that RING1 helix H3 is straightened and a neighbouring HOIP
molecule shows the RING2 poised for transthiolation with the backbent E2-Ub
conjugate. Two HHARI:E2-Ub structures also show Ub in open conformations, however
Ub is oriented towards the closed E2 surface while making contact to the UBA-like
domain in one structure (PDB ID 5TTE) (Yuan et al., 2017) or not making any contacts
in the other (PDB ID 5UDH) (Dove et al., 2017). In both of these structures, the RING1
helix H3 is bent which is an emerging feature of autoinhibition (Wauer et al., 2015;
Kumar et al., 2017) and no regulatory proteins are bound to HHARI to activate it,
suggesting that the open conformation with Ub oriented towards the E2 backside seen in
the activated HOIP structure is the optimal primed binding state. Finally, and similar to
HECTS E3s, polyubiquitin chain type specificity is directed by the catalytic domain of
the RBR E3s rather than the E2 (Stieglitz et al., 2013).
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Figure 1.2 Domain architectures of RING, RBR and HECT E3 ligases. Domain architectures are
presented for (A) RING, (B) RBR and (C) HECT E3 ligases. All E3 ligases were aligned to the E2 binding
site which is the RING1 for RING E3 ligases and RBR E3 ligases, or the HECT N-lobe domain for HECT
E3 ligases. Ub from the E2-Ub conjugate must attach to the catalytic site located on RING2 for RBR E3
ligases or to the HECT C-lobe for HECT E3 ligases, but the distance from the E2 binding site is too far in
these inactive E3 states. The E2 binding site and catalytic site domains for both RBR and HECT E3 ligases
are linked together by a flexible linker that acts as a hinge to bring the two domains together in HECT E3
ligases. RING1: RING1 domain, BIR: Baculovirus IAP (inhibitor of apoptosis) repeat, SIM: SUMOinteracting motifs, Ubl: ubiquitin-like domain, RING0: RING0 domain, IBR: in-between-RING domain,
RING2: RING2 domain, UBA-like: ubiquitin-associated-like domain, Ariadne: ariadne domain, PUB:
PNGase/ubiquitin-associated domain, NZF: NPL4 zinc-fingers, LDD: linear ubiquitin chain determining
domain, AZUL: AZUL/ N-terminal zinc-binding domain, C2: C2 domain, WW: WW domain, HECT Nlobe and C-lobe: bilobal HECT domain.
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B

Figure 1.3 Comparison of E2 binding to RING E3 and RBR E3 RING domains. (A) Ribbon diagram
comparison of RING E3 and RBR E3 RING domains (grey) bound to E2s (green). E2s share a wellconserved surface used for interacting with RING domains that includes the E2 helix H1, loop L4 and loop
L7. RING domains use Zn2+-loop L1, helix H1 and Zn2+-loop L2 to bind to E2s. Structures of RING E3
ligases RNF4 (PDB ID 4AP4), BIRC7 (PDB ID 4AUQ) and RNF165 (PDB ID 5D0M) as well as RBR E3s
HOIP (PDB ID 5EDV), HHARI (PDB ID 5UDH) and parkin (PDB ID 5C1Z) were superimposed to all
atoms in the RING domain using the super command in PyMOL. All structures contained bound E2s
except parkin. (B) RING E3 and RBR E3 RING domain Zn2+-loop L2 sequence alignment comparison.
RING E3 RING domains contain a basic linchpin residue (red highlight) in Zn2+-loop L2 responsible for
orienting E2-Ub conjugates in closed conformations. RBR E3 RING1 domains do not contain a basic
linchpin residue and have typically elongated Zn2+-loop L2s. These two differences are proposed to
facilitate E2-Ub orientations in open conformations.
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1.2.6 Parkin cellular function and activation
Parkin is an RBR E3 ligase that mediates mitochondrial quality control by
regulating damaged mitochondrial turnover (mitophagy) and ubiquitination of
mitochondrial proteins. Althought parkin is widely expressed throughout the body, the
effects of its malfunctioning are inexplicably most influential in dopaminergic neurons.
Parkin was thought to be constitutively active until 2011, when it was discovered that
parkin required regulatory elements to relieve its autoinhibition (Chaugule et al., 2011).
PINK1 kinase works upstream of parkin to relieve this autoinhibition and together they
mediate mitophagy as follows (Figure 1.4). PINK1 kinase localises to the outer
mitochondrial membrane upon mitochondrial damage (Narendra et al., 2010) where it
phosphorylates low levels of parkin and Ub already present at the mitochondria, acting as
a positive feed-forward signal to recruit cytosolic parkin to the mitochondria (Narendra et
al., 2008; Kim et al., 2008; Shiba-Fukushima et al., 2012). Importantly, both Ub and the
parkin Ubl domain are specifically phosphorylated by PINK1 at a conserved S65 and
both phosphorylation events activate parkin E3 ligase activity (Sha et al., 2010;
Kondapalli et al., 2012; Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014;
Ordureau et al., 2014). Activated parkin then poly-ubiquitinates outer mitochondrial
proteins (Sarraf et al., 2013) with K6-, K11-, K48-, and K63-linkages (Ordureau et al.,
2014) leading to the formation of an autophagosome around the heavily ubiquitinated
mitochondria, which then signals the damaged mitochondria to be eliminated by
mitophagy (Ashrafi et al., 2014; Lazarou et al., 2015; Heo et al., 2015). Although
phosphorylation of both Ub and parkin are greatly validated events that lead to parkin
activation, an atomic-level structural approach to determining why parkin is
autoinhibitied and how activation is achieved has not been determined.

Figure 1.4 The role of parkin and PINK1 in cellular mitophagy. First, damage occurs to mitochondria leading to depolarisation of the mitochondrial
membrane potential. Second, PINK1 kinase is recruited to the outer mitochondrial membrane where it phosphorylates low levels of parkin and Ub. Third,
cytosolic parkin is recruited to the mitochondria in response to mitochondrial phosphorylation signals. Both Ub and parkin phosphorylation are events that
activate parkin E3 ligase activity to ubiquitinate mitochondrial proteins. Fourth, a phagophore forms around the heavily-ubiquitinated mitochondria inducing
mitophagy of the damaged mitochondria.
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1.2.7 Parkin structure
Parkin comprises Ubl-RING0-RING1-IBR-RING2 domains (Figure 1.5). Prior to
starting my research, there were no full-length structures available and only little was
known about the individual domains. Previously thought to be constitutively active,
parkin was eventually recognised as being autoinhibited and that this autoinhibition was
regulated through the ubiquitin-like (Ubl) domain (Chaugule et al., 2011). The Nterminal Ubl domain shares 32% sequence identity with Ub resulting in a similar
structural fold that confers many binding interactions such as substrate recognition
(Fallon et al., 2006; Trempe et al., 2009) and proteasome association (Sakata et al.,
2003). Connecting the Ubl domain to RING0 is a long and poorly conserved flexible
tether approximately 64 residues long. RING0 is a recently discovered domain found to
coordinate two zinc ions (Hristova et al., 2009) and was not predicted from sequence
alignments. However, rather than adopting a canonical RING configuration, it is now
known to have a hairpin arrangement unique to parkin. RING1 is the only correctly
named RING domain in parkin having a cross-brace zinc coordination topology.
Because RING1 and RING2 were originally proposed to be structurally similar to other
RING E3 RING domains, both were proposed to be binding site for E2s, however today
only RING1 is considered an actual E2 recruitment domain. The IBR domain
coordinates two zinc ions in a novel fold (Beasley et al., 2007), however its functional
role is unclear. Following the IBR domain is a flexible 34 residue linker with little
known function that precedes RING2. RING2 is another misnamed domain that
coordinates two zinc ions and actually resembles the IBR fold (Spratt et al., 2013).
RING2 harbours a catalytic cysteine C431 that is conserved amongst RBR E3s. C431 is
capable of forming a thioester bond with Ub (Wenzel et al., 2011; Stieglitz et al., 2012)
as a result of a transthiolation reaction with an E2-Ub conjugate prior to catalyzing
transfer towards a substrate (Figure 1.1B).
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Figure 1.5 Parkin domains and ARJP variants. (A) Human parkin domain architecture and ARJP variants. UblR0RBR is the nomenclature used to describe
full-length parkin in this thesis and R0RBR describes a truncated form containing RING0-RING1-IBR-RING2 domains. Selected ARJP variants are shown
above the domain structure and manifest throughout the entire parkin sequence. (B) Ribbon diagrams of individual parkin domains. Structures are coloured and
aligned to their corresponding domains in panel A. Structures include human Ubl (PDB ID 1IYF), human IBR (PDB ID 2JMO) and Drosophila melanogaster
RING2 (PDB ID 2LWR).
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1.2.8 ARJP parkin variants
Parkin is encoded by the PARK2 gene in which mutations account for 50% of all
ARJP cases (Kitada et al., 1998). There are over 120 reported parkin mutations to-date
including exon deletions, exon multiplications, missense and nonsense mutations (Cruts
et al., 2012). ARJP gene mutations that result in residue variants can be found
throughout all domains of parkin (Figure 1.5A) having numerous effects on parkin
solubility, protein interactions, catalytic functioning and recruitment to mitochondria.
For instance, A46P and V56E are parkin ARJP variants found in the Ubl domain that
make the Ubl domain highly insoluble (Safadi et al., 2011). T240R and R271S are
variants located at the proposed E2 binding site, suggesting a link between ARJP and a
loss of binding to the E2. The catalytic C431F ARJP variant has been shown to reduce or
completely eliminate parkin activity (Chen et al., 2010; Shin et al., 2011). Finally, nonARJP variants H302A and S65A are proposed to impair parkin activation and have
shown impaired parkin recruitment to the mitochondria (Tang et al., 2017). The
elucidation of complete full-length parkin structures would provide extensive
breakthroughs into determining structural-based origins of parkin-associated ARJP cases.

1.2.9 E2-Ub conjugates
Approximately 40 E2 ubiquitin-conjugating enzymes (E2s) exist in the human
genome and they function mainly as Ub carriers within the ubiquitination pathway
(Stewart et al., 2016). E2s interact with E1 and E3 enzymes to transfer Ub to a substrate.
Functional work has shown that E2s have individual reactivity profiles and they can
specify poly- or mono-ubiquitin chains when paired with RING E3s (Christensen et al.,
2007; Rodrigo-Brenni and Morgan, 2007; Windheim et al., 2008). For instance, UbcH5c
can transfer Ub to cysteine or lysine residues, explaining its ability to pair with RING,
HECT or RBR E3 ligases (Wenzel et al., 2011). However, UbcH7 is inefficient at
transferring Ub to lysine residues and rather it only exhibits reactivity towards cysteines,
suggesting that UbcH7 can only be paired with RBR and HECT E3s (Wenzel et al.,
2011). Contrary to RING E3:E2 pairings, E2s play a smaller role in Ub chain-linkage
specificity when paired with HECT and RBR E3s (Kim and Huibregtse, 2009; Stieglitz et
al., 2013). These mechanistic differences can be simplified by remembering that the last
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enzyme attached to Ub prior to substrate ubiquitination typically confers linkage
specificity (Stewart et al., 2016). Together, the intrinsic reactivity of the E2 can be
predictive of the type of E3 that it functions with as well as the final substrate Ub-linkage
product.
All E2s contain a conserved catalytic domain of approximately 150 amino acids
that shares a consistent canonical structure equipped with an active site cysteine for
accepting and transferring Ub. This core adopts an α/β fold with typically four α-helices
and four β-sheets (Stewart et al., 2016). The E2 helix H1, loop L4 and loop L7 elements
make up a relatively well-conserved surface that is used for binding to RING domains
(Budhidarmo et al., 2012) (Figure 1.3A). Solution studies show that E2-Ub conjugates
can be extremely dynamic when Ub is conjugated to the E2 catalytic cysteine. These
dynamics are the result of flexibility in the C-terminal tail of Ub and therefore conjugates
can take on an array of closed, open or backbent orientations that are identified based on
Ub positioning in relation to the E2 (Pruneda et al., 2011; Page et al., 2012). Closed
states involve the Ub hydrophobic I44 patch making contacts with the E2 crossover helix
H2. Ubc1-Ub was the first example of a conjugate to take on a closed state in solution
(Hamilton et al., 2001). Open states extend Ub away from making any contact with the
E2, and backbent states fold Ub back onto E2 loops L2, L4, or L5. E2s have a tendency
to favour one of these orientations in solution, specific to each E2, and can bind to E3s in
the same orientation. For instance, the Ubc13-Ub conjugate favours a closed
conformation in solution (Pruneda et al., 2011; Page et al., 2012), and can also bind to
E3s in a closed conformation (Middleton et al., 2017). Despite the tendency for an
individual E2 to adopt a certain conformation in solution, these conformations can
change dramatically upon binding to an E3. For instance, the UbcH5c-Ub conjugate
populates extended open and backbent conformations in solution (Pruneda et al., 2011;
Page et al., 2012), but has a propensity to bind in a closed state to a RING/U-Box E3
(Pruneda et al., 2012). As discussed in section 1.2.5, structural studies to-date indicate
that regardless of the preferred state in solution, E2-Ub conjugates bind to RING E3
ligases in a closed conformation and to HECT or RBR E3 ligases in open conformations
(Figure 1.6).
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Figure 1.6 E2-Ub conjugate closed, open and backbent conformations. Ribbon diagrams are presented
of E2-Ub conjugates showing a spectrum of adoptable conformations. Closed states show Ub using its I44
hydrophobic patch to interact with the E2 crossover helix H2, open states show Ub extending away from
the E2 while making little to no contact, and backbent states show Ub in proximity to the E2 “backside”
which includes E2 loops L2, L4 or L5. E2s share a canonical fold as seen when all atoms are aligned using
the align command in PyMOL. Structures used were RING RNF4:UbcH5a-Ub (PDB ID 4AP4) (closed),
HECT NEDD4L:UbcH5b-Ub (PDB ID 3JW0) (open), RBR HOIP:UbcH5b-Ub (PDB ID 5EDV) (open)
and UbcH5b-Ub (PDB ID 3A33) (backbent). Full E3 cartoon structures were omitted for clarity.
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1.3 Scope of Thesis
E2-ubiquitin conjugates are key regulators of ubiquitination and are extremely
dynamic while being able to adopt multiple conformations. Because ubiquitination plays
a large role in cellular homeostasis, diseases can arise when activity is compromised.
Common to many bacterial pathogens like the shigellosis-inducing Shigella, the host
ubiquitination pathway is often hijacked by bacterial effector proteins like OspG. As
another example, patients with parkin-linked ARJP can have hindered ubiquitination
activities due to hereditary variants in parkin. This thesis examines underlying molecular
mechanisms contributing to shigellosis and Parkinson’s disease by examining the
conformational arrangements of UbcH7-Ub in solution, bound to the shigellosisassociated kinase OspG and bound to the Parkinson’s disease-associated E3 ligase parkin.
Research here has significant implications for understanding the molecular basis of
shigellosis and hereditary forms of Parkinson’s disease.
The first goal was to determine how the bacterial effector OspG helps bacteria to
hijack host ubiquitination by seeing how UbcH7-Ub interacts with OspG. To do-so,
isothermal titration calorimetry (ITC) and nuclear magnetic resonance spectroscopy
(NMR) were used to determine whether an E2-Ub conjugate like UbcH7-Ub was a
biological target of OspG by looking at binding affinity. Crystallography and NMR were
used to characterise the OspG:UbcH7-Ub interaction and to determine which
conformation UbcH7-Ub adopts upon binding. The OspG:UbcH7-Ub crystal structure
was compared to other structures of E2-Ub conjugates bound to E3s to determine
whether OspG mimics a type of E3 binding. Based on results suggesting that OspG
would competitively bind to E2-Ub conjugates, ubiquitination assays were performed in
the presence of OspG to view whether bacterial OspG reduced host E3 activity.
The second goal was to determine how parkin autoinhibition is regulated by its
Ubl domain, and how both phosphorylation of parkin S65 and Ub S65 (pUb) activate this
autoinhibition. To do-so, we used crystallography to determine the structures of fulllength parkin and full-length parkinS65D. ITC was used to determine how
phosphorylation signals on parkin and Ub either allosterically or directly affect pUb
binding. NMR was used to determine a docked model of pUb bound to parkin. NMR
was also used to perform competitive binding experiments and illustrate how pUb

23

binding affects parkin inhibition regulated by the autoinhibitory Ubl domain. Results
from this section have had significant impact on the molecular understandings of parkin
autoinhibition and activation.
The third goal was to determine how UbcH7-Ub engages with parkin and to show
how ARJP mutations affect this event. To do-so, we first determined the crystal structure
of pUb bound to full-length parkin. NMR was used to determine the conformation of
UbcH7-Ub in solution and while bound to parkin by determining a docked pUb-bound
parkin:UbcH7-Ub model. Finally, ubiquitination assays were performed to determine
how ARJP parkin variants affect activity. Together, research here impacts molecular
understandings of UbcH7-Ub conformational arrangements, proper parkin functioning,
and provides an explanation for how ARJP parkin variants result in disease.
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Chapter 2
STRUCTURAL BASIS FOR THE INHIBITION OF HOST PROTEIN
UBIQUITINATION BY SHIGELLA EFFECTOR KINASE OSPG
2.1 Introduction
The shigellosis-inducing bacterial pathogen Shigella secretes OspG into host cells
to reduce host inflammatory responses upon infection (Kim et al., 2005). Dampening of
the inflammatory response is specifically done by the ability of OspG to prevent the NFκB pathway degradation of inhibitor IκBα (Kim et al., 2005; Zhou et al., 2013).
Inhibition of NF-κB-directed ubiquitination of IκBα has been suggested to occur when
OspG manipulates the crucial step of host E2-Ub conjugate binding to host E3s by an
unknown mechanism (Kim et al., 2005).
Structures of free and E3-bound E2-Ub conjugates show that Ub can be found in
open, closed, or backbent orientations relative to the E2 that it is linked to. E2
conjugating enzymes use a conserved region for binding to RING- and HECT-type E3
enzymes that includes residues from the α-helix H1, loop L4 and loop L7 of the E2
(Budhidarmo et al., 2012).
I studied the interaction of OspG with Ub, UbcH7 and UbcH7-Ub to determine
the mechanism of how OspG inhibits IκBα ubiquitination. My research determined that
the biological binding target of OspG is the E2-Ub conjugate and that OspG inhibits E3
ubiquitination by competitively binding to the E2-Ub conjugate. OspG was found to
mimic host HECT E3 enzymes by orienting UbcH7-Ub in an open conformation and by
binding to the region on UbcH7 that is typically used for binding to E3 ligases.

*Sections of this chapter have been taken from the following published paper:
Grishin, A.M., Condos, T.E., Barber, K.R., Campbell-Valois, F.X., Parsot, C., Shaw,
G.S., and Cygler, M. (2014). Structural basis for the inhibition of host protein
ubiquitination by Shigella effector kinase OspG. Structure 22, 878–888.
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2.2 Materials and Methods
2.2.1 Source of materials
BL21(DE3)pLysS cells containing yeast UbK48R/G76C in a pET3a plasmid and
BL21(DE3)CodonPlus-RIL cells containing human His-tagged UbcH7 C17S/C137S in a
pET28a plasmid (Serniwka and Shaw, 2008) were obtained from Kathy Barber
(University of Western Ontario, Canada). BL21(DE3)Star cells containing a truncated
version of Shigella flexneri 2a strain 2457T His-tagged OspG (residues 26-196) in a
pMCSG7 plasmid were obtained from Dr. Andrey Grishin (University of Saskatchewan,
Canada). Dr. Andrey Grishin also supplied OspG L99R/P102E, OspGF154R and
OspGL99R/P102E/F154R which had variants that were incorporated using QuickChange
mutagenesis. All UbcH7 samples used in this chapter were UbcH7 C17S/C137S.
2.2.2 Expression and purification of UbcH7C17S/C137S
Unlabelled UbcH7C17S/C137S in BL21(DE3)CodonPlus-RIL cells was grown in LB
media for ITC experiments, while

15

N-labelled UbcH7C17S/C137S was obtained by growing

the cells in M9 minimal media supplemented with 15NH4Cl for NMR experiments.
Labelled and unlabelled growths contained kanamycin and chloramphenicol. Cells were
grown at 37°C to an OD600 of 0.8 and expression was induced with 1 mM IPTG at 30°C
for 12 hours. Cells were harvested by centrifugation at 6000 × g for 10 minutes and
resuspended in 50 mM Tris, 200 mM NaCl, 250 μM TCEP, 25 mM imidazole, pH 8.0
buffer. Cells were lysed in the presence of protease inhibitor using an Avestin
EmulsiFlex-C5 homogenizer and were further centrifuged at 148,230 × g for 70 minutes.
The supernatant was collected and His-tagged UbcH7 C17S/C137S was purified on a HisTrap
FF column by batch-binding and washing with 50 mM Tris, 200 mM NaCl, 250 μM
TCEP, 25 mM imidazole, pH 8.0 buffer. His-tagged UbcH7 C17S/C137S was eluted with 50
mM Tris, 200 mM NaCl, 250 μM TCEP, 250 mM imidazole, pH 8.0 buffer, TEVcleaved at 25°C for 1 hour, and dialysed against 50 mM Tris, 200 mM NaCl, 250 μM
TCEP, pH 8.0 buffer at 4°C overnight. TEV-cleaved UbcH7 C17S/C137S was purified on a
second HisTrap FF column using 50 mM Tris, 200 mM NaCl, 250 μM TCEP, pH 8.0
wash buffer and the purified flowthrough was collected for experimental use. Purity was
monitored by SDS-PAGE.
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2.2.3 Expression and purification of UbK48R/G76C
Unlabelled UbK48R/G76C in BL21(DE3)pLysS cells was grown in LB media for
ITC experiments, while

15

N-labelled UbK48R/G76C was obtained by growing the cells in

M9 minimal media supplemented with 15NH4Cl for NMR experiments. Labelled and
unlabelled growths contained ampicillin and chloramphenicol. Cells were grown at 37°C
to an OD600 of 0.5 and expression was induced with 0.4 mM IPTG while remaining at
37°C. Unlabelled growths were expressed for 4 hours and labelled growths for 8 hours.
Cells were harvested by centrifugation at 6000 × g for 10 minutes, resuspended in 20 mM
NaOAc, 1 mM EDTA, pH 5.0 buffer and flash-frozen in liquid nitrogen. Cells were
lysed in the presence of protease inhibitor by thawing and sonication. Lysate pH was
then dropped to just below 5.0 with HCl to precipitate contaminating proteins, but not
UbK48R/G76C. The lysate was further centrifuged at 148,230 × g for 70 minutes and the
supernatant was run through a HiTrap Q anion exchange column. Ub K48R/G76C is
positively charged in 20 mM NaOAc, 1 mM EDTA, pH 5.0 wash buffer because its pI is
6.55, so it is collected in the flowthrough of the HiTrap Q column. Ub K48R/G76C was
purified on a final Sephadex G-75 size-exclusion column using 25 mM Tris, 150 mM
NaCl, 1 mM EDTA, pH 8.0 buffer. Ub K48R/G76C purity was monitored by SDS-PAGE
throughout both HiTrap Q and Sephadex G-75 column purifications.
2.2.4 Expression and purification of OspG and OspG variants
Unlabelled OspG and its variants OspG L99R/P102E, OspGF154R and
OspGL99R/P102E/F154R in BL21(DE3)Star cells were all grown, expressed and purified
similarly with the following protocol. Cells were grown in LB media containing
ampicillin at 37°C to an OD600 of 0.6 when 0.5g L-arabinose was added to each 1L
growth and the temperature was dropped to 20°C. After 30 minutes, expression was
induced with 1 mM IPTG for 16 hours. Cells were harvested by centrifugation at 6000 ×
g for 10 minutes and resuspended in 50 mM HEPES, 1M NaCl, 250 μM TCEP, 25 mM
imidazole, pH 7.5 buffer. Cells were lysed in the presence of protease inhibitor using an
Avestin EmulsiFlex-C5 homogenizer and further centrifuged at 148,230 × g for 70
minutes. The supernatant was collected and His-tagged OspG was purified on a HisTrap
FF column by batch-binding and washing with 50 mM HEPES, 1M NaCl, 250 μM
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TCEP, 25 mM imidazole, pH 7.5 buffer. His-tagged OspG was eluted with 50 mM
HEPES, 400 mM NaCl, 250 μM TCEP, 250 mM imidazole, pH 7.5 buffer, TEV-cleaved
at 25°C for 1 hour, and dialysed against 50 mM HEPES, 150 mM NaCl, 250 μM TCEP,
pH 7.5 buffer at 4°C overnight. TEV-cleaved OspG was purified on a second HisTrap
FF column using 50 mM HEPES, 1M NaCl, 250 μM TCEP, 25 mM imidazole, pH 7.5
wash buffer and the purified flowthrough was collected. OspG purity was monitored by
SDS-PAGE throughout both HisTrap FF column purifications.
2.2.5 UbcH7-Ub disulphide-linked conjugate formation and purification
Purified UbK48R/G76C and UbcH7C17S/C137S were incubated separately with 2 mM
TCEP at room temperature for 30 minutes to reduce di-Ub and di-UbcH7 disulphide
bonds. 200 µM UbK48R/G76C and 100 µM UbcH7C17S/C137S were combined and dialyzed
against 4L of 85 mM Na2HPO4, 15 mM NaH2PO4, 100 mM NaCl, 10 μM CuCl2, pH 7.5
buffer. Dialysis was performed at 4°C and buffer was changed twice over the course of
48 hours. During this Cu2+-induced oxidation reaction, Ub’s C-terminal G76C reacts
with UbcH7’s catalytic C86 to form the UbcH7-Ub disulphide-linked conjugate
(Serniwka and Shaw, 2009). Excess UbK48R/G76C was added in order to deplete
UbcH7C17S/C137S for aid in purification. The newly formed UbcH7-Ub disulphide-linked
conjugate was then purified on a Sephadex G-75 size-exclusion column using 25 mM
Tris, 1 mM EDTA, 250 mM NaCl, pH 7.5 buffer. UbcH7-Ub disulphide-linked
conjugate formation and its purity after Sephadex G-75 purification was monitored by
non-reducing SDS-PAGE.
2.2.6

ITC of OspG and variants binding to Ub, UbcH7 and UbcH7-Ub
ITC experiments were performed on a Microcal VP-ITC system (GE Healthcare)

using freshly purified proteins. UbK48R/G76C, UbcH7C17S/C137S or UbcH7-Ub disulphidelinked conjugate were titrated into the calorimeter cell containing OspG. UbcH7-Ub
disulphide-linked conjugate was also titrated into the calorimeter cell containing
OspGL99R/P102E or OspGL99R/P102E/F154R. Calorimeter cell and syringe protein
concentrations varied between 0.01-1.22 mM for each experiment depending on the
magnitude of heats observed. All experiments were performed 2-3 times each using 100
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mM NaH2PO4, 100 mM NaCl, pH 7.5 buffer at 25°C. Protein concentrations were
verified using amino acid analysis from the SPARC BioCentre Amino Acid Facility
(Toronto, Canada). Data was analysed using a single-site binding model in OriginLab to
determine stoichiometry (N), association (Ka) and enthalpy change (ΔH) values. Gibb’s
free energy (ΔG) was calculated using equation 1 while entropy change (ΔS) was
calculated using equation 2:
ΔG = -RTlnKa

(1)

ΔG = ΔH-TΔS

(2)

2.2.7 NMR of OspG binding to Ub, UbcH7 and UbcH7-Ub
All NMR experiments were collected on a 600 MHz Varian Inova spectrometer
(Biomolecular NMR Facility, University of Western Ontario, Canada) equipped with a
triple- resonance probe and x,y,z gradients. Samples were prepared in 100 mM
NaH2PO4, 100 mM NaCl, pH 7.5 buffer with 10% D2O (v/v) and 1% 10 mM DSS (v/v).
Samples contained 100 μM of 15N-labelled UbK48R/C76G, 15N-labelled UbcH7C17S/C137S or
UbcH7-Ub disulphide-linked conjugate in which only the UbcH7 moiety was 15Nlabelled. For protein interaction studies, 1H-15N HSQC spectra were collected of each
15

N-labelled sample in the absence and presence of 200 μM unlabelled OspG at 25°C

using the sensitivity-enhanced method (Barbato et al., 1992). UbK48R/C76G spectral
windows were 8000.0 Hz centred on 4.790 ppm for 1H and 2005.0 Hz centred on 115.5
ppm for 15N, while UbcH7C17S/C137S spectral windows were 7002.8 Hz centred on 4.800
for 1H and 2005.0 Hz centred on 115.5 ppm for 15N. All samples were referenced to the
DSS internal standard and all data was collected using identical spectral parameters.
Data was processed using 60°-shifted cosine bell-weighting functions in the 1H
and 15N dimensions using NMRPipe (Delaglio et al., 1995) and was analyzed using
NMRView (Johnson and Blevins, 1994). 1H-15N resonance assignments were performed
using previously reported assignments (Hamilton et al., 2000), (Serniwka and Shaw,
2008). Chemical shift pertubations (CSPs) were calculated using equation 3:
𝐶𝑆𝑃 =

(∆𝛿𝐻) + ((∆𝛿𝑁) × 0.2)

(3)

CSPs were mapped to the OspG:UbcH7-Ub crystal structure (PDB ID code 4Q5E) using
PyMOL (Delano, 2002).

42

2.3 Results
2.3.1 UbcH7C17S/C137S was expressed and purified
Unlabelled and 15N-labelled UbcH7C17S/C137S was successfully purified using an
initial HisTrap FF column followed by TEV-cleavage and a second HisTrap FF column.
Purity was monitored successfully by SDS-PAGE as seen by the expected band around
18 kDa (Figure 2.1). Unlabelled UbcH7C17S/C137S was later used for ITC experiments
involving OspG binding.

15

N-labelled UbcH7C17S/C137S was later used for NMR studies

involving OspG binding.

2.3.2 UbK48R/G76C was expressed and purified
Unlabelled and 15N-labelled UbK48R/G76C was successfully purified using an initial
HiTrap Q anion exchange column followed by a Sephadex G-75 size-exclusion column.
Purity was monitored successfully by SDS-PAGE as seen by the expected band around
8.6 kDa (Figure 2.2). Unlabelled UbK48R/G76C was later used for ITC experiments
involving OspG binding.

15

N-labelled UbK48R/G76C was later used for NMR studies

involving OspG binding.

2.3.3 OspG and OspG variants were expressed and purified
OspG and its variants OspGL99R/P102E and OspGL99R/P102E/F154R were all
successfully purified using an initial HisTrap FF column followed by TEV-cleavage and
a second HisTrap FF. Purity was monitored successfully by SDS-PAGE as seen by the
expected band around 20.1 kDa (Figure 2.3). OspGF154R expression and purification did
not yield sufficient amounts for experimental use. Unlabelled OspG and its variants were
later used for ITC experiments involving Ub, UbcH7 and UbcH7-Ub binding.
Unlabelled OspG was also used for NMR studies involving 15N-labelled Ub, 15N-labelled
UbcH7 and 15N-labelled UbcH7-Ub binding.
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Figure 2.1 UbcH7C17S/C137S purification. Unlabelled UbcH7C17S/C137S was purified on a HisTrap column
followed by TEV-cleavage and a second HisTrap column. Purity was verified by SDS-PAGE with the
expected MW of UbcH7C17S/C137S being around 18 kDa.
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Figure 2.2 UbK48R/G76C purification. Unlabelled UbK48R/G76C was purified on a (A) HiTrap Q column
followed by a (B) Sephadex G-75 column. Purity was verified by SDS-PAGE with the expected MW of
UbK48R/G76C being around 8.6 kDa. Because buffer conditions during Sephadex G-75 column purification
and gel preparation contained no reducing agent, a small band around 17 kDa is observed corresponding to
di-UbK48R/G76C because disulphide bridges are formed between two molecules.
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Figure 2.3 OspG and OspG variants purifications. (A) OspG, (B) OspGL99R/P102E and (C)
OspGL99R/P102E/F154R were purified on a HisTrap column followed by TEV-cleavage and a second HisTrap
column. Purity was verified by SDS-PAGE with the expected MW of OspG being around 20 kDa.
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2.3.4 UbcH7-Ub disulphide-linked conjugate was formed and purified
UbcH7-Ub disulphide-linked conjugate was successfully formed under Cu 2+
oxidizing conditions by adding excess UbK48R/G76C to UbcH7C17S/C137S to deplete
UbcH7C17S/C137S supplies and to facilitate its subsequent purification by Sephadex G-75
size-exclusion. Purity was monitored successfully by non-reducing SDS-PAGE as seen
by the expected band around 26.7 kDa (Figure 2.4). Unlabelled UbcH7-Ub was later
used for ITC experiments involving OspG binding. UbcH7-Ub in which only the UbcH7
moiety was 15N-labelled was used for NMR experiments involving unlabelled OspG
binding.
2.3.5 The E2-Ub conjugate is the biological binding target of OspG
ITC was used to determine the affinity of interaction of OspG with Ub, UbcH7
and UbcH7-Ub (Figure 2.5). Results showed that OspG binds tighter to the UbcH7-Ub
conjugate (Kd 580 ± 20 nM) than to Ub (Kd 9 ± 0.4 μM) or UbcH7 (Kd 86 ± 3 μM) (Table
2.1). All stoichiometry constants (N) were approximately equal to 1, which indicates a
1:1 binding site. The change in enthalpy (ΔH) for OspG binding to UbcH7-Ub is more
negative than OspG binding to Ub or UbcH7 which suggests that UbcH7-Ub binds with a
larger surface area than the individual Ub and Ubch7 components. The change in
entropy (ΔS) for OspG binding to Ubch7-Ub is the most negative which suggests that
that system is becoming more ordered. UbcH7 and Ub within the conjugate are flexible
in relation to one another in solution and OspG binding to the conjugate may stabilize
this flexibility, leading to a decrease in entropy. Gibbs free energy (ΔG) is most negative
for OspG binding to UbcH7-Ub than to Ub or UbcH7 which suggests that UbcH7-Ub
binding is the most favourable. Results here suggest that UbcH7-Ub binds cooperatively
to OspG and that OspG preferentially recruits an E2-Ub conjugate rather than the
individual Ub or E2 components.
ITC was also used to determine the affinity of interaction of UbcH7-Ub with the
variants OspGL99R/P102E and OspGL99R/P102E/F154R. Mutations were chosen because they are
located at the proposed interaction site between OspG and UbcH7, and they were
expected to reduce or eliminate the binding seen by ITC between OspG and UbcH7-Ub.
ITC results showed that UbcH7-Ub binding to OspG L99R/P102E (Kd 620 ± 30 nM) and
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OspGL99R/P102E/F154R (Kd 320 ± 10 nM) was not affected by the mutations and that binding
was similar to UbcH7-Ub and wild-type OspG binding. OspG binds much tighter to Ub
than to UbcH7, and so it is possible that Ub within the conjugate directs binding to OspG.
For this reason, OspGL99R/P102E and OspGL99R/P102E/F154R may still be able to bind tightly to
the UbcH7-Ub conjugate because the interaction site on OspG for Ub is still intact.
1

H-15N HSQC NMR spectra were collected of UbcH7-Ub, where only the UbcH7

moiety was 15N-labelled, in the absence and presence of unlabelled OspG to assess the
strength of binding. The addition of OspG to UbcH7-Ub resulted in significant
broadening of a large majority of signals indicating the formation of a large 46.8 kDa
complex between OspG and UbcH7-Ub (Figure 2.6A). A third spectrum was collected
with the addition of 8 mM DTT to the NMR sample containing OspG bound to UbcH7Ub in order to observe the strength of binding after the reduction and elimination of the
disulphide bond between UbcH7 and Ub. The amide resonances for UbcH7 residues C86
and L87 were shifted with respect to their positions seen when UbcH7 was conjugated to
Ub, indicating that the UbcH7-Ub complex is no longer intact with DTT added. The
reappearance of many signals indicated the loss of the large OspG:UbcH7-Ub complex
(Figure 2.6B). These findings suggest that OspG binds tightly to UbcH7-Ub, but not to
free UbcH7, further suggesting that UbcH7-Ub is the biological binding target of OspG.
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Figure 2.4 UbcH7-Ub disulphide-linked conjugate formation and purification. (A) UbcH7-Ub
disulphide-linked conjugate was formed under Cu2+ oxidizing conditions by adding UbK48R/G76C and
UbcH7C17S/C137S together. (B) UbcH7-Ub disulphide-linked conjugate was then purified on a Sephadex G75 column. Purity was verified by non-reducing SDS-PAGE with the expected MW of UbcH7-Ub being
around 27 kDa.
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Figure 2.5 ITC of OspG variants binding to Ub, UbcH7 and UbcH7-Ub. Isotherm graphs shown are
for: (A) OspG and Ub, (B) OspG and UbcH7, (C) OspG and UbcH7-Ub, (D) OspG L99R/P102E and UbcH7Ub, (E) OspGL99R/P102E/F154R and UbcH7-Ub. The upper panels represent raw data, and the lower panels
represent integrated heat changes performed assuming a single-site binding model. Data was collected at
25⁰C with 100 mM NaH2PO4, 100 mM NaCl, pH 7.5 buffer conditions.
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Table 2.1 Thermodynamics of OspG binding to Ub, UbcH7 and UbcH7-Ub. Values are shown for
stoichiometry (N), dissociation constant (Kd), enthalpy change (ΔH), entropy change (ΔS) and Gibbs free
energy (ΔG).
Cell Protein
Titrant
N
Kd
ΔH
TΔS
ΔG
(μM)
(kJ/mol) (kJ/mol) (kJ/mol)
OspG
Ub
0.97±0.01 9.1±0.4
-5.5±0.1
23±1
-29±1
OspG
UbcH7
0.96±0.02 86±3
-27±1
-4±1
-23±1
OspG
UbcH7-Ub 0.91±0.01 0.58±0.02 -126±1
-90±2
-36±1
OspGL99R/P102E
UbcH7-Ub 0.86±0.01 0.62±0.03 -88±1
-53±2
-35±2
OspGL99R/P102E/F154R
UbcH7-Ub 0.83±0.01 0.32±0.01 -194±3
-157±4
-37±1
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Figure 2.6 NMR of UbcH7-Ub binding affinity to OspG. (A) Selected regions of 1H-15N-HSQC spectra
of UbcH7-Ub in which only UbcH7 is 15N-labelled in the absence (black contours) and presence (red
contours) of 2 equivalents unlabelled OspG. Signifcant signal broadening indicates a large 46.8 kDa
complex formed between OspG and UbcH7-Ub. (B) Selected regions of 1H-15N-HSQC spectra of the
same OspG:UbcH7-Ub sample from before but with 8 mM DTT added (blue contours) superimposed with
the spectra collected in panel A (black and red contours). The reappearance of signals indicates the loss of
the large OspG:UbcH7-Ub binding complex. UbcH7 residues C86 and L87 shift with respect to the
unbound UbcH7-Ub spectrum affirming that DTT reduced and eliminated the disulphide bond between
UbcH7 and Ub. All data was collected at 25°C in 100 mM NaH2PO4, 100 mM NaCl, pH 7.5 buffer and all
peak contour levels are shown equal between spectra.
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2.3.6 OspG and UbcH7-Ub surfaces of interaction determined by NMR
1

H-15N HSQC NMR spectra were collected of 15N-labelled UbcH7 in the absence

and presence of unlabelled OspG to determine the interface on UbcH7 used for
interaction (Figure 2.7A). UbcH7 amide resonances were successfully assigned using
previously reported assignments. The measured chemical shift pertubations (CSPs) were
minor and exhibited fast exchange indicating a weak interaction. UbcH7 resonances that
either disappear or change the most upon addition of OspG include R6 (helix H1), K64
(loop L4) and K96 (loop L7) (Figure 2.7B). These residues comprise a surface on
UbcH7 that is typically involved in E3 binding and were plotted onto the structure of
OspG:UbcH7-Ub (PDB ID code 4Q5E) using PyMOL showing good agreement with
surfaces used for interaction in the crystal structure (Figure 2.9).
1

H-15N HSQC NMR spectra were collected of 15N-labelled Ub in the absence and

presence of unlabelled OspG to determine the interface on Ub used for interaction
(Figure 2.8A). Ub amide resonances were successfully assigned using previously
reported assignments. The measured CSPs were large and exhibited slow exchange
indicating a moderately tight interaction. Ub resonances that change the most upon
addition of OspG include A46, Q49 and H68 (Figure 2.8B). These residues are found
within the surface on Ub known as the hydrophobic patch and were plotted onto the
structure of OspG:UbcH7-Ub (PDB ID code 4Q5E) using PyMOL showing good
agreement with surfaces used for interaction in the crystal structure (Figure 2.9).
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A

B

Figure 2.7 NMR of the UbcH7 binding interface with OspG. (A) 1H-15N HSQC NMR spectra of 15Nlabelled UbcH7C17S/C137S in the absence (black contours) and presence of 2 equivalents unlabelled OspG
(green contours). (B) Measured UbcH7 CSPs upon OspG binding. Grey bars indicate that the resonance
was undetectable. The horizontal dashed line indicates the average CSP ± 1 standard deviation. CSPs were
minor and exhibited fast exchange indicating a weak interaction. All data was collected at 25°C in 100 mM
NaH2PO4, 100 mM NaCl, pH 7.5 buffer.
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A

B

Figure 2.8 NMR of the Ub binding interface with OspG. (A) 1H-15N HSQC NMR spectra of 15Nlabelled Ub in the absence (black contours) and presence of 2 equivalents unlabelled OspG (orange
contours). (B) Measured Ub CSPs upon OspG binding. The horizontal dashed line indicates the average
CSP ± 1 standard deviation. CSPs were large and exhibited slow exchange indicating a moderately tight
interaction. All data was collected at 25°C in 100 mM NaH2PO4, 100 mM NaCl, pH 7.5 buffer.

55

Figure 2.9 OspG:UbcH7-Ub crystal structure with NMR binding interface. Surfaces of UbcH7
(green) conjugated to Ub (orange) are shown binding to a ribbon diagram of OspG (PDB ID code 4Q5E).
Residues in UbcH7 and Ub determined to be important for binding OspG by NMR are highlighted in
magenta. UbcH7 residues important for binding include R6 (helix 1), K64 (loop 4) and K96 (loop 7). Ub
residues important for binding include A46, Q49 and H68. Residues determined by NMR to be important
for OspG binding align well with surfaces used for contact within the crystal structure.
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2.3.7 OspG mimics E3s by binding UbcH7-Ub in an open conformation
The crystal structure of UbcH7-Ub bound to OspG (PDB ID code 4Q5E) was
determined by collaborator Dr. Andrey Grishin (University of Saskatchewan, Canada),
while the interpretation that revealed that UbcH7-Ub binds in an open conformation was
achieved through my individual work (Figure 2.10A). This finding is similar to a
separate crystal structure in which the UbcH5b-Ub conjugate is seen binding in an open
conformation to HECT E3 NEDD4L (PDB ID code 3JW0) (Kamadurai et al., 2009)
(Figure 2.10B). Superposition of the two E2 components shows that the two
arrangements are very similar. A third crystal structure of UbcH5a-Ub bound to RING
E3 RNF4 (PDB ID code 4AP4) (Plechanovová et al., 2012) shows the contrasting
capability of the E2-Ub conjugate to orient itself in a closed conformation (Figure
2.10C). These observations suggested that OspG may interfere with host E3-mediated
ubiquitination by recruiting an E2-Ub conjugate through HECT-like structural
mimicking.

Figure 2.10 UbcH7-Ub binds to OspG in an open conformation. (A) Ribbon diagram of UbcH7-Ub bound in the open conformation to OspG (PDB ID code
4Q5E). (B) Ribbon diagram of UbcH5b-Ub bound in the open conformation to HECT E3 NEDD4L (PDB ID code 3JW0). In NEDD4L, only residues 734–796
and 872–949 are shown for clarity. (C) Ribbon diagram of UbcH5a-Ub bound in the closed conformation to RING E3 RINF4 (PDB ID code 4AP4). Only
residues 131–195 from RNF4 are shown for clarity. Residues from each E2 found in the helix αH1, loops L4 and loops L7 conservatively make contacts with
E3s and are highlighted in red. Residues from Ub’s hydrophobic patch that make important contacts with OspG are also highlighted in red. Panels were prepared
by aligning all atoms in the E2 structures of UbcH7, UbcH5b, and UbcH5a using the align command in PyMOL.
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2.3.8 OspG inhibits E3 parkin ubiquitination activity
To investigate whether or not OspG can inhibit E3 ubiquitination activity,
Western blots following E3 parkin autoubiquitination activity were performed in the
absence and presence of OspG. Results showed a strong decrease in the appearance of
parkin autoubiquitination bands when increasing amounts of OspG were present, and
parkin ubiquitination activity was almost completely lost at an UbcH7:OspG molar ratio
of 1:1 (Figure 2.11A). OspGL99R/P102E and OspGF154R contain residue variants at the
binding interface with UbcH7 and were made to abolish OspG binding to the UbcH7-Ub
conjugate. Western blot analysis showed that parkin ubiquitination activity was not
affected in the presence of these variants in comparison to wild type OspG as expected
because OspG can no longer competitively bind to UbcH7-Ub (Figure 2.11B). In
conclusion, results from Western blot analyses show that OspG can inhibit the
ubiquitination activity of an E3 and that the binding site of UbcH7 onto OspG is
necessary for this inhibition. Since OspG has previously been shown to bind to several
E2-Ub conjugates, and since the E2-Ub conjugate functions upstream of E3s, then it is
logical to suggest that OspG can inhibit the activity of multiple E3s.
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Figure 2.11 OspG inhibits E3 parkin ubiquitination activity. (A) Western blot analysis following
ΔUblD-parkin autoubiquitination using anti-parkin (top) and anti-Ub (bottom) antibodies from 4%-15%
SDS-PAGE. The first two lanes of each blot contain either Ub or ΔUblD-parkin alone. Remaining lanes
contain E1, ATP and reactants indicated above the lanes. OspG amounts are equivalents to UbcH7.
Autoubiquitination products are represented as [Ub]n. (B) Coomassie-stained 8% Bis-Tris SDS-PAGE as
described in (A).
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2.4 Discussion
2.4.1 Model for OspG inhibition of host ubiquitination
Shigella infect host cells by secreting effector proteins to manipulate host cellular
pathways as a way to survive and replicate. Previous studies have shown that the role of
OspG during cellular invasion is to prevent the NF-κB pathway degradation of
phosphorylated-IκBα. This manipulation involves hijacking host ubiquitination pathways
at the step involving E2-Ub conjugate binding to an E3 (Kim et al., 2005; Zhou et al.,
2013), however a structural explanation for how this event occurs has been unknown
until now. We determined the crystal structure of OspG bound to UbcH7-Ub and this
structure shows a similar mode of binding as seen in another structure of OspG bound to
UbcH5c-Ub (PDB ID code 4BVU) (Pruneda et al., 2014), suggesting that OspG binds to
E2-Ub conjugates in a universal manner. The manner by which OspG orients the E2-Ub
conjugate in an open conformation is reminiscent of the HECT E3 NEDD4L:UbcH5b-Ub
structure (PDB ID code 3JW0) (Kamadurai et al., 2009). Since conformations of E2-Ub
conjugates are dictated by the E3:E2 pairing (Page et al., 2012), these results suggest that
OspG mimics HECT E3 binding to the E2-Ub conjugate. We used NMR and
crystallography to show that key residues in UbcH7 used for interaction with OspG
include R6 (α-helix H1), K64 (loop L4) and K96 (loop L7). These residues are located in
the conserved regions on E2s used for binding to RING and HECT E3s (Budhidarmo et
al., 2012) further suggesting that OspG mimics E3 binding. This similar binding mode
may also account for the observed ability of OspG to bind a number of different E2s
(Kim et al., 2005). Together, comparisons here suggest that OspG mimics HECT E3s by
orienting the E2-Ub conjugate in a similar open conformation and by binding to the same
surface on E2s that is typically used to recruit the E3.
OspG has been shown to bind to free Ub (Zhou et al., 2013), as well as to E2s and
their E2-Ub conjugate forms (Kim et al., 2005). We used NMR and ITC to show that
OspG preferentially binds to the UbcH7-Ub conjugate with tight affinity (K d 580 ± 20
nM) in comparison to the individual UbcH7 (Kd 86 ± 3 μM) and Ub (Kd 9 ± 0.4 μM)
moieties, suggesting that the conjugate is the biological target of OspG. Since OspG
lacks a typical kinase activation loop (Zhou et al., 2013), the binding to a host factor such
as UbcH7-Ub may serve to activate OspG kinase activity, for a currently unknown
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function. Studies have already shown that both Ub and E2-Ub conjugates can activate
OspG autophosphorylation or phosphorylation of artificial histone substrates (Zhou et al.,
2013; Grishin et al., 2014; Pruneda et al., 2014). The affinity that OspG has for UbcH7Ub is much tighter than when compared to typical E3 affinities for E2-Ub conjugates.
For instance, the E3 E6AP binds to UbcH7-Ub with only a moderate K d 6.5 μM affinity
(Purbeck et al., 2010). This finding suggests that OspG would compete with E3s for
binding to the E2-Ub conjugate. We confirmed this hypothesis by following
ubiquitination assays of an E3 in the absence and presence of OspG, and showed that
OspG can inhibit E3 ubiquitination.
Here, we propose a mechanism for how OspG inhibits typical host NF-κB
pathway degradation of phosphorylated-IκBα. OspG is first secreted into the host cell
cytoplasm by the Shigella T3SS. OspG competitively binds to host E2-Ub conjugates
with high affinity leading to its own activation while preventing typical host E3 binding
to the E2-Ub conjugate. OspG binds to E2-Ub conjugates in a manner that mimics host
HECT E3 binding. The curtailment of host E3 binding to E2-Ub conjugates results in a
reduction in host ubiquitination of substrates such as phosphorylated-IκBα, explaining
how OspG inhibits the NF-κB pathway degradation of phosphorylated-IκBα.
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Chapter 3
DISRUPTION OF THE AUTOINHIBITED STATE PRIMES THE E3 LIGASE
PARKIN FOR ACTIVATION AND CATALYSIS
3.1 Introduction
Autosomal recessive juvenile Parkinsonism (ARJP) is a hereditary form of
Parkinson’s disease in which 50% of cases are directly linked to mutations in the E3
ubiquitin-ligase parkin (Kitada et al., 1998). Parkin’s protective features mediate
mitochondrial control in dopaminergic neurons by attaching a small ubiquitin molecule to
damaged proteins in a process called ubiquitination (Grenier et al., 2013).
Parkin autoinhibition is known to be regulated by the autoinhibitory parkin Ubl
domain (Chaugule et al., 2011). The discovery of parkin autoinhibition has driven efforts
to uncover activators such as the upstream kinase PINK1 (Clark et al., 2006; Park et al.,
2006). PINK1 can phosphorylate both Ub and the parkin Ubl domain at S65 leading to
activation of parkin ubiquitination activity (Kondapalli et al., 2012; Kane et al., 2014;
Kazlauskaite et al., 2014; Koyano et al., 2014). PINK1 can phosphorylate preformed
mitochondrial Ub chains allowing parkin to bind tightly for retention at the mitochondria
and for enhancement of ubiquitination activity suggesting a feed-forward mechanism
(Ordureau et al., 2014).
Research here was performed to determine a structural model for how parkin
autoinhibition and activation occurs. We determined the crystal structure of autoinhibited
parkin and a docked model of pUb bound to parkin. We present a molecular mechanism
showing that parkin is autoinhibited through interdomain interactions, that parkin S65
phosphorylation optimises pUb binding and that pUb binding regulates activation through
release of the Ubl domain. The model presented provides important insights into parkin
regulation and can help explain how ARJP variants affect parkin activity.

*Sections of this chapter have been taken from the following published paper:
Kumar, A., Aguirre, J.D., Condos, T.E., Martinez-Torres, R.J., Chaugule, V.K., Toth, R.,
Sundaramoorthy, R., Mercier, P., Knebel, A., Spratt, D.E., Barber, K.R., Shaw, G.S., and
Walden, H. (2015). Disruption of the autoinhibited state primes the E3 ligase parkin for
activation and catalysis. EMBO J. 34, 2506–2521.
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3.2 Materials and Methods
3.2.1 Source of materials
BL21(DE3) E.coli cells containing human His-SUMO-tagged parkin R0RBR
(residues 141-465), human His-SUMO-tagged parkin R0RBR 380-384G (residues 141-465)
and human His-SUMO-tagged parkin UblS65E (residues 1-76) in pET-SUMO plasmids as
well as BL21(DE3)CodonPlus-RIL cells containing non-cleavable Pediculus GST-tagged
PINK1 (residues 126-575) in a pGEX6P-1 plasmid were obtained from Dr. Helen
Walden (University of Dundee, Scotland). BL21(DE3)CodonPlus-RIL E.coli cells
containing yeast His-tagged Ub in a pMCG7 plasmid were obtained from Dr. Hong Ling
(University of Western Ontario, Canada). Ubl and R0RBR will be the nomenclature used
to describe the truncated forms of parkin described above while UblR0RBR will be used
to describe full-length parkin used in this chapter.
3.2.2 Mutagenesis of UbS65E
A S65E substitution was incorporated into Ub using the following protocol.
Plasmids were isolated from harvested JM109 E. coli cells using the Bio Basic Inc. EZ10 spin column miniprep kit. Forward and reverse primers were designed containing the
desired mutations (Table 3.1). Base pair mutations were incorporated into DNA using
the QuikChange Site-Directed Mutagenesis protocol (Agilent) and Polymerase chain
reaction (PCR). Methylated parental strands that remained in the PCR reaction were
digested by Dpn1 for 16 hours at 37°C. All PCR products were transformed into JM109
and BL21(DE3)CodonPlus-RIL E. coli cells. JM109 E. coli cells with the transformed
plasmids were plated on antibiotic-resistant plates, colony-picked and grown in LB.
Plasmids were isolated from harvested cells using the Bio Basic Inc. EZ-10 spin column
miniprep kit and were sequenced (London Regional Genomics Centre, Canada) to ensure
that the correct mutations were incorporated.
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Table 3.1 Mutagenesis primers for UbS65E.
DNA Template
Mutation
Primer Sequence
Ub
S65E
Forward: 5’- caacatccaaaaggaagaaactctacacttggtc - 3’
Reverse: 5’ - gaccaagtgtagagtttcttccttttggatgttg - 3’
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3.2.3 Expression and purification of R0RBR
Unlabelled R0RBR in BL21(DE3) cells was grown in LB media. 1 L growths
were supplemented with kanamycin for antibiotic resistance and 1 mL 0.5 mM ZnCl 2
because R0RBR coordinates Zn2+ ions. Cells were grown at 37°C to an OD600 of 0.8 and
expression was induced with 0.1 mM IPTG at 16°C for 16 hours.
13 15

C N2H- and 12C14N2H-labelled R0RBR in BL21(DE3) cells were grown in D 2O

MOPS media supplemented with desired isotopes. pET-SUMO plasmids containing
R0RBR were first freshly transformed into BL21(DE3) cells and plated on kanamycin
plates. Colonies were picked and inoculated into a 25 mL MOPS media starter
containing kanamycin that was incubated at 37°C for 24 hours. The 25 mL starter was
spun down at 3,000 × g for 20 minutes and 10°C. The spun-down cells were resuspended
in a 150 mL sterilized 70%- D2O MOPS media starter with kanamycin and were
incubated for approximately 8 hours at 37°C until the OD 600 reached 0.8. The 150 mL
70%- D2O starter was spun down at 3,000 × g for 20 minutes and 10°C. The spun-down
cells were resuspended in two 1 L flasks containing sterilized 100%- D 2O pH 7.5 MOPS
media with kanamycin and either 2 g 12C2H-D-glucose, 2 g 13C2H-D-glucose, 1 g
15

NH4Cl or 1 g 14NH4Cl isotopes. Cells were grown at 37°C for approximately 12 hours

until the OD600 reached 0.8. Temperature was turned down to 16°C for 1 hour and 1 mL
0.5 mM ZnCl2 was added to each 1 L flask. Expression was induced with 0.1 mM IPTG
for 8 hours.
Both unlabelled and labelled R0RBR cell cultures were harvested and purified
using the following protocol. Cells were harvested by centrifugation at 6000 × g for 10
minutes and resuspended in 50 mM Tris, 350 mM NaCl, 250 μM TCEP, 25 mM
imidazole, pH 8.0 buffer. Cells were lysed in the presence of protease inhibitor using an
Avestin EmulsiFlex-C5 homogenizer and were further centrifuged at 148,230 × g for 70
minutes. The supernatant was collected and His-SUMO-tagged R0RBR was purified on
a HisTrap FF column by batch-binding and washing with 50 mM Tris, 200 mM NaCl,
250 μM TCEP, 25 mM imidazole, pH 8.0 buffer. His-tagged R0RBR was eluted with 50
mM Tris, 200 mM NaCl, 250 μM TCEP, 250 mM imidazole, pH 8.0 buffer, Ulp1cleaved at 25°C for 1 hour, and dialysed against 50 mM Tris, 200 mM NaCl, 250 μM
TCEP, pH 8.0 buffer at 4°C overnight. Ulp1-cleaved R0RBR was purified on a second
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HisTrap FF column using 50 mM Tris, 200 mM NaCl, 250 μM TCEP, pH 8.0 wash
buffer and the purified flowthrough was collected. R0RBR was run on a final Superdex
75 size-exclusion column using a flow rate of 0.3 mL/min and collecting 0.5 mL
fractions. Fractions containing the desired R0RBR protein were collected for
experimental use. Purity was monitored by SDS-PAGE.
3.2.4 Expression and purification of UblS65E
12 14

C N2H-labelled parkin UblS65E was expressed, harvested and purified using the

same protocol for deuterated-labelled R0RBR growths (section 3.2.3) except 0.5 mM
IPTG was used for induction and no ZnCl2 was added to growths because the Ubl domain
does not coordinate Zn2+ ions.

3.2.5 Expression and purification of Ub and Ub S65E
Unlabelled Ub and UbS65E in BL21(DE3)CodonPlus-RIL cells were grown in LB
media.

13 14

C N1H-labelled Ub as well as 13C14N1H- and 13C15N1H-labelled UbS65E

growths were performed in M9 minimal media supplemented with 2 g 13C1H-D-glucose,
1 g 15NH4Cl or 1 g 14NH4Cl isotopes. The unlabelled and labelled growths described
above were supplemented with ampicillin and chloramphenicol at 37°C until an OD 600 of
0.8 was reached and expression was induced with 0.5 mM IPTG at 37°C for 8 hours.
12 14

C N2H-labelled Ub and 12C15N2H-labelled UbS65E in BL21(DE3)CodonPlus-

RIL cells were grown in D2O M9 minimal media supplemented with desired isotopes for
NMR experiments. pMCG7 plasmids containing His-tagged Ub and Ub S65E were first
freshly transformed into BL21(DE3)CodonPlus-RIL cells and plated on
ampicillin/chloramphenicol plates. Colonies were picked and inoculated into a 25 mL
LB media starter containing ampicillin/chloremphenicol that was incubated at 37°C for
24 hours. The 25 mL starter was spun down at 3,000 × g for 20 minutes and 10°C. The
spun-down cells were resuspended in a 150 mL sterilized 70%-D 2O M9 minimal media
starter with ampicillin/chloremphenicol and were incubated for approximately 8 hours at
37°C until the OD600 reached 0.8. The 150 mL 70%- D2O starter was spun down at 3,000
× g for 20 minutes and 10°C. The spun-down cells were resuspended in two 1 L flasks
containing sterilized 100%- D2O pH 7.5 M9 minimal media with
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ampicillin/chloremphenicol and either 2 g 12C2H-D-glucose, 2 g 13C2H-D-glucose, 1 g
15

NH4Cl or 1 g 14NH4Cl isotopes. Cells were grown at 37°C for approximately 12 hours

until the OD600 reached 0.8. Expression was induced with 0.5 mM IPTG at 37°C for 8
hours. All labelled and unlabelled growths were harvested and protein was purified using
the same protocol for UbcH7C17S/C137S (section 2.2.2). Purity was monitored by SDSPAGE.
3.2.6 Expression and purification of PINK1
Unlabelled GST-tagged PINK1 in BL21(DE3)CodonPlus-RIL cells was grown
and expressed in LB media containing ampicillin/chloramphenicol at 37°C to an OD 600 of
0.8. Expression was induced with 50 µM IPTG at 26°C for 16 hours. Unlabelled PINK1
cells were harvested by centrifugation at 6000 × g for 10 minutes and resuspended in 50
mM Tris, 250 mM NaCl, 0.5 mM EGTA, 0.5 mM EDTA, 1 mM DTT, pH 7.5 lysis
buffer. Cells were lysed in the presence of protease inhibitor using an Avestin
EmulsiFlex-C5 homogenizer and were further centrifuged at 148,230 × g for 70 minutes.
The supernatant was collected and non-cleavable GST-tagged PINK1 was purified on a
GSTrap FF column by batch-binding and washing with 50 mM Tris, 250 mM NaCl, 1
mM DTT, pH 7.5 wash buffer. GST-tagged PINK1 was eluted with 50 mM Tris, 150
mM NaCl, 1 mM DTT, 10 mM GSH, pH 7.5 elution buffer and was dialysed against 50
mM Tris, 250 mM NaCl, 1 mM DTT, pH 7.5 buffer at 4°C overnight to remove all traces
of GSH. Purity was monitored by SDS-PAGE.
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3.2.7 Optimisation of pUb formation and purification
Assays to optimise pUb formation were performed as follows. All sample
reactions were performed with 10 µM PINK1 and 100 µM Ub in 50 mM Tris, 0.5 mM
DTT, 10 mM MgCl2, 100 µM ATP, pH 7.5 buffer at 24°C while dialysing against the
same fresh ATP buffer unless stated otherwise. Three conditions were assayed: (1)
dialysis or no dialysis to fresh ATP buffer, (2) ATP concentrations of 100 µM, 500 µM, 1
mM, 5 mM or 10 mM, and (3) Ub concentrations of 100 µM or 500 µM.
Once optimal conditions were identified, unlabelled and 12C14N2H-labelled pUb
was synthesised using unlabelled or labelled Ub that was purified as in section 3.2.5 and
the optimised protocol for pUb synthesis in section 3.3.6. Unlabelled or labelled pUb
was then purified from PINK1 and any unphosphorylated-Ub as follows. The finished
reaction mixture was first dialysed against 20 mM Bis-Tris propane, pH 8.7 buffer for 12
hours. The mixture was purified on a HiTrap Q anion exchange column. Using 20 mM
Bis-Tris propane, pH 8.7 wash buffer, unphosphorylated Ub flows through while pUb
and PINK1 bind to the column because they have sufficient negative charge. 2 mL
fractions were then collected using a 0-100% 20 mM Bis-Tris propane, 0.5 mM NaCl, pH
8.7 elution buffer gradient and 0.8 mL/min flow rate. pUb elutes around 40% of the
elution gradient while PINK1 elutes around 100% because it is more negatively charged
than pUb. The pH of eluted fractions was neutralized by adding 1 M Tris, pH 7.5 buffer.
Fractions containing purified pUb were collected for experimental use. Integrity and
purity of pUb was assessed by mass spectrometry and Wako Phos-tag-gel analysis.

3.2.8 Production of a 1:1 complex of R0RBR bound to pUb
12 14

C N2H-labelled pUb was added 1.5 times in excess to 13C15N2H-labelled

R0RBR so that pUb would saturate R0RBR. The 1:1 complex mixture was purified from
unbound pUb on a Superdex 75 size-exclusion column in 25 mM HEPES, 100 mM NaCl,
500 µM TCEP pH 7.0 buffer using a flow rate of 0.3 mL/min and collecting 1 mL
fractions. Fractions containing the desired pUb-R0RBR complex were collected for
experimental use. Purity was monitored by SDS-PAGE.
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3.2.9 ITC of R0RBR binding to Ub, UbS65E and pUb
ITC experiments were performed on either a Microcal VP-ITC system (GE
Healthcare) or a Nano ITC system (TA Instruments) using freshly purified proteins. Ub,
UbS65E or pUb were titrated into the calorimeter cell containing R0RBR or a construct of
parkin containing a stretch of glycine substitutions from residues 380-384 termed
R0RBR380-384G. Calorimeter cell and syringe protein concentrations varied between 0.011.5 mM for each experiment depending on the magnitude of heats observed. Each
experiment was performed 2-3 times each using 50 mM HEPES, 50 mM NaCl, 250 µM
TCEP, pH 7.5 buffer at 25°C. Protein concentrations were verified using amino acid
analysis from the SPARC BioCentre Amino Acid Facility (Toronto, Canada). Data from
the Microcal VP-ITC system was analysed with OriginLab while data from the Nano ITC
system was analysed with NanoAnalyze using a single-site binding model to determine
stoichiometry (N), association (Ka) and enthalpy change (ΔH) values. Gibb’s free energy
(ΔG) and entropy change (ΔS) from the Microcal VP-ITC system experiments were
calculated using the same equations in section 2.2.6, while ΔG and ΔS from the Nano
ITC system experiments were calculated using equation 2 from section 2.2.6 and
NanoAnalyze software respectively.
3.2.10 Circular dichroism of Ub, UbS65E and pUb
Spectra were collected on a Jasco J-810 instrument using 30 µM of each sample
in 10 mM KH2PO4, 1 mM EDTA, pH 7.0 buffer at 25°C. Structure curves were recorded
and averaged using five scans from 260-190 nm. Ellipticity signals were converted to
mean residue ellipticity units using the following equations:
MRW =
[𝜃] =

(1)
×
×

×

(2)

MRW is the mean residue weight of the protein in g/mol, MW is the molecular weight of
the protein and n is the number of residues. [θ] is the mean residue ellipticity in
deg·cm2/dmol, θ is the degree of ellipticity in mdeg, C is the concentration in mg/mL and
l is the pathlength of the cuvette in cm. Thermal denaturing spectra recorded at 218 nm
from 5-105°C were used to make melting curves. Ellipticity signals were processed
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using GraphPad Prism software and melting temperatures were calculated using a
nonlinear fit to the data.
3.2.11 NMR spectroscopy setup and processing
All NMR data was collected at 25°C on a Varian Inova 600 MHz NMR
spectrometer equipped with a triple resonance cryogenic probe and z-field gradients.
Samples were prepared in 25 mM HEPES, 100 mM NaCl, 500 µM TCEP pH 7.0 buffer
with 10% D2O (v/v) and DSS as an internal reference. All 1H-15N HSQC spectra (Kay et
al., 1992) were collected in TROSY mode (Pervushin et al., 1997) to follow amide
backbone chemical shift pertubations (CSPs). R0RBR spectral windows were 8000.0 Hz
centred on 4.780 ppm for 1H and 1700.0 Hz centred on 118.0 ppm for 15N, while Ub
spectral windows were 7002.8 Hz centred on 4.790 for 1H and 2000.0 Hz centred on
120.2 ppm for 15N. All 1H-13C HMQC spectra (Tugarinov et al., 2004) were collected to
monitor chemical shifts of Ub side chain methyl groups using spectral windows of 7000.0
Hz centred on 4.790 ppm for 1H and 10,000 Hz centred on 35.00 ppm for 13C. CSPs for
amide backbone resonances were calculated using equation 3, while CSPs for side chain
methyl groups were calculated using equation 4:
CSPamide = (∆𝛿𝐻) + ((∆𝛿𝑁) × 0.2)

(3)

CSPmethyl = (∆𝛿𝐻) + ((∆𝛿𝐶) × 0.3)

(4)

All data was processed using 60°-shifted cosine bell-weighting functions using NMRPipe
and NMRDraw (Delaglio et al., 1995), and was analysed using NMRViewJ (Johnson and
Blevins, 1994).
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3.2.12 NMR assigning of Ub and UbS65E backbone and methyl groups
Backbone amide 1H, 15N assignment for unbound UbS65E was made by collecting
1

H-15N HSQC and HNCA (Kay et al., 1990) spectra of 13C15N1H-labelled UbS65E in non-

TROSY mode and by using them in conjunction with previous assignments of Ub K48R
(Hamilton et al., 2000). The 1H, 15N backbone chemical shift assignments for UbS65E
have been deposited to the Biological Magnetic Resonance Bank under the accession
number 25708.
1

H, 13C side-chain methyl identification of yeast Ub and UbS65E in the free state

and bound to R0RBR was performed by collecting 1H-13C HMQC spectra (Tugarinov et
al., 2004) of 13C14N1H-labelled Ub alone and bound to 13C15N2H-labelled R0RBR. The
same experiments were collected of 13C14N1H-labelled UbS65E alone and bound to
13 15

C N2H-labelled R0RBR. Resonance identification was performed using well-aligned

and previously assigned yeast UbK48R resonances (Hamilton et al., 2000). The 1H, 13C
side-chain methyl chemical shift assignments for Ub and Ub S65E both bound to R0RBR
have been deposited to the Biological Magnetic Resonance Bank under accession
numbers 25707 and 25709 respectively. A list of all NMR experiments performed can be
found in Table 3.2.
3.2.13 NMR of R0RBR interactions with Ub, UbS65E, pUb and PO4
TROSY 1H-15N HSQC spectra were collected in variations of selectively-labelled
R0RBR with selectively-labelled Ub, UbS65E, pUb and PO4 titrations. 1H-13C HMQC
spectra were collected in variations of selectively-labelled Ub or Ub S65E with selectivelylabelled R0RBR titrations. CSP analysis was performed on amide backbone and side
chain methyl groups to determine ambiguous restraints used for docking pUb to R0RBR.
CSPs used for docking were mapped to the docked pUb-R0RBR complex computed in
section 3.2.14 using PyMOL (Delano, 2002). TROSY 1H-15N NOESY experiments were
used with TROSY 1H-15N HSQC and 1H-13C HMQC spectra to determine distance
restraints between amide backbone protons on 13C15N2H-labelled R0RBR and side chain
methyl protons on 13C14N1H-labelled Ub or UbS65E. A list of all NMR experiments
performed can be found in Table 3.2.

74

Table 3.2 NMR experiments of R0RBR with Ub, UbS65E, pUb, PO4 and UblS65E. All experiments were performed at 25°C in 25 mM HEPES, 100 mM NaCl,
500 µM TCEP, pH 7.0 buffer. All 1H -15N HSQC spectra were collected in TROSY mode unless otherwise noted.
13 15 2
13 15 1
12 14 2
12 14 2
Experiment
C N H 12C14N2H 13C14N1H 12C14N2H 13C14N1
C N H 12C15N2H
C NH
C NH
S65E
S65E
S65E
R0RBR
R0RBR
Ub
Ub
Ub
Ub
Ub
pUb
PO4
UblS65E
1
H-15N HSQC*
320 µM
HNCA*
320 µM
1
H-15N HSQC
150 µM
1
H-15N HSQC
150 µM
150 µM
1
H-15N HSQC
150 µM
450 µM
1
H-15N HSQC
120 µM
1
H-15N HSQC
120 µM
30 µM
1
H-15N HSQC
120 µM
60 µM
1
H-15N HSQC
120 µM
120 µM
1
H-15N HSQC
120 µM
240 µM
1
H-15N HSQC
120 µM
120 µM
1
H-15N HSQC
120 µM
240 µM
1
H-15N HSQC**
200 µM
200 µM
1
H-13C HMQC
150 µM
1
H-13C HMQC
150 µM
150 µM
1
H-15N NOESY
150 µM
150 µM
1
H-15N HSQC
150 µM
150 µM
1
H-13C HMQC
300 µM
150 µM
1
H-13C HMQC
450 µM
150 µM
1
H-13C HMQC
290 µM
1
H-13C HMQC
290 µM
290 µM
1
H-15N NOESY
290 µM
290 µM
1
H-15N HSQC
290 µM
290 µM
1
H-15N HSQC
50 µM
1
H-15N HSQC
50 µM
50 µM
1
H-15N Heteronuclear NOE***
270 µM
270 µM
1
H-13C HMQC
130 µM
1
H-13C HMQC
130 µM
130 µM
1
H-13C HMQC
130 µM
130 µM
130 µM
*
Collected in non-TROSY mode
**
A 1:1 complex was purified using a Superdex 75 size-exclusion column as in section 3.2.8
***
Performed in duplicate
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3.2.14 HADDOCK of R0RBR and pUb binding
Interacting residues determined while following both R0RBR and Ub S65E amide
backbone resonance CSPs during NMR experiments were defined as those that shifted
greater than the average +1 standard deviation and had greater than 20% side chain
accessible surface area. Interacting residues determined while following both Ub and
UbS65E side chain methyl group resonance CSPs during NMR experiments were defined
as having shifted and were used regardless of accessible surface area due to having a
limited number of methyl-containing residues. Unambiguous restraints determined from
TROSY 1H-15N NOESY NMR data and 1 unambiguous restraint determined through
mutagenesis experiments were used for docking. The full list of ambiguous and
unambiguous restraints used for docking are shown in Table 3.3.
pUb was docked to R0RBR using HADDOCK (Dominguez et al., 2003). The
coordinates from the crystal structure of UblR0RBR S65D (PDB ID code 5C23) were used
for docking after removal of the Ubl domain and adjoining linker coordinates. A
phosphate group was added at S65 to Ub coordinates (PDB ID code 1UBQ) (VijayKumar et al., 1987) and missing regions in the R0RBR coordinates were modelled-in
using the Modeller (Eswar et al., 2006) plug-in for UCSF Chimera (Pettersen et al.,
2004). An upper distance limit of 5.0 Å was set for ambiguous distance restraints while
unambiguous distance restraints were set to 3.0 Å. Standard parameters were used except
inter_rigid (0.1) which was set to allow tight packing of the two proteins, and the
unambiguous force constants were increased by five-fold compared to the ambiguous
constants. A total of 1,000 initial complexes were calculated and the best 100 structures
were water-refined.
3.2.15 NMR heteronuclear NOEs of R0RBR binding to pUb
1

H-15N heteronuclear NOE NMR experiments (Farrow et al., 1994) were collected

using a sample of 13C15N2H-labelled R0RBR and 12C14N2H-labelled pUb. Proton
saturation was achieved through a 5 second irradiation time following an 11 second
relaxation delay. The equivalent non-saturated experiment contained a 16 second
relaxation delay. Both saturated and non-saturated experiments were conducted in
duplicate and NOEs were averaged.
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Table 3.3 HADDOCK restraints for R0RBR and pUb binding. Restraints were determined using NMR
CSP analysis, 1H-15N NOESY experiments, mutagenesis and ITC data.
Restraint Type Experiment
R0RBR
pUb
Ambiguous
NMR CSPs
K151 G152 R275 V278 D280
K6 T7 L8 T9 G10 R42
Q282 G284 Y285 G308 E309 N313 L43 I44 F45 A46 K48
Q317 G319 A320 L325 M327
Q49 N60 I61 S65 T66
R334 C337 G338 A339 L342 E344 H68 V70 L71 L73 R74
E353 G355 G361 F362
Unambiguous
Mutagenesis
H302 atom N
pS65 atom P
NMR 1H-15N NOESY
E353 atom N
L8 atom HD21
NMR 1H-15N NOESY
L342 atom N
L73 atom HD11
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3.2.16 NMR of UbS65E and UblS65E competitive binding to R0RBR
Competitive binding experiments that assessed the binding of Ub S65E and UblS65E
to R0RBR utilised 1H-13C HMQC and TROSY 1H-15N HSQC spectra collected to follow
side chain methyl CSPs of 13C14N1H-labelled UbS65E alone, with 1 equivalent of
13 15

C N2H-labelled R0RBR and with 1 equivalent of 12C14N2H-labelled UblS65E added to

the UbS65E and R0RBR sample.

3.3 Results
3.3.1 UbS65E was synthesised
Prior to determining a protocol to synthesise pUb, UbS65E was used as a functional
mimetic of S65 phosphorylation. For this reason, a S65E substitution was incorporated
into Ub. Sequencing results verified that QuikChange Site-Directed Mutagenesis and
PCR successfully incorporated the substitution with the previously described primers
(Table 3.1).
3.3.2 R0RBR was expressed and purified
Unlabelled and labelled R0RBR (parkin residues 141-465) were successfully
expressed and purified using an initial HisTrap FF column followed by Ulp1-cleavage, a
second HisTrap FF column and a final Superdex 75 size-exclusion column. Purity was
monitored by SDS-PAGE as seen by the expected band around 36 kDa (Figure 3.1).
Mass spectrometry was previously used and correctly verified the mass of R0RBR.
Unlabelled R0RBR was later used for ITC experiments, while labelled R0RBR was used
for NMR experiments.
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Figure 3.1 R0RBR purification. 13C15N2H-labelled R0RBR was purified on (A) a HisTrap column
followed by Ulp1-cleavage and a second HisTrap column, and (B) a final Superdex 75 size-exclusion
column. Purity was verified by SDS-PAGE with the expected MW of R0RBR being around 36 kDa.
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3.3.3 UblS65E was expressed and purified
Prior to determining a protocol for sufficient production of pUbl, Ubl S65E (parkin
residues 1-76) was used as a mimetic.

12 14

C N2H-labelled UblS65E was successfully

expressed and purified using an initial HisTrap FF column followed by Ulp1-cleavage, a
second HisTrap FF column and a final Superdex 75 size-exclusion column. Purity was
monitored by SDS-PAGE as seen by the expected band around 8.9 kDa (Figure 3.2).
Mass spectrometry was previously used and correctly verified the mass of Ubl S65E.
12 14

C N2H-labelled UblS65E was later used for NMR competition interaction studies with

UbS65E and R0RBR.

3.3.4 Ub and UbS65E were expressed and purified
Unlabelled Ub and UbS65E, 13C14N1H- and 12C14N2H-labelled Ub, as well as
13 14

C N1H-, 13C15N1H- and 12C15N2H-labelled UbS65E were successfully purified using an

initial HisTrap FF column followed by TEV-cleavage and a second HisTrap FF column.
Purity was monitored by SDS-PAGE as seen by the expected band around 8.6 kDa
(Figure 3.3). Mass spectrometry was previously used and correctly verified the mass of
Ub. Unlabelled Ub and UbS65E were later used for ITC and circular dichroism
experiments, while labelled Ub and UbS65E were used for NMR experiments.
3.3.5 PINK1 was expressed and purified
Unlabelled GST-tagged PINK1 kinase was successfully purified using a GSTrap
FF column. Purity was monitored by SDS-PAGE as seen by the expected band around
64 kDa (Figure 3.4). PINK1 purity was sufficient for later enzymatic use in
phosphorylating Ub samples.
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S65E

Figure 3.2 Ubl
purification. 12C14N2H-labelled UblS65E was purified on (A) a HisTrap column
followed by Ulp1-cleavage and a second HisTrap column, and (B) a final Superdex 75 size-exclusion
column. Purity was verified by SDS-PAGE with the expected MW of UblS65E being around 8.9 kDa.
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Figure 3.3 Ub and UbS65E purification. (A) WT Ub and (B) 12C15N2H-labelled UbS65E were purified on a
HisTrap column followed by TEV-cleavage and a second HisTrap column. Purity was verified by SDSPAGE with the expected MWs of Ub and UbS65E being around 8.6 kDa.
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Figure 3.4 PINK1 purification. GST-tagged PINK1 was purified on a GSTrap column. Purity was
verified by SDS-PAGE with the expected MW being around 64 kDa.
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3.3.6 pUb formation and purification was optimised
pUb is formed when Ub is phosphorylated by PINK1 under optimal conditions,
therefore a protocol for pUb synthesis was optimised in order to minimize reagent
requirements and the time required for formation. Conditions that were assayed included
comparing dialysis against fresh ATP buffer with no dialysis (Figure 3.5A), ATP
concentrations (Figure 3.5B) and Ub concentrations (Figure 3.5C). Assays showed that
optimal pUb formation required 10 µM PINK1 with 100 µM Ub in 50 mM Tris, 0.5 mM
DTT, 10 mM MgCl2, 5 mM ATP, pH 7.5 buffer while dialysing against the same fresh
ATP buffer at 24°C for 1 hour. Higher concentrations of 500 µM Ub can be sufficiently
phosphorylated if the reaction time is extended to 4 hours with 10 mM ATP
concentrations. Assays were visualised by Phos-tag gel.
Unlabelled and 12C14N2H-labelled pUb was successfully purified using a HiTrap
Q anion exchange column. Purity was monitored by Phos-tag gel (Figure 3.6AB).
Integrity of pUb was confirmed by mass spectrometry as seen by a 8,908 Da MW which
corresponds to the addition of 1 phosphate group to Ub (Figure 3.6C). Unlabelled pUb
was later used for ITC and circular dichroism experiments while 12C14N2H-labelled pUb
was used for NMR experiments.
3.3.7 A 1:1 complex of R0RBR to pUb was purified
In order to obtain a 1:1 complex of 13C15N2H-labelled R0RBR bound to 12C14N2Hlabelled pUb, the two proteins were co-purified on a Superdex 75 size-exclusion column
because pUb binds tight enough to R0RBR to allow the high MW 1:1 complex to be
separated from unbound pUb. The elution profile was monitored by absorbance and
denaturing SDS-PAGE as seen by the expected bands around 36 kDa for R0RBR and 8.9
kDa for pUb that co-elute in early fractions. Later fractions contain unbound pUb and
were discarded (Figure 3.7). The purified complex was used in NMR experiments.
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Figure 3.5 pUb formation optimisation. Phos-tag gels show pUb formation was optimised by assaying (A) dialysis or no dialysis against fresh ATP buffer, (B)
ATP concentrations and (C) Ub concentrations. Optimal conditions for pUb formation include using 10 µM PINK1 with 100 µM Ub in 50 mM Tris, 0.5 mM
DTT, 10 mM MgCl2, 5 mM ATP, pH 7.5 buffer while dialysing ag ainst the same fresh ATP buffer at 24°C for 1 hour, as denoted by * in panel B. Higher
concentrations of 500 µM Ub can be sufficiently phosphorylated if the reaction time is extended to 4 hours with higher 10 mM ATP concentrations as denoted by
* in panel C.
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Figure 3.6 pUb purification. Phostag-gels showing (A) Ub was successfully phosphorylated by PINK1 to
form pUb and (B) pUb purification on a HiTrap Q column. (C) Integrity was verified by mass
spectrometry as seen by the observed 8,908 Da MW peak corresponding to pUb.
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A

B

Figure 3.7 pUb-R0RBR complex purification. (A) Absorbance elution profile of pUb-R0RBR purified
on a Superdex 75 10/300 size-exclusion column from unbound pUb. pUb-R0RBR co-elutes as seen by the
earlier shift in absorbance in comparison to the unbound R0RBR profile. (B) Superdex 75 10/300 sizeexclusion elution profile of pUb-R0RBR purification visualised by SDS-PAGE with pUb-R0RBR eluting
in fractions 21-24 and unbound pUb eluting in fractions 26-29.
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3.3.8 Parkin autoinhibition is regulated through interdomain interactions
To determine a structural understanding for parkin autoinhibition, a crystal
structure of UblR0RBR was solved to 1.8 Å and comprises the five domains of parkin:
Ubl, RING0, RING1, IBR and RING2 (Figure 3.8A). Residues 383–390 and 406–413
within a large linker connecting IBR and RING2 domains are missing in the density due
to high flexibility. Parkin takes on a globular structure with many notable interdomain
interactions that illustrate an autoinhibited state. The largest buried interface is 2,150 Å 2
comprising interactions between the autoinhibitory Ubl domain to RING1 and IBR
domains with predominant contacts between the Ubl sheets β3 and β5 to RING1 helix
H1. The extent and nature of the Ubl/RING1 interface suggests it is important for
autoinhibition of parkin which is consistent with several activating ARJP mutations that
are found at this interface such as R42P, A46P and R33Q within the Ubl domain
(Chaugule et al., 2011). Further contacts from N8 in the Ubl β1-β2 sheet loop sits
between E310 and Q311 of a bent RING1 helix H3, as well as H11 within the Ubl β1-β2
sheet loop is seen interacting with P333 and K369 of the IBR. RING1 takes on a
canonical RING fold and is the suggested E2 binding site. However, two more
justifications for parkin autoinhibition exist when considering E2 binding. First, residues
390-400 comprise a repressor (REP) helix that interacts with RING1 and blocks
accessibility to the E2 (Figure 3.8A). Second, when an E2 is modelled onto the RING1
binding site, transthiolation cannot occur due to a large 50 Å distance between the E2
catalytic cysteine and the RING2 catalytic C431. Furthermore, RING0/RING2
interactions bury the catalytic C431 making it inaccessible for transthiolation. Together,
the full-length crystal structure of parkin shows that large conformational changes are
required to relieve autoinhibition mediated through the presence of (1) Ubl interactions,
(2) REP/RING1 interactions blocking the E2 binding site, (3) a large 50 Å distance
between the E2 and RING2 C431 catalytic sites and (4) RING0/RING2 interactions that
occlude the catalytic C431.
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3.3.9 Parkin phosphorylation leads to remodelling of a hinge interface
Superposition of the UblR0RBR and R0RBR structures (PDB ID code 4I1H)
reveal good alignment with an rmsd of 1.8 Ȧ. The observed difference is largely due to a
change in positioning of the IBR domain which experiences a 12 Ȧ swing from a hinge at
the RING0/RING1 interface (Figure 3.8B). The RING0/RING1 hinge interface
comprises a basic triad that includes residues K151, H302 and R305 that are thought to
coordinate pUb binding. To observe the effects of phosphorylation at parkin S65, a
crystal structure of phosphorylation-mimetic UblR0RBR S65D (PDB ID code 5C23) was
solved to 2.4 Å. Superposition of UblR0RBR and UblR0RBR S65D reveal an excellent
0.58 Ȧ rmsd indicating that no global conformational changes occur. However, close
observation and comparison of the hinge interface between the structures reveals that
H227, E300 and H302 residues are remodelled to produce a continuous basic patch when
UblR0RBR has a S65D substitution, much like the R0RBR structure (Figure 3.8CD).
This data suggests that the addition of a negative charge or phosphate group at S65 of
parkin is enough to allosterically alter the distal RING0/RING1 hinge interface and prime
parkin for optimal pUb binding.
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Figure 3.8 Crystal structure of UblR0RBR. (A) Ribbon diagram of UblR0RBR parkin (PDB ID code 5C1Z) showing the Ubl domain (green), RING0 (blue),
RING1 (purple), IBR (black), repressor element (REP) (yellow) and RING2 (brown). Loops outside domains are modelled in cyan. Zinc atoms are represented
as grey spheres. (B) Overlay of UblR0RBR (coloured as in panel A) with R0RBR (PDB ID code 4I1H) (grey). Absence of the Ubl domain causes the IBR
domain to swing 12 Å from a hinge opening at the RING0/RING1 interface. (C) Ribbon and stick comparison of the UblR0RBR, UblR0RBRS65D (PDB ID code
5C23) and R0RBR structures. H227, E300 and H302 at the RING0/RING1 hinge interface are remodelled in the UblR0RBRS65D structure to resemble the
R0RBR hinge interface. (D) Surface representation of the continuous basic patch formation at the RING0/RING1 hinge interface comprising K151, H302 and
R305 when the phosphorylation-mimetic S65D substitution is present. Panels were prepared by aligning all RING0/RING2 atoms with the align command in
PyMol.
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3.3.10 Phosphorylation causes pUb to bind parkin with high affinity
ITC was used to determine the affinity of interaction of R0RBR, UblR0RBR and
pUblR0RBR with Ub, UbS65E and pUb (Figure 3.9). Results showed that R0RBR and
pUb bind with high affinity (Kd 16 ± 2 nM), phosphorylation-mimetic UbS65E binds with
an intermediate affinity (Kd 6.6 ± 0.1 μM) and unmodified Ub binds with weak affinity
(Kd 40 ± 1 μM) (Table 3.4). All stoichiometry constants (N) are approximately equal to
1, which indicates a 1:1 binding site. The change in entropy (ΔS) is identically positive
for R0RBR binding to pUb and UbS65E (+78 kJ/mol) suggesting that pUb and UbS65E
increase disorder in the system to the same extent. The ΔS for pUb and Ub S65E binding to
R0RBR is more positive than the ΔS of Ub binding, suggesting that pUb and Ub S65E
increase disorder more than Ub. Gibbs free energy (ΔG) is most negative for R0RBR
binding to pUb and UbS65E than to Ub which suggests that pUb and UbS65E binding are
more favourable. The affinity of pUb for UblR0RBR (K d 160 ± 20 nM) and pUblR0RBR
(Kd 17 ± 5 nM) (Ordureau et al., 2014) shows that phosphorylation of the Ubl domain
causes more than a 10-fold increase in affinity of pUb for parkin. pUb binding to
UblR0RBR is also highly entropically driven (+86 kJ/mol). Results here suggest that
phosphorylation of Ub at S65 is a modification that results in parkin being able to recruit
pUb with high affinity and that this recruitment is enhanced when parkin is also
phosphorylated at S65. These binding events are highly entropic indicating that binding
leads to increased movement or disorder in the system, likely due to parkin undergoing a
structural change.
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Figure 3.9 ITC of R0RBR variants binding to Ub, UbS65E and pUb. Isotherm graphs shown are for: (A)
R0RBR and Ub, (B) R0RBR and UbS65E, (C) R0RBR and pUb, (D) R0RBR380-384G and Ub, (E) R0RBR380384G
and UbS65E. The upper panels represent raw data, and the lower panels represent integrated heat
changes performed assuming a single-site binding model. Data was collected at 25⁰C with 50 mM HEPES,
50 mM NaCl, 250 µM TCEP, pH 7.5 buffer conditions.

Table 3.4 Thermodynamics of R0RBR constructs binding to Ub, UbS65E and pUb. ITC experiments were collected at 25⁰C with 50 mM HEPES, 50 mM
NaCl, 250 µM TCEP, pH 7.5 buffer conditions and were performed in duplicate. Values are shown for stoichiometry (N), dissociation constant (Kd), enthalpy
change (ΔH), entropy change (ΔS) and Gibbs free energy (ΔG). Relative exchange rates determined by NMR are presented for comparison. Dashed lines
indicate that data was not collected.
Cell Protein
Titrant
N
Kd
ΔH
TΔS
ΔG
NMR Exchange Rate
(μM)
(kJ/mol)
(kJ/mol)
(kJ/mol)
R0RBR
Ub
1.1 ± 0.0
40 ± 1
30 ± 1
55 ± 1
-25 ± 1
Fast
R0RBR
UbS65E
1.1 ± 0.0
6.6 ± 0.1
48 ± 0
78 ± 1
-30 ± 1
Slow-intermediate
R0RBR
pUb
0.93
0.016 ± 0.002*
32
78
-46
Slow
R0RBR380-384G
Ub
0.9 ± 0.0
44 ± 1
14 ± 0
39 ± 0
-25 ± 0
R0RBR380-384G
UbS65E
0.9 ± 0.0
8.2 ± 0.6
30 ± 0
59 ± 0
-29 ± 0
UblR0RBR
Ub
0.9
45 ± 9*
10
34
-24
UblR0RBR
pUb
1.09
0.16 ± 0.02*
50
86
-36
UblR0RBR
pUb
0.37 ± 0.04**
pUblR0RBR
pUb
0.017 ± 0.005**
*
Data collected by Dr. Julio Martinez-Torres
**
Data from Ordureau et al (2014)
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3.3.11 Phosphorylation of Ub causes a loss of stability
Circular dichroism (CD) spectropolarimetry thermal denaturation and structural
curves were produced for Ub, UbS65E and pUb to assess protein stability and fold. The
melting temperatures for Ub (80.5⁰C), UbS65E (77.7⁰C) and pUb (74.0⁰C) indicate that
phosphorylation causes Ub to become less stable (Figure 3.10A). CD structural curves
produced for Ub, UbS65E and pUb assessed protein fold (Figure 3.10B) and showed a
large dip around 205 nm indicative of the presence of alpha-helices in all curves. pUb
has a less negative mean residue ellipticity than Ub indicating that it is less folded than
Ub.
3.3.12 UbS65E backbone amide assignments
Backbone 1H, 15N assignment for UbS65E was performed for use in later NMR
interaction studies with R0RBR because chemical shifts for residue resonances around
S65 deviate from previous UbK48R assignments. Assignments were made by collecting
1

H-15N HSQC and HNCA spectra of 13C15N1H-labelled UbS65E (Figure 3.11AB) and

using them in conjunction with previous backbone amide 1H, 15N assignments of UbK48R.
The largest changes in backbone amide chemical shifts in Ub S65E in comparison to wild
type Ub occur at residues adjacent to S65E such as Q62, K63, E64, E65, T66 and L67.
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Figure 3.10 Circular dichroism of Ub, UbS65E and pUb. (A) CD thermal denaturation curves were
recorded at 218 nm from 5-105°C and (B) CD structural-fold curves were an average of five scans from
260-190 nm for Ub, UbS65E and pUb. Spectra were collected on a Jasco J-810 instrument using 30 µM of
each sample in 10 mM KH2PO4, 1 mM EDTA, pH 7.0 buffer at 25°C. Thermal denaturation and structural
curves suggest that phosphorylation is a modification that destabilizes Ub.

A

B

C
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Figure 3.11 UbS65E backbone amide assignments. (A) HNCA strip plot of 13C15N1H-labelled UbS65E indicating connectivity (dashed line) between the i and i-1
residues from K63, E64, E65, T66 and L67. Peaks corresponding to Cα are shown (black contours). Amino acid labels are listed above the strips. (B) 1H-15N
HSQC NMR spectra of 12C15N2H-labelled Ub (black contours) and 13C15N1H-labelled UbS65E (purple contours). Resonances corresponding to Q62, K63, E64,
E65, T66 and L67 experience the greatest CSP from wild type Ub as indicated by arrows. (C) Measured UbS65E CSPs compared to wild type Ub. The horizontal
dashed line indicates the average CSP ± 1 standard deviation. Data was collected at 25°C in 25 mM HEPES, 100 mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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3.3.13 Identifying pUb-bound R0RBR HSQC spectrum resonances
Identifying resonances in the 1H-15N HSQC spectrum of pUb-bound 13C15N2Hlabelled R0RBR is difficult because binding produces very large, slow-exchanging
resonance CSPs that are compounded with the presence of over 320 resonances. In order
to follow the movement of R0RBR resonances and to identify the new locations when
bound to pUb, a series of TROSY 1H-15N HSQC spectra were collected of titration
experiments between 13C15N2H-labelled R0RBR with 1 and 3 equivalents of Ub, 1
equivalent of UbS65E and 1 equivalent of pUb (Table 3.2). Analysis of the spectra showed
that Ub titrations cause resonances in R0RBR to experience fast exchange corresponding
to a weak affinity of binding, UbS65E titration causes resonances in R0RBR to experience
slow-intermediate exchange corresponding to moderate binding and pUb titration causes
resonances in R0RBR to experience slow exchange corresponding to tight binding. The
relative affinities determined by NMR exchange rates are in good agreement with
affinities determined by ITC (Table 3.4). Accordingly, the magnitude of CSPs observed
in R0RBR for each form of Ub titrated corresponds with the relative affinity of binding.
For instance, Ub has a weak affinity and CSPs observed in R0RBR were the smallest in
magnitude even with 3 equivalents of Ub added. pUb has a tight affinity for R0RBR and
showed the largest magnitude of CSPs, whereas Ub S65E has a moderate affinity for
R0RBR and showed CSPs in R0RBR that were intermediate in magnitude between those
observed for Ub and pUb. The trajectory of R0RBR resonances with the three forms of
Ub followed a near-linear path and aided in the identification of R0RBR resonances that
experienced large CSPs when pUb was bound (Figure 3.12).
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Figure 3.12 NMR titrations of Ub, UbS65E and pUb into R0RBR. Selected regions shown are TROSY
1
H-15N HSQC spectra of 13C15N2H-labelled R0RBR taken alone (black contours), with 1 and 3 equivalents
Ub (red and orange contours respectively), with 1 equivalent UbS65E (yellow contours) and with 1
equivalent of pUb (cyan contours). R0RBR residue resonances shown that are perturbed upon binding are
at the binding interface and include Y312 (RING1 alpha helix), D280 (RING1 unique beta sheet), as well
as G308 and G152 (RING0/RING1 hinge). The trajectory of R0RBR resonances with Ub (fast exchange),
UbS65E (slow-intermediate exchange) and pUb (slow exchange) follow a near-linear path.
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3.3.14 pUb binds to the RING0/RING1 hinge with the pS65 interface
In order to determine the surfaces used for interaction between R0RBR and pUb,
NMR titration experiments of selectively labelled R0RBR with Ub, Ub S65E, pUb and PO4
were conducted as well as TROSY NOESY experiments between R0RBR and Ub or
UbS65E (Table 3.2). CSP analysis of TROSY 1H-15N HSQC NMR data shows that the
addition of pUb to R0RBR results in a cluster of residues with significant chemical shift
changes in R0RBR including Y149, C150, K151 and G152 in the RING0 domain, R275,
F277, V278, D280, Q282, G284, Y285 and S286 in β1–β2 of RING1, and I306, G308,
E309, Y312 and N313 in helices H2 and H3 of RING1 (Figures 3.12 and 3.13). These
residues surround the hinge region at the RING0/RING1 interface that includes the basic
triad composed of K151, H302 and R305 proposed to be responsible for interaction with
pS65 of pUb. There are no significant chemical shift changes in the RING2 domain or at
the RING0/RING2 interface, indicating that pUb binding does not alter the interface
between these two domains where the catalytic cysteine is located. Data here reinforces
the notion that the hinge region at the RING0/RING1 interface is the pUb-binding site.
Analysis of TROSY 1H-15N HSQC and 1H-13C HMQC NMR data acquired of selectively
labelled R0RBR with UbS65E shows that UbS65E uses residues predominantly in the loop 1
(K6, T7, L8 and T9), hydrophobic patch surrounding pS65 (R42, L43, I44, F45, A46,
K48, and Q49), and C-terminal tail (V70, L71, L73, R74) for interaction with R0RBR
(Figure 3.14). The experiment titrating PO4 into 13C15N2H-labelled R0RBR was designed
to show the site of interaction between pUb pS65 and R0RBR, but it showed no
observable changes in the 1H-15N HSQC spectrum of R0RBR.
TROSY 1H-15N NOESY experiments between selectively-labelled R0RBR and
Ub did not provide any unambiguous restraints due to a weak affinity of interaction,
however the same experiments conducted between UbS65E and R0RBR provided 2
unambiguous restraints due to the higher affinity of interaction (Table 3.3). Mutagenesis
experiments determined 1 unambiguous restraint between pUb pS65 and R0RBR H302
located in the RING0/RING1 hinge interface.
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Figure 3.13 NMR of the R0RBR binding interface with pUb. (A) TROSY 1H-15N HSQC NMR spectra
of 13C15N2H-labelled R0RBR in the absence (black contours) and presence of 1 equivalent 12C14N2Hlabelled pUb (blue contours). (B) Measured R0RBR CSPs upon pUb binding. Grey bars indicate that the
resonance was undetectable. The horizontal dashed line indicates the average CSP ± 1 standard deviation.
CSPs were very large and exhibited slow exchange indicating a tight affinity. pUb-R0RBR was purified as
a 1:1 complex on a Superdex 75 size-exclusion column. Data was collected at 25°C in 25 mM HEPES, 100
mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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Figure 3.14 NMR of the UbS65E binding interface with R0RBR. (A) TROSY 1H-15N HSQC NMR
spectra of 12C15N2H-labelled UbS65E in the absence (black contours) and presence of 1 equivalent 12C14N2Hlabelled R0RBR (red contours). (B) Measured UbS65E CSPs upon R0RBR binding. Grey bars indicate that
the resonance was undetectable. The horizontal dashed line indicates the average CSP ± 1 standard
deviation. CSPs were large and exhibited slow-intermediate exchange indicating a moderate affinity. Data
was collected at 25°C in 25 mM HEPES, 100 mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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3.3.15 pUb-R0RBR HADDOCK structure
In order to understand how pUb binds to parkin, a model for the pUb-R0RBR
complex was determined. pUb was successfully docked to R0RBR in HADDOCK using
data from NMR experiments (Table 3.3), mutagenesis experiments and ITC. The
location and orientation of pUb with respect to R0RBR was similar in all 100 waterrefined complexes and the best 20 complexes had a backbone rmsd of 0.36 ± 0.02.
The structure shows that pUb orientation is governed by the loop 1 in pUb that
interacts with residues on the helix H3 of the RING1 domain and residues in the adjacent
IBR domain. The phosphate group at S65 locks pUb in place making key contacts with
the RING0/RING1 hinge composed of K151, H302 and R305. The C-terminal tail of
pUb including residues V70 and L71 runs parallel to helix H3 of the RING1 domain and
also makes contacts with the IBR. In addition, pUb residues I44 and A46 in the β3–β4
region intercalate between strands β1–β2 and helix H3 of the RING1 domain (Figure
3.15). Interestingly, the short β1–β2 region in RING1 appears to be absent in all other
RING domain protein structures and the position of the β1–β2 is replaced by a ubiquitinassociated-like domain in a RBR E3 ligase HHARI structure (Duda et al., 2013). This
finding might suggest an important role for the β1–β2 of RING1 in parkin for pUb
recognition, and that other RBR E3 ligases have specialized recognition domains for pUb
as well.
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Figure 3.15 pUb-R0RBR HADDOCK structure. The surface of R0RBR (grey) is shown binding to a
ribbon diagram of pUb (orange). Residues used for ambiguous HADDOCK restraints are highlighted in
blue for parkin and red for pUb. Unambiguous restraints are labelled and were the following: pUb L8 to
R0RBR E353, pUb pS65 to R0RBR H302, and pUb L73 to R0RBR L342. R0RBR residues important for
binding are located in β-sheet 1 (β1), β-sheet 2 (β2), helix 2 (H2) and helix 3 (H3) of the RING1 domain.
pUb residues important for binding are located in loop 1, β-sheet 3 (β3), β-sheet 4(β4) and the C-terminal
tail. The location and orientation of pUb with respect to R0RBR was similar in all 100 water-refined
complexes and the best 20 complexes had a backbone rmsd of 0.36 ± 0.02.
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3.3.16 R0RBR backbone flexibility with pUb bound
Heteronuclear NOE experiments were conducted to determine the effect that pUb
binding has on R0RBR backbone flexibility. 1H-15N NOE experiments of 13C15N2Hlabelled R0RBR with 1 equivalent of 12C14N2H-labelled pUb bound were acquired
(Figure 3.16) and compared to unbound 13C15N2H-labelled R0RBR experiments. Upon
addition of pUb, notable flexibility is seen in the linker region of parkin from residues
380-390 and from 410-412. Those two regions are separated by residues 391-403 which
form the repressor (REP) helix that compacts tightly with RING1. Residues in this helix
show high rigidity from NOE data indicating that this helix is likely still interacting with
the RING1 domain. Residues that surround the RING0/RING1 hinge interface show
high flexibility such as residues 157-160 that comprise the N-terminal region of RING0,
and residues K299, F304 and N313 from RING1. A large number of dispersed residues
spanning the entire IBR domain become more rigid upon pUb binding likely because the
C-terminal tail of pUb binds the IBR providing supporting interactions to lock it in place.
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Figure 3.16 R0RBR backbone flexibility with pUb bound. (A) 1H-15N heteronuclear NOE NMR of
13 15 2
C N H-labelled R0RBR showing relative parkin flexibility and rigidity upon 1 equivalent of 12C14N2Hlabelled pUb binding. Flexibility is present in the linker region of R0RBR from residues 380-390 and 410412. Flexibility is also noted in residues 157-160, K299, F304 and N313 which surround the
RING0/RING1 hinge. Residues 391-409 that form the REP helix in the linker region of R0RBR stay rigid
upon pUb binding, suggesting that it still compacts tightly with the RING1 domain. Residues spanning the
entire IBR domain become more rigid upon pUb binding. (B) Ribbon and stick figure of the pUb-R0RBR
HADDOCK structure showing R0RBR (grey), pUb (orange), and flexible residues (green) from panel A
data. Both saturated and non-saturated experiments were conducted in duplicate and NOEs were averaged.
NMR data was collected at 25°C in 25 mM HEPES, 100 mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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3.3.17 pUb binding induces a structural change in parkin
Examination of the UblR0RBR crystal structures showed that the RING0/RING1
hinge interface is altered when the Ubl domain is either absent or phosphorylated at S65
and that this event facilitates pUb binding. We therefore proposed that a similar
allosteric change in parkin structure might occur upon pUb binding. Consistent with this,
pUb binding results in R0RBR exhibiting several chemical shift changes in residues at
the junction of the C-terminus of the bent helix H3 and the IBR domain as well as in a
stretch of residues from 379-395 (Figure 3.17) that are located in a flexible linker
between IBR and RING2 domains. These residues are not directly involved in making
contact with pUb and we therefore proposed that the chemical shift changes seen were
the result of a pUb-induced structural change. The binding of pUb to R0RBR is an
endothermic binding event marked by large positive enthalpy (32 kJ/mol) and positive
entropy (78 kJ/mol) changes (Table 3.4). The large increase in entropy suggests that pUb
binding drives an increase in disorder or movement of the system which can be explained
by an allosteric structural change. A R0RBR 380-384G construct in which a stretch of
residues from 380-384 were mutated to glycines was used to determine if the binding
affinity of Ub and UbS65E to R0RBR380-384G was disrupted by ITC (Figure 3.9). Results
showed that R0RBR380-384G binds to Ub (44 ± 1 μM) and UbS65E (8.2 ± 0.6 μM) with
similar affinities as wild type R0RBR (Table 3.4). This confirmed that pUb does not use
this stretch of residues in R0RBR for binding and rather, CSPs seen in R0RBR residues
379-395 are likely the result of an allosteric structural change. Structures of the isolated
IBR domain show little structure in the C-terminal portion of the bent helix H3 (Beasley
et al., 2007) which is in contrast to the UblR0RBR crystal structures that show a welldefined bent helix. Taken together, this data suggests that pUb binding results in an
increase in movement and loss of structure near the C-terminus of RING1 helix H3 and at
the beginning of the IBR domain.
Chemical shift changes seen in residues 379-395 that form the flexible linker
between IBR and RING2 as well as residues at the junction of the C-terminus of helix H3
and the IBR domain were later confirmed to be the result of structural changes in parkin.
Specifically, the bent RING1 helix H3 straightens when pUb binds as seen in crystal
structures of the pUb-parkin complexes (Kumar et al., 2017; Wauer et al., 2015).
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Figure 3.17 pUb binding causes allosteric changes in R0RBR. (A) Selected TROSY 1H-15N HSQC
NMR spectral regions of 13C15N2H-labelled R0RBR in the absence (black contours) and presence of 1
equivalent of 12C14N2H-labelled pUb (blue contours). Resonances for residues in the R0RBR linker located
between IBR and RING2, including residues 379-395, are distal from the pUb binding site yet experience a
change in chemical shift upon pUb binding. Residues A379, S384 and D394 that are located in this linker
region have large CSPs and are shown here. NMR data was collected at 25°C in 25 mM HEPES, 100 mM
NaCl, 500 µM TCEP, pH 7.0 buffer.
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3.3.18 pUb binding causes displacement of the Ubl domain from parkin
The UblR0RBRS65D crystal structure shows that phosphorylation of the Ubl
domain optimises the RING0/RING1 interface for pUb binding while NMR and ITC
experiments show that pUb binding causes a structural change in the RING1 helix H3
near the IBR domain. These allosteric structural changes suggested that pUbl and pUb
cannot be bound to parkin simultaneously since the proposed sight of structural
rearrangement is adjacent to the Ubl domain. To test this hypothesis, competitive
binding experiments were performed by NMR to see if the N-terminal Ubl S65E domain
could still bind to the C-terminal R0RBR portion while Ub S65E is bound. UblS65E and
UbS65E were used as mimetics of pUbl and pUb, which are the product of PINK1 kinase
phosphorylation in the actual parkin activation pathway. 1H-13C HMQC spectra were
collected to follow side chain methyl group CSPs of 13C14N1H-labelled UbS65E alone,
with 1 equivalent of 13C15N2H-labelled R0RBR and with 1 equivalent of 12C14N2Hlabelled UblS65E added to the UbS65E and R0RBR sample. Experiments showed slowexchange chemical shift changes and considerable peak broadening in Ub S65E resonances
such as I44, A46, T6 and V70 when R0RBR was added indicating slow-intermediate
exchange and moderately tight binding. When Ubl S65E was added to the UbS65E and
R0RBR sample, there were no visible changes in Ub S65E chemical shifts or peak
intensities suggesting that UbS65E remained bound to R0RBR (Figure 3.18A). TROSY
1

H-15N HSQC spectra of the same samples were collected to follow amide resonances in

13 15

C N2H-labelled R0RBR and showed that the addition of Ubl S65E to the UbS65E-R0RBR

sample produced no further CSPs in R0RBR (Figure 3.18B), indicating that Ubl S65E can
no longer bind to R0RBR while UbS65E is bound. Taken together, these results were the
first to suggest that pUb binding causes the release of pUbl from parkin. This would also
indicate that activation of parkin through pUb binding would prevent re-engagement with
the Ubl domain until pUb is released.
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Figure 3.18 pUb binding displaces the Ubl domain from R0RBR. (A) (Top) Selected regions of 1H-13C
HMQC spectra for 13C14N1H-labelled UbS65E alone (black contours) and with 1 equivalent of R0RBR
(orange contours). Boxes show the position of the bound UbS65E signal upon R0RBR binding visible at
lower contour levels. (Bottom) The same sample following the addition of 1 equivalent of unlabelled
UblS65E (magenta contours) shows no change in the intensities or position of the bound Ub S65E signals
indicating that UbS65E is still bound to R0RBR in the presence of UblS65E. (B) (Left) TROSY 1H-15N HSQC
spectra for 13C15N2H-labelled R0RBR alone (black contours) and with 1 equivalent of UbS65E (orange
contours). Many CSPs are seen in R0RBR indicating that UbS65E is bound. (Right) The same sample
following the addition of 1 equivalent of unlabelled Ubl S65E (magenta contours) shows no change in the
intensities or position of the UbS65E-bound R0RBR signals indicating that the UblS65E is unable to bind to
R0RBR in the presence of UbS65E.
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3.4 Discussion
3.4.1 A molecular model for parkin inhibition and activation
Parkin autoinhibition and activation has been well-studied and structural
explanations discovered here are in good agreement with literature. The Ubl domain
plays a key role in regulating parkin activity by having an autoinhibitory effect when
present (Chaugule et al., 2011). The catalytic cysteine C431 is occluded by the
RING0/RING2 interactions (Riley et al., 2013; Trempe et al., 2013; Wauer and
Komander, 2013) and a REP helix blocks the E2 binding site on RING1 (Trempe et al.,
2013). Comparing the structures of UblR0RBR, UblR0RBR S65D and R0RBR shows no
observable change in the environment around the catalytic C431 which indicates that
phosphorylation and release of the Ubl domain are events that activate parkin through
means other than by altering the C431 environment. CSP experiments of R0RBR
binding to pUb complement this finding by showing minimal chemical shift changes for
residues in this region and indicate that parkin does not undergo any large structural
change that exposes C431 upon pUb binding (Figure 3.13). Heteronuclear NOE data
shows that pUb binding does not affect rigidity of the repressor helix blocking the E2
binding site on RING1 (Figure 3.16), suggesting that pUb binding does not cause release
of the occluding interaction. Rather, results here suggest that pUb works to activate
parkin through relief of autoinhibition caused by the Ubl domain (Figure 3.18).
The discovery of such autoinhibition has driven efforts to uncover activators of
parkin such as the upstream kinase PINK1 (Clark et al., 2006; Park et al., 2006). PINK1
phosphorylates both Ub and parkin Ubl domain at residue S65 leading to the activation of
parkin ubiquitination activity (Kondapalli et al., 2012; Kane et al., 2014; Kazlauskaite et
al., 2014; Koyano et al., 2014). Until now, a molecular basis for parkin activation by
PINK1 has been unknown. Based on our structural, biochemical and biophysical
approaches, we present a mechanistic model of parkin inhibition and allosteric activation
(Figure 3.19). First, parkin rests in the autoinhibited state while engaged in
intramolecular interactions to the Ubl domain. PINK1 then phosphorylates both Ub and
the Ubl domain to induce a remodelling of the RING0/RING1 hinge interface composed
of K151, H302 and R305 responsible for interaction with the phosphate on pUb (Figure
3.8). pUb can then bind to this basic patch with high affinity (K d 17 ± 5 nM) (Ordureau

110

et al., 2014), which is more than a 10-fold increase in affinity compared to when the Ubl
phosphorylation signal is not present (Kd 160 ± 29 nM). This pUb binding leads to an
entropically-favoured (Table 3.4) allosteric structural change in the RING1 helix H3
validated by CSPs seen in distal regions from the pUb binding (Figure 3.17). Two recent
crystal structures showing pUb bound to R0RBR parkin (Wauer et al, 2015) and
UblR0RBR parkin (Kumar et al., 2017) confirm our pUb-R0RBR structure and show that
the observed entropically-driven structural change is due to straightening of the RING1
helix H3. pUb binding leads to release of the autoinhibitory Ubl domain and exposure of
the E2-Ub binding surface for enhanced recruitment of the E2-Ub conjugate. A recent
crystal structure of E2-Ub bound to RBR E3 ligase pUb-HOIP strengthens the hypothesis
that the E2-Ub will be oriented to bind this pocket (Lechtenberg et al., 2016). Although
there is still some debate over the order of events, phosphorylation of both Ub and Ubl
enhances activation of parkin and both are likely major mechanisms of parkin regulation.
For example, parkin can be phosphorylated by PINK1 in the absence of pUb, but the
addition of pUb enhances parkin phosphorylation, suggesting that pUb-parkin is a better
substrate for PINK1 (Kazlauskaite et al., 2015). At the same time, when the only
ubiquitin source is non-phosphorylatable UbS65A, parkin is still phosphorylatable
(Ordureau et al., 2015). Finally, another study shows that parkin associates tightly with
ubiquitin chains only when both ubiquitin and parkin are phosphorylated (Ordureau et al.,
2014), proposing that both phosphorylation signals are a part of a feed-forward
mechanism.
3.4.2 Parkin mutations and Parkinson’s disease
The mechanistic model for pUb-induced activation of parkin proposed here
involves an autoinhibited structure, numerous binding sites and structural changes. The
multiple steps that lead to parkin activation explain why ARJP mutations have different
effects on parkin activity. The model presented here provides important insights into
parkin regulation that will be key to designing therapeutics that can control the activity of
parkin and may be useful in the treatment of hereditary forms of Parkinson’s disease.
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Figure 3.19 Model for parkin inhibition and activation. (1) Inhibition: Parkin is autoinhibited in the
absence of pUb. PINK1 activation leads to phosphorylation of S65 in both parkin and Ub. (2)
Optimisation: Parkin phosphorylation stabilizes the flipped-out conformation of H302, thus optimising the
pUb binding site. (3) Release: pUb binds to the optimised RING0/RING1 hinge, leading to a structural
change near the RING1/IBR interface and displacement of the Ubl domain. (4) Engagement: The Ub and
E2 binding surfaces uncovered by displacement of the Ubl domain engage with charged E2-Ub conjugate
poised for ubiquitin transfer. The yellow box represents the REP repressor that blocks the E2 binding site
on RING1.
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Chapter 4
THE CLOSED UBCH7-UBIQUITIN CONJUGATE UNDERGOES
REARRANGEMENT FOR LOADING ONTO ACTIVATED PARKIN IN AN OPEN
CONFORMATION
4.1 Introduction
Parkin RBR E3 ubiquitin-ligase autoinhibition and activation is highly regulated
whereby the malfunctioning of these steps is attributed with autosomal recessive juvenile
parkinsonism (ARJP ) (Kitada et al., 1998). Parkin adopts an autoinhibited conformation
mediated by the Ubl domain (Kumar et al., 2015), the presence of a repressor REP linker
blocking the RING1:E2 binding site and by occlusion of the catalytic C431 through
RING0/RING2 interactions (Riley et al., 2013; Trempe et al., 2013; Wauer and
Komander, 2013). Previous work has shown that PINK1 phosphorylation of both parkin
and Ub at S65 activate parkin (Kondapalli et al., 2012; Shiba-Fukushima et al., 2012;
Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014). Studies propose that
activation is done through relief of Ubl association and movement of RING1 helix H1
leading to the emergence of a E2-Ub binding surface (Kumar et al., 2015). However,
structural insights into relief of the catalytic C431 occlusion and RING1:E2 binding site
occlusion are still unknown in addition to how the E2-Ub conjugate interacts with parkin.
The goal of this research was to determine how parkin recognises E2-Ub. We
confirmed that pUb binding opens a RING1/IBR pocket to allow E2-Ub engagement with
parkin by determining the crystal structure of pUb-UblR0RBR and an NMR structure of
pUb-R0RBR bound to UbcH7-Ub. UbcH7-Ub was found to have a closed conformation
in solution that undergoes rearrangement to bind parkin in an open conformation. This
binding was able to bypass REP occlusion of the RING1:E2 binding site and cause
rearrangment around the RING0/RING2 interface occluding the catalytic C431.
Furthermore, we were able to associate parkin certain ARJP variants with disease by
determining the effects of ARJP variants on parkin activity.
*Sections of this chapter have been taken from the following published paper:
Kumar, A., Chaugule, V.K., Condos, T.E.C., Barber, K.R., Johnson, C., Toth, R.,
Sundaramoorthy, R., Knebel, A., Shaw, G.S., and Walden, H. (2017). Parkinphosphoubiquitin complex reveals cryptic ubiquitin-binding site required for RBR ligase
activity. Nature Structural and Molecular Biology 24(5), 475-483.
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4.2 Materials and Methods
4.2.1

Source of materials
BL21(DE3) E.coli cells containing human His-SUMO-tagged parkin UblR0RBR

(residues 1-465) and human His-SUMO-tagged parkin Ubl (residues 1-76) in pETSUMO plasmids were obtained from Dr. Helen Walden (University of Dundee,
Scotland). BL21(DE3) E.coli cells containing Drosophila melanogaster His-SUMOtagged parkin RING2 (residues 410-482) in pET-SUMO plasmids were obtained from
Emmy Sun (University of Western Ontario, Canada). BL21(DE3)CodonPlus-RIL E.coli
cells containing non-cleavable human His-tagged Uba1 in a pET3a plasmid were
obtained from Dr. Hong Ling (University of Western Ontario, Canada). pUblR0RBR
protein was synthesised by Dr. Atul Kumar for use in SEC experiments. All other
proteins were obtained in plasmids as in sections 2.2.1 and 3.2.1. Ubl, R0RBR and
RING2 will be the nomenclature used to describe the truncated forms of parkin described
above while UblR0RBR will be used to describe full-length parkin used in this chapter.
4.2.2 Mutagenesis of UbcH7C17S/C86K/C137S, UbA0C and parkin variants
A C86K substitution was made to the catalytic cysteine of UbcH7 C17S/C137S. All
UbcH7 constructs used in this chapter were UbcH7 C17S/C86K/C137S unless otherwise stated.
As well, an A0C substitution was incorporated into Ub just before the N-terminal starting
sequence, and full-length parkin UblR0RBR constructs (residues 1-465) with ARJP
(T240R, R271S, N273S, R402C) and non-ARJP (R314A, P335G/C337G, W403A)
variants were generated. Each mutation was incorporated using the same protocol in
section 3.2.2. Forward and reverse primers were designed containing the desired
mutations (Table 4.1).
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Table 4.1 Mutagenesis primers for UbcH7C17S/C86K/C137S, UbA0C and parkin variants.
DNA Template Mutation
Primer Sequence
UbcH7C17S/C137S C86K
Forward: 5’- cgaaaaggggcaggtcaaactgccagtaattagtgc - 3’
Reverse: 5’- gcactaattactggcagtttgacctgccccttttcg - 3’
Ub
A0C
Forward: 5’- gtacttccaatccaattgcatgcaaattttcgtc - 3’
Reverse: 5’ - gacgaaaatttgcatgcaattggattggaagtac - 3’
UblR0RBR
T240R*
Forward: 5’- cggaacatcacttgcattcggtgcacagacgtcaggagccccg - 3’
Reverse: 5’ - cggggctcctgacgtctgtgcaccgaatgcaagtgatgttccg - 3’
UblR0RBR
R271S*
Forward: 5’- atactgtgtgacaagcctcaatgatcgg - 3’
Reverse: 5’ - ccgatcattgaggcttgtcacacagtat - 3’
UblR0RBR
N273S*
Forward: 5’- gtgacaagactcagcgatcggcagtttg - 3’
Reverse: 5’ - caaactgccgatcgctgagtcttgtcac - 3’
UblR0RBR
R314A
Forward: 5’- gagcagtacaacgcgtaccagcagtatg - 3’
Reverse: 5’ - catactgctggtacgcgttgtactgctc - 3’
UblR0RBR
P335G/C337G Forward: 5’- ggcgtgttatgcccccgcggtggtggtggagcggggctgctgccg - 3’
Reverse: 5’ - cggcagcagccccgctccaccaccaccgcgggggcataacacgcc -3’
UblR0RBR
R402C*
Forward: 5’- gccgagcaggcttgttgggaagcagcc - 3’
Reverse: 5’ - ggctgcttcccaacaagcctgctcggc - 3’
UblR0RBR
W403A
Forward: 5’- gccgccgagcaggctcgtgcggaagcagcctccaaagaaacc - 3’
Reverse: 5’ - ggtttctttggaggctgcttccgcacgagcctgctcggcggc - 3’
R0RBR
W403A
Forward: 5’- gccgccgagcaggctcgtgcggaagcagcctccaaagaaacc - 3’
Reverse: 5’ - ggtttctttggaggctgcttccgcacgagcctgctcggcggc - 3’
*ARJP variant
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4.2.3 Expression and purification of UbcH7C17S/C86K/C137S
Unlabelled UbcH7 in BL21(DE3)CodonPlus-RIL cells were grown in LB media,
while

12 15

C N1H-labelled UbcH7 growths were performed in M9 minimal media

supplemented with 1 g 15NH4Cl. Unlabelled and non-deuterated-labelled expressions/
purifications were performed according to the protocol in section 2.2.2.
12 14

C N2H-labelled and 12C15N2H-labelled UbcH7 in BL21(DE3)CodonPlus-RIL

cells were grown in D2O M9 minimal media supplemented with 2 g 12C2H-D-glucose, 1 g
15

NH4Cl or 1 g 14NH4Cl isotopes. Expression and purifications were performed using the

same protocol in section 3.2.5, but with the following changes: growth media contained
kanamycin and chloramphenicol while expression was induced with 0.7 mM IPTG at
16°C for 12 hours.
4.2.4 Expression and purification of Ub and Ub A0C
Unlabelled Ub and UbA0C in BL21(DE3)CodonPlus-RIL cells were grown in LB
media. Unlabelled expressions and purifications were performed according to the
protocol in section 3.2.5.
12 14

C N2H-labelled Ub was expressed and purified using the same protocol as in

section 3.2.5. Selective-labelling was used to express Ub so that it was 12C14N2H-labelled
but with the side-chain terminal methyl groups of valine, isoleucine and leucine residues
being 13C1H-labelled (Goto et al., 1999). This 13C1H-VIL 12C14N2H-labelled Ub was
expressed and purified using the protocol in section 3.2.5, but with the following
exceptions: cells were grown in 100% D2O media containing 1 g 14NH4Cl and 2 g 12C2HD-glucose isotopes until an OD600 reached 0.5 when 50 mg/L 13C4 3,3-D2 α-ketobutyric
acid and 85 mg/L 13C5 3-D1 α -ketoisovaleric acid were added. Cells continued to grow
until the OD600 reached 0.8 when expression was induced with 0.5 mM IPTG at 37°C for
8 hours.
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4.2.5 Expression and purification of parkin constructs and variants
Unlabelled, 13C15N2H- and 12C14N2H-labelled R0RBR in BL21(DE3) cells were
expressed and purified using the protocol in section 3.2.3. All other parkin constructs
and variants were expressed and purified using same protocol but with the following
exceptions. Unlabelled UblR0RBR, UblR0RBR T240R, UblR0RBR R271S, UblR0RBR
N273S

, UblR0RBR R314A, UblR0RBR P335G/C337G, UblR0RBR R402C and UblR0RBR W403A

expression was induced with 25 µM IPTG and the final Superdex 75 size-exclusion
column was not used. Unlabelled Ubl expression was induced with 0.5 mM IPTG and no
ZnCl2 was added to growths because the Ubl domain does not coordinate Zn 2+ ions.
12 15

C N1H-labelled RING2 and R0RBRW403A in BL21(DE3) cells were grown in

M9 minimal media supplemented with 15NH4Cl isotopes. Growths were supplemented
with kanamycin at 37°C until an OD600 of 0.8 was reached and expression was induced
with 0.5 mM IPTG for RING2 or 0.1 mM IPTG for R0RBR W403A at 16°C for 8 hours. 1
mL 0.5 mM ZnCl2 was also added to each 1 L flask of R0RBRW403A upon induction.
4.2.6 Expression and purification of Uba1
Unlabelled His-tagged Uba1 in BL21(DE3)CodonPlus-RIL cells was grown in
LB media for use in ubiquitination assays and later synthesis of the stable UbcH7-Ub
isopeptide-linked conjugate. Growths contained ampicillin and chloramphenicol. Cells
were grown at 37°C to an OD600 of 0.8. After turning the temperature down to 16°C and
waiting 20 minutes, expression was induced with 0.5 mM IPTG at 16°C for 12 hours.
Cells were harvested by centrifugation at 6000 × g for 10 minutes and resuspended in 50
mM Tris, 200 mM NaCl, 250 μM TCEP, 25 mM imidazole, pH 8.0 buffer. Cells were
lysed in the presence of protease inhibitor using an Avestin EmulsiFlex-C5 homogenizer
and were further centrifuged at 148,230 × g for 70 minutes. The supernatant was
collected and His-tagged Uba1 was purified on a HisTrap FF column by batch-binding
and washing with 50 mM Tris, 200 mM NaCl, 250 μM TCEP, 25 mM imidazole, pH 8.0
buffer. 5% and 17.5% of elution buffer that contained 50 mM Tris, 200 mM NaCl, 250
μM TCEP, 250 mM imidazole at pH 8.0 was used to further wash the batch-bound Histagged Uba1. The His-tagged Uba1 was then eluted with 100% elution buffer and was
collected for experimental use. Purity was monitored by SDS-PAGE.
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4.2.7 Expression and purification of PINK1
Unlabelled GST-tagged PINK1 was expressed and purified using the same
protocol in section 3.2.6.
4.2.8 pUb and pUbl formation and purification
Unlabelled and 12C14N2H-labelled pUb was synthesised using unlabelled or
labelled Ub that was purified as in section 3.2.5 and the optimised protocol for pUb
synthesis in section 3.3.6. Unlabelled pUbl was synthesised using unlabelled Ubl that
was purified as in section 3.2.4 and the optimised protocol for pUb synthesis shown in
section 3.3.6.
4.2.9 UbcH7-Ub isopeptide-linked conjugate formation and purification
Assays to optimise the formation of UbcH7-Ub isopeptide-linked conjugate were
performed. Conditions that were manipulated included reaction time, buffer type,
temperature, pH as well as concentrations of Mg2+/ATP, Ub, UbcH7C17S/C86K/C137S and
Uba1. All UbcH7-Ub conjugates used in this chapter were isopeptide-linked.
The optimised protocol for UbcH7-Ub isopeptide-linked conjugate formation is as
follows. 200 µM His-tagged Ub, 400 µM UbcH7C17S/C86K/C137S, 25 µM His-tagged Uba1
and 10 mM Mg2+/ATP were added together in 50mM CHES, 150 mM NaCl, pH 9.0
buffer. The pH was slowly adjusted to 9.0 using 1 M NaOH and the sample mixture was
then incubated at 37°C for 6-16 hours. UbcH7 is the limiting reagent and the final
reaction results in 50% of it being conjugated.
UbcH7-Ub isopeptide-linked conjugate was purified from the above mixture
using the following protocol. The reaction mixture was dialysed against 2 L of 50 mM
Tris, 200mM NaCl, 250 µM TCEP, pH 8.0 at 4°C for 2 hours. The mixture was first
purified on a HisTrap FF column using the protocol in section 2.2.2 to eliminate
unconjugated UbcH7 from the mixture because it is the only protein without a His-tag.
Next, the eluted His-tagged proteins were TEV-cleaved and dialysed using the protocol
in section 2.2.2. Uba1 contains a non-cleavable His-tag, therefore free His-tagged Ub
and conjugated His-tagged Ub are the only proteins that get cleaved. After TEVcleavage and dialysis, the protein mixture was purified on a second HisTrap FF column
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using the protocol in section 2.2.2. His-tagged Uba1 sticks to the column while untagged
UbcH7-Ub and Ub flow through. The flowthrough was collected and UbcH7-Ub was
purified from the lower molecular weight of Ub on a HiLoad Superdex 16/60 sizeexclusion column using 25 mM HEPES, 100 mM NaCl, 500 µM TCEP, pH 7.0 buffer, a
0.3 mL/min flow rate and collecting 2 mL fractions. Integrity and purity of isopeptidelinked UbcH7-Ub was assessed by mass spectrometry and SDS-PAGE.
4.2.10 SEC of parkin binding to pUb, Ub, UbcH7 and UbcH7-Ub
50 µl samples containing 40 µM R0RBR, UblR0RBR or pUblR0RBR with 40
µM pUb, Ub, UbcH7 or UbcH7-Ub were prepared in 20 mM Tris, 75 mM NaCl, 250 µM
TCEP, pH 8 buffer and loaded onto a Superdex 75 10/300 size-exclusion column. Runs
were performed with a 0.5 mL/min flow rate while collecting 1 mL fractions. Elution
profiles were verified by SEC-MALS and SDS-PAGE.
4.2.11 ITC of R0RBR variants binding to Ub, UbcH7 and UbcH7-Ub
ITC experiments were performed on either a Microcal VP-ITC system (GE
Healthcare) or a Nano ITC system (TA Instruments) using the same protocol as in section
3.2.9.

4.2.12 NMR spectroscopy setup and processing
All NMR data was collected, processed and analysed using the same parameters
and protocols in section 3.2.11 with the following additions. 1H-15N HSQC spectra were
collected in TROSY mode (Pervushin et al., 1997) or non-TROSY mode (Kay et al.,
1992) to follow amide backbone chemical shift pertubations (CSPs) as noted in Table
4.2. UbcH7 spectral windows were 8000.0 Hz centred on 4.780 ppm for 1H and 1700.0
Hz centred on 118.0 ppm for 15N.
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4.2.13 NMR of pUb-R0RBR interactions with Ub, UbcH7 and UbcH7-Ub
TROSY 1H-15N HSQC spectra were collected in variations of selectively-labelled
pUb-R0RBR or R0RBR with selectively-labelled Ub, UbcH7 and UbcH7-Ub. 1H-13C
HMQC spectra were collected using conjugated and unconjugated 13C1H-VIL 12C14N2H
Ub with selectively-labelled pUb-R0RBR. CSP analysis was performed on amide
backbone and side chain methyl groups to determine ambiguous restraints used for
docking UbcH7-Ub to pUb- R0RBR. CSPs used for docking were mapped to the docked
pUb-R0RBR:UbcH7-Ub complex computed in section 4.2.14 using PyMOL (Delano,
2002). A list of all NMR experiments performed can be found in Table 4.2.

Table 4.2 NMR experiments for pUb-R0RBR:UbcH7-Ub structure determination. All experiments were performed at 25°C in 25 mM HEPES, 50 mM
NaCl, 500 µM TCEP pH 7.0 buffer with 10% D2O (v/v) and DSS as an internal reference on a Varian Inova 600 MHz NMR spectrometer. Experiments were
run in either TROSY or non-TROSY mode, as noted. All pUb-R0RBR samples here were purified as a 1:1 complex on a Superdex 75 size-exclusion column as
in section 3.2.8. All UbcH7 constructs were UbcH7C17S/C86K/C137S unless stated otherwise. All pUb moieties were 12C14N2H-labelled.
13 15 2
12 14 2
12 14 2
12 14 2
12 14 2
12 15 2
13 1
Experiment
C N H 13C15N2H
C NH
C NH
C N H UbcH7–
C NH
C NH
C H-VIL 12C14N2H
13 1
12 14 2
R0RBR
pUb-R0RBR pUb-R0RBR UbcH7-Ub
Ub C H-VIL C N H
UbcH7
UbcH7-Ub Ub
1 -15
H N HSQC
150 µM
1 -15
H N HSQC
150 µM
450 µM
1 -15
H N HSQC
150 µM
1 -15
H N HSQC
150 µM
150 µM
1 -15
H N HSQC
210 µM
1
H-13C HMQC
210 µM
1 -15
H N HSQC
210 µM
210 µM
1
H-13C HMQC
210 µM
210 µM
1 -15
H N HSQC
210 µM
420 µM
1
H-13C HMQC
210 µM
420 µM
1 -15
H N Cross-Sat**
210 µM
420 µM
1 -15
H N HSQC
175 µM
1 -15
H N HSQC
175 µM
88 µM
1
H-13C HMQC
175 µM
88 µM
1 -15
H N Cross-Sat**
175 µM
88 µM
1 -15
H N HSQC
175 µM
175 µM
1
H-13C HMQC
175 µM
175 µM
1 -15
H N Cross-Sat**
175 µM
175 µM
1
H-13C HMQC
175 µM
1 -15
H N HSQC
105 µM
1 -15
H N HSQC
105 µM
105 µM
1 -15
H N HSQC
210 µM
105 µM
*
Collected in non-TROSY mode
**
Performed in duplicate
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Table 4.2 (continued)
13 15 2
C N H 12C15N1H
Experiment
R0RBR
R0RBRW403A
1 -15
H N HSQC
150 µM
1 -15
H N HSQC*
150 µM
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
1 -15
H N HSQC*
*
Collected in non-TROSY mode
**
Performed in duplicate

12

C15N1H
RING2

12

C14N1H
pUbl

200 µM
200 µM
200 µM
200 µM
200 µM
200 µM
200 µM
200 µM

12

C14N1H
UbcH7

12

C15N1H
UbcH7C17S/C137S

12

C15N2H
UbcH7

12

C15N2H
UbcH7-Ub

12

C15N2H
Ub

12

C14N1H
Ub

400 µM
800 µM
1200 µM
400 µM
800 µM
1200 µM
200 µM
400 µM
600 µM

200 µM
200 µM
200 µM
200 µM
200 µM
200 µM
200 µM
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4.2.14 HADDOCK of pUb-R0RBR and UbcH7-Ub binding
Interacting residues determined while following pUb-R0RBR and UbcH7-Ub
amide backbone resonance CSPs during NMR experiments were defined as those that
shifted greater than the average +1 standard deviation and had greater than 20% side
chain accessible surface area. Several interacting residues were determined by
mutagenesis and ubiquitination assays. Passive residues that neighboured active residues
were included as interacting residues and were defined as having greater than 20% side
chain accessible surface area as well as having a noticeable chemical shift change. A full
list of restraints used for docking is shown in Table 4.3.
UbcH7 and Ub were docked to pUb-R0RBR sequentially in HADDOCK
(Dominguez et al., 2003) using 1 unambiguous restraint to position the C-terminal G76 of
Ub in proximity to the catalytic C86K of UbcH7. The coordinates from the crystal
structure of pUb-UblR0RBR (PDB ID code 5N2W) were used for docking after removal
of the Ubl domain and adjoining linker coordinates. R0RBR REP linker residues (387405) occluding the RING1 binding site were moved on average 5.3 Å in PyMOL
(Delano, 2002) in order to facilitate UbcH7 docking. Missing regions in the R0RBR
coordinates were modelled-in using the Modeller (Eswar et al., 2006) plug-in for UCSF
Chimera (Pettersen et al., 2004). Ub coordinates (PDB ID code 1UBQ) (Vijay-Kumar et
al., 1987) were used as well as UbcH7 coordinates isolated from the OspG:UbcH7-Ub
crystal structure (PDB ID code 4Q5E) (Grishin et al., 2014). An upper distance limit of
4.0 Å was set for ambiguous distance restraints while the unambiguous distance restraint
was set to 6.8 Å. Standard parameters were used except inter_rigid (0.1) which was set
to allow tight packing of the proteins, and the unambiguous force constants were
increased by five-fold compared to the ambiguous constants. A total of 1,000 initial
complexes were calculated and the best 100 structures were water-refined.
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Table 4.3 HADDOCK restraints for pUb-R0RBR:UbcH7-Ub docking. Restraints were determined
using NMR CSP analysis and mutagenesis data.
Restraint Type Experiment pUb-R0RBR
UbcH7
Ub
Ambiguous
NMR CSPs
T242 L266 T270 Q276 A291
K9 A59 E60
G292 Q389 A390 Y391 R392 F63 K64 E93
V393 D394 R396
N94 K96 A98
Ambiguous
Mutagenesis T240
Ambiguous
NMR CSPs
Q276 V330 L331 R366 A379
F4 T7 L8 T9 G10
V380 F381 E382 A383 S384
I13 E34 I36 V70
G385 T386
L71 L73 G75 G76
Ambiguous
Mutagenesis R275* R314 Y318* E321*
R334* P335 C337
Unambiguous
C86K atom CA
G76 atom CA
*Restraints determined by Dr. Viduth Chaugule

127

4.2.15 Ubiquitination assays of ARJP parkin variants
A maleimide-containing fluor DyLight800 was attached to UbA0C using the
Thermo Fisher Scientific protocol for DyLight Sulfhydryl-Reactive Dyes to make Ub A0C800

. Ubiquitination assays were performed in triplicate using the following reagents: 1

µM E1 Uba1, 5 µM E2 UbcH7C17S/C137S, 5 µM E3 UblR0RBR or variants, 40 µM Ub, 10
µM UbA0C-800 and 5 mM Mg2+/ATP. E3 ARJP and non-ARJP variants assayed were
UblR0RBR T240R, UblR0RBR R271S, UblR0RBR N273S, UblR0RBR R314A, UblR0RBR
P335G/C337G

, UblR0RBR R402C and UblR0RBR W403A. Each reaction was performed either

in the absence or presence of 5 µM pUb. Reactions were run for 30 minutes at 30°C in
50 mM HEPES, pH 7.4 buffer and were quenched with SDS/DTT when complete.
Assays were visualized by SDS-PAGE and on a LI-COR Odyssey Classic imaging
system at 800 nm. Images were processed in ImageJ (Schneider et al., 2012).
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4.3 Results
4.3.1 UbcH7C17S/C86K/C137S, UbA0C and parkin variants were synthesised
The study of parkin and UbcH7-Ub interactions requires reducing conditions in
order to eliminate the possibility of disulphide bridges forming between cysteine-rich
parkin molecules. For this reason, the disulphide-linked UbcH7-Ub conjugate used
previously was replaced with a more stable isopeptide-linked UbcH7-Ub conjugate for all
parkin interaction studies. A C86K substitution was made to the catalytic cysteine of
UbcH7C17S/C137S to enable the formation of an isopeptide-bond between C86K of UbcH7
and the C-terminal G76 of Ub during later conjugate synthesis. This E2 substitution has
been used successfully to form other E2-Ub isopeptide-linked conjugates for interaction
studies with other E3s (Plechanovova et al., 2012).
In order to track ubiquitination activity of parkin in later assays, Ub was later
tagged with a fluor. DyLight800 is a maleimide-containing fluor that reacts with
sulfhydryl groups of target compounds to form a stable thioether-conjugated bond. Ub
requires a free cysteine for conjugation to occur and therefore a A0C substitution was
incorporated into Ub just before the N-terminal starting sequence.
Several UblR0RBR constructs with ARJP and non-ARJP variants positioned at
the proposed UbcH7-Ub binding interface were generated to follow their effects on
ubiquitination activity: T240R, R271S, N273S, R314A, P335G/C337G, R402C and
W403A. A R0RBRW403A construct was created for NMR studies as well. Sequencing
results verified that QuikChange Site-Directed Mutagenesis and PCR successfully
incorporated each substitution with the previously described primers (Table 4.1).
4.3.2 UbcH7C17S/C137S and UbcH7C17S/C86K/C137S were expressed and purified
Unlabelled and 12C15N1H-labelled UbcH7C17S/ C137S as well as unlabelled,
12 14

C N2H- and 12C15N2H-labelled UbcH7C17S/C86K/C137S were successfully purified as

monitored in section 2.3.1. Unlabelled UbcH7C17S/C137S was later used for ubiquitination
assays and ITC while unlabelled UbcH7C17S/C86K/C137S was used for ITC, size-exclusion
chromatography (SEC) and one NMR experiment. Labelled UbcH7 C17S/ C137S as well as
labelled UbcH7C17S/C86K/C137S were later used for NMR experiments.
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4.3.3 Ub and UbA0C were expressed and purified
Unlabelled Ub and UbA0C were successfully purified as monitored in section 3.3.4
and were later used for SEC, ITC, ubiquitination assays and NMR experiments.
12 14

C N2H-labelled Ub and 13C1H-VIL 12C14N2H-labelled Ub were successfully purified as

monitored in section 3.3.4 and were later used for NMR experiments.
4.3.4 Parkin constructs and variants were expressed and purified
The following unlabelled full-length parkin constructs (residues 1-465) were
successfully purified, monitored by SDS-PAGE as seen by the expected band around
51.6 kDa in Figure 4.1, and verified by mass spectrometry for later use in SEC and
ubiquitination assays: UblR0RBR 51,642.87 Da, UblR0RBR T240R 51,699.72 Da,
UblR0RBRR271S 51,572.88 Da, UblR0RBRN273S 51,616.93 Da, UblR0RBRR314A
51,556.69 Da, UblR0RBRP335G/C337G 51,556.42 Da, UblR0RBRR402C 51,589.79 Da and
UblR0RBRW403A 51,528.81 Da (Figure 4.2). Unlabelled R0RBR (parkin residues 141465) was successfully purified for later use in SEC and ITC experiments as monitored in
section 3.3.2. Unlabelled Ubl (parkin residues 1-76) was successfully purified for later
use in NMR experiments as monitored in section 3.3.3.
12 15

C N1H-labelled RING2 (Drosophila parkin residues 410-482) was successfully

purified for later use in NMR experiments. Purity was monitored successfully by SDSPAGE as seen by the expected band around 8.3 kDa (Figure 4.1).

13

C15N2H- and

12 14

C N2H-labelled R0RBR as well as 12C15N1H-labelled R0RBRW403A were successfully

purified for later use in NMR experiments as monitored in section 3.3.2.

4.3.5 Uba1 was expressed and purified
Unlabelled His-tagged Uba1 was successfully purified using a HisTrap FF
column. Purity was monitored successfully by SDS-PAGE as seen by the expected band
around 118 kDa (Figure 4.3). Unlabelled His-tagged Uba1 was used for ubiquitination
assays and later synthesis of the stable UbcH7-Ub isopeptide-linked conjugate.
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Figure 4.1 UblR0RBR and RING2 purification. (A) Unlabelled UblR0RBR was purified on a HisTrap
column followed by Ulp1-cleavage and a second HisTrap column. Purity was verified by SDS-PAGE with
the expected MW of UblR0RBR being around 51.6 kDa. (B) 12C15N1H-labelled RING2 was purified on a
HisTrap column followed by Ulp1-cleavage, a second HisTrap column and (C) a final Superdex 75 sizeexclusion column. Purity was verified by SDS-PAGE with the expected MW of RING2 being around 8.3
kDa.
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Figure 4.2 Mass spectrometry of UblR0RBR variants. Integrity was verified of (A) UblR0RBR, (B)
UblR0RBRT240R, (C) UblR0RBRR271S, (D) UblR0RBRN273S, (E) UblR0RBRR314A, (F) UblR0RBRP335G/C337G,
(G) UblR0RBRR402C and (H) UblR0RBRW403A by mass spectrometry as seen by the expected observed MW
peaks. Each UblR0RBR variant showed 2 additional prominent peaks with MWs of 28 Da and 56 Da
below the expected MW corresponding to the correct variant having a loss of 1 and 2 carbonyl groups
respectively.
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Figure 4.3 His-tagged Uba1 purification. Unlabelled His-tagged Uba1 was purified on a HisTrap column.
Purity was verified by SDS-PAGE with the expected MW of His-tagged Uba1being around 118 kDa.
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4.3.6 PINK1 was expressed and purified
Unlabelled GST-tagged PINK1 kinase was successfully purified as monitored in
section 3.3.5 and was later used for phosphorylation of Ub and Ubl.

4.3.7 pUb and pUbl were purified
Unlabelled pUbl and 12C14N2H-labelled pUb were successfully purified as
monitored in section 3.3.6 for use in NMR experiments. Unlabelled pUb was
successfully purified as monitored in section 3.3.6 for use in SEC, ITC and ubiquitination
assays.
4.3.8 UbcH7-Ub isopeptide-linked conjugate was formed and purified
Assays were performed in order to optimise UbcH7-Ub isopeptide-linked
conjugate formation (Figure 4.4) and a protocol was successfully developed as shown in
section 4.2.9. Assays showed that the best conditions for enzymatically forming UbcH7Ub included incubating 200 µM His-tagged Ub, 400 µM UbcH7 C17S/C86K/C137S, 25 µM
His-tagged Uba1 and 10 mM Mg2+/ATP in 50mM CHES, 150 mM NaCl, pH 9.0 buffer
at 37°C for 6-16 hours. UbcH7-Ub was purified using an initial HisTrap FF column
followed by TEV-cleavage, a second HisTrap FF column and a final HiLoad Superdex
16/60 size-exclusion column. Purity was monitored by SDS-PAGE as seen by the
expected band around 26.9 kDa (Figure 4.5). Integrity of UbcH7-Ub was confirmed by
mass spectrometry as seen by a 26,860.27 Da MW peak (Figure 4.5D). Unlabelled
UbcH7-Ub was later used for ITC and SEC while selectively labelled UbcH7-Ub
conjugates were used for NMR experiments.

Figure 4.4 UbcH7-Ub isopeptide-linked conjugate formation assays. Conditions manipulated included (A) buffer type, (B) temperature, (C) Mg2+/ATP
concentration, (D) pH, (E) His-Uba1 concentration, (F) UbcH7C17S/C86K/C137S concentration, (G) His-Ub concentration and (H) reaction time. All reactions were
performed at 37°C for 6 hours in 50mM CHES, 150 mM NaCl, pH 9 buffer with 20 µM Uba1, 50 µM UbcH7C17S/C86K/C137S, 200 µM Ub and 10 mM Mg2+/ATP
with only one of these conditions being varied as noted on each panel. Reactions were monitored by SDS-PAGE as seen by the appearance of His-tagged
UbcH7-Ub being formed at a MW of 29.9 kDa.
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Figure 4.5 UbcH7-Ub isopeptide-linked conjugate purification. (A) His-tagged UbcH7-Ub was
enzymatically conjugated as seen by the appearance of a band being formed at a MW of 29.9 kDa. UbcH7Ub was then purified on (B) a HisTrap column followed by TEV-cleavage and a second HisTrap column,
and (C) a final HiLoad Superdex 16/60 size-exclusion column. Purity was verified by SDS-PAGE with the
expected MW of UbcH7-Ub being around 26.9 kDa. (D) Integrity was verified by mass spectrometry as
seen by the observed 26,860.27 Da MW peak corresponding to isopeptide-linked UbcH7-Ub.
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4.3.9 pUb binding leads to allosteric opening of a Ub-binding pocket
The 2.7 Å crystal structure of human UblR0RBR Δ84–143 in complex with pUb
reveals the activated state of parkin comprising the five domains Ubl, RING0, RING1,
IBR and RING2 (Figure 4.6A). Comparison of activated pUb-UblR0RBR (PDB ID code
5N2W) to inactive UblR0RBR (PDB ID code 5C1Z) shows that while there are some
small rearrangements, the autoinhibitory Ubl domain remains packed against helix H3 of
RING1. The largest structural rearrangement resulting from pUb binding is the
straightening of the previously bent helix H3 in RING1 which leads to global movement
of the IBR domain by 22 Å (Figure 4.6B). Previous NMR and thermodynamic data of
pUb binding to parkin suggested that RING1 helix H3 would undergo rearrangment due
to observed CSPs and an increase in entropy of the system. These observations are
confirmed as seen in our crystal structure, as well as in the structure of Pediculus
humanus pUb-R0RBR (Wauer et al., 2015). Importantly, movement of the IBR domain
results in loosening of the Ubl/IBR interface, further affirming that pUb binding causes
release of the Ubl domain by inducing weakened Ubl interactions. Interestingly,
movement of the IBR domain induced by pUb binding also creates of a pocket in
between RING1 and IBR. Analysis of the pUb-R0RBR crystal packing showed that this
void is occupied by the Ubl domain of a neighbouring parkin molecule. Since the Ubl
domain and Ub share homology and sequence similarity, we proposed that the pocket
created by pUb-induced structural rearrangements would be the Ub binding site for the
UbcH7-Ub conjugate.
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Figure 4.6 Crystal structure of pUb-UblR0RBR. (A) Ribbon diagram of pUb-UblR0RBRΔ84–143 (PDB
ID code 5N2W) showing pUb (orange), the Ubl domain (green), RING0 (blue), RING1 (white), IBR
(cyan), repressor element (REP) (yellow) and RING2 (purple). The phosphate group on pUb is shown as
red sticks. (B) Overlay of activated pUb-UblR0RBR (coloured as in panel A) with inactive UblR0RBR
(PDB ID code 5C1Z) (grey). pUb binding causes straightening of RING1 helix H3 and a global 22 Å
movement of the IBR domain. This movement of the IBR domain leads to a loss of Ubl/IBR contacts and
an open RING1/IBR pocket for Ub binding. Panels were created using PyMol and alignment was
performed to all atoms in UblR0RBR using the align command.
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4.3.10 pUb must activate R0RBR to allow UbcH7-Ub engagement
In order to determine under what conditions UbcH7-Ub binds to parkin optimally,
SEC, ITC and NMR experiments were performed. Three constructs of parkin (R0RBR,
UblR0RBR and pUblR0RBR) were assayed in the presence and absence of pUb in order
to determine relative binding affinities to UbcH7-Ub by SEC. Results showed that
UbcH7-Ub would only co-elute with the pUblR0RBR construct and only when pUb was
present (Figure 4.7). This indicates that parkin is required to be phosphorylated at S65
and have pUb bound in order to bind to UbcH7-Ub optimally. pUb binding is necessary
because it allosterically opens a RING1/IBR pocket for Ub within the conjugate to bind
parkin however, the necessity for a phosphorylation signal at S65 on parkin was not
known, so we proposed that pUbl may be stabilizing UbcH7-Ub binding by making
contacts with UbcH7. To test this, we collected 1H-15N HSQC spectra of 12C15N1Hlabelled UbcH7C17S/C137S with unlabelled pUbl (Table 4.2). Results indicated that the
isolated pUbl domain does not interact with UbcH7, suggesting that parkin
phosphorylation at S65 functions to stabilize UbcH7-Ub binding by a different means.
To further characterise the importance of creating a pocket for Ub within the
UbcH7-Ub conjugate to bind, ITC experiments were performed to compare both pUbpUblR0RBR and pUb-pUblR0RBR E321A binding to UbcH7-Ub (Figure 4.8BC). E321A
is located on the RING1 helix H3 proposed to be a part of the binding site for Ub within
the UbcH7-Ub conjugate. Importantly, this residue is occluded by RING1/IBR
interactions in the absence of pUb binding, and is only accessible for Ub binding when
pUb activates parkin to open the RING1/IBR pocket. UbcH7-Ub bound to activated
pUb-pUblR0RBR (Kd 0.46 ± 0.03 µM) much tighter than to activated pUbpUblR0RBRE321A (Kd 9.42 ± 0.63 µM), indicating an important role for E321 binding to
Ub within the UbcH7-Ub conjugate. To ensure that this reduction in affinity was the
result of perturbing Ub binding rather than UbcH7 within the conjugate, further ITC
experiments were performed and showed that UbcH7 alone bound to both pUbpUblR0RBR (Kd 19 ± 1.3 µM) and pUb-pUblR0RBRE321A (Kd 23.5 ± 2.1 µM) with
similar affinities (Table 4.4). Together, this data suggests that Ub within the UbcH7-Ub
conjugate interacts with the RING1 helix H3 of parkin and analysis of crystal structures
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show that this site is only accessible when pUb is bound to allosterically open the
RING1/IBR pocket.
Further ITC experiments were performed to determine the affinities of inactive
R0RBR (no pUb bound) for Ub (Kd 40 ± 1 µM), UbcH7C17S/C137S (Kd 5.5 ± 0.2 µM) and
UbcH7-Ub (Kd 30 ± 3 µM) (Table 4.4). UbcH7-Ub was expected to bind tighter to
inactive R0RBR than the free UbcH7C17S/C137S and free Ub only if both moieties within
the conjugate were binding using one continuous patch with synergistic binding
contributions. However it was found that UbcH7-Ub only bound with an apparent K d
that is an averaged intermediate of the UbcH7C17S/C137S and Ub affinities, indicating that
UbcH7-Ub is likely not binding to R0RBR using one continuous binding surface. This
result affirms the importance of having pUb bound in order to allow opening of the
RING1/IBR pocket and full engagement of the UbcH7-Ub conjugate since UbcH7-Ub
binds to pUb-pUblR0RBR (Kd 0.46 ± 0.03 µM) with a much higher affinity than to
R0RBR alone.
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Figure 4.7 Parkin and UbcH7-Ub SEC elution profiles. Combinations of pUb, Ub, UbcH7 and UbcH7-Ub were run on a Superdex 75 10/300 size-exclusion
column with (A) R0RBR, (B) UblR0RBR an d (C) pUblR0RBR. The addition of pUb to all three parkin constructs results in a shift in absorbance to the left
(cyan) indicating that pUb binds tight enough to co-elute with all three constructs. UbcH7-Ub only binds tight enough to co-elute with pUb-pUblR0RBR as
shown by the additional second shift in absorbance to the left in panel C (orange) suggesting an importance for pUb and a phosphorylation signal on the Ubl
domain. The standard reference peak is the black elution profile of the unbound parkin constructs in each panel. V0 represents the void volume. (D) SDS-PAGE
gel of pUblR0RBR elution profiles showing composition of samples loaded onto the column (Load) and in the 9-11 mL (9-11) fractions. UbcH7-Ub is only
present in the 9-1l mL fractions for pUb-pUblR0RBR as denoted by *. Results were verified by SEC-MALS as measured by a large pUb-pUblR0RBR:UbcH7Ub complex of MW 87.4 kDa co-eluting.
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Figure 4.8 ITC of R0RBR constructs binding to Ub, UbcH7 and UbcH7-Ub. (A) Isotherm graphs of R0RBR with Ub (left), R0RBR with UbcH7C17S/C137S
(middle) and R0RBR with UbcH7-Ub (right). Results indicate that UbcH7-Ub binds to R0RBR with an apparent Kd that is an intermediate between Ub and
UbcH7 affinities. (B) Isotherm graphs of UbcH7 with pUb-pUblR0RBR (left) and UbcH7 with pUb-pUblR0RBRE321A (right), and (C) UbcH7-Ub with pUbpUblR0RBR (left) and UbcH7-Ub with pUb-pUblR0RBRE321A (right). Results indicate that E321 is important for conjugated-Ub binding and that this residue
does not perturb UbcH7 binding. The upper panels represent raw data, and the lower panels represent integrated heat changes performed assuming a single-site
binding model. Data was collected at 25⁰C with 50 mM HEPES, 50 mM NaCl, 250 µM TCEP, pH 7.5 buffer conditions.

Table 4.4 Thermodynamics of parkin binding to Ub, UbcH7 and UbcH7-Ub. ITC experiments were collected at 25⁰C with 50 mM HEPES, 50 mM NaCl,
250 µM TCEP, pH 7.5 buffer conditions and were performed in duplicate. Values are shown for stoichiometry (N), dissociation constant (Kd), enthalpy change
(ΔH), entropy change (ΔS) and Gibbs free energy (ΔG). Relative exchange rates determined by NMR are presented for affinity comparison. Dashed lines
indicate that data was not collected.
Cell Protein
Titrant
N
Kd
ΔH
TΔS
ΔG
NMR Exchange Rate
(μM)
(kJ/mol)
(kJ/mol)
(kJ/mol)
R0RBR
Ub
1.1 ± 0.0
40 ± 1
30 ± 1
55 ± 1
-25 ± 1
Fast
R0RBR
UbcH7C17S/C137S
1.1 ± 0.0
5.5 ± 0.2
26 ± 0
56 ± 1
-30 ± 1
Slow
R0RBR
UbcH7-Ub
1.1 ± 0.0
30 ± 3
7.6 ± 1.4
33 ± 1
-25 ± 2
Fast (Ub) and slow (UbcH7)
pUb-R0RBR
Ub
Fast
pUb-R0RBR
UbcH7-Ub
Slow (Ub) and slow (UbcH7)
pUb-pUblR0RBR
UbcH7
19±1.3*
pUb-pUblR0RBRE321A UbcH7
23.5±2.1*
pUb-pUblR0RBR
UbcH7-Ub
0.46±0.03*
pUb-pUblR0RBRE321A UbcH7-Ub
9.42±0.63*
*
Data collected by Dr. Viduth Chaugule
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4.3.11 UbcH7-Ub takes on a closed conformation in solution
CSP analysis comparing 1H-15N HSQC spectra of free 12C15N2H-labelled UbcH7
and free 12C15N2H-labelled Ub to spectra collected of their conjugated form (Figure 4.9A)
can reveal important insights into the closed, open or backbent states of UbcH7-Ub in
solution. The comparison revealed that upon conjugation, UbcH7 and Ub exhibit CSPs
that localise to a surface of interaction between the two molecules. For instance, CSPs
seen in Ub were hallmarks of the closed state localising to the hydrophobic patch (G47L50), loop L1 (T9), and C-terminal tail (V70 and R72-G76) (Figure 4.9B) while the
UbcH7 cross-over helix spanning residues K100-N113 exhibited CSPs also indicative of
the closed state (Figure 4.9C). UbcH7 also presents CSPs from residues in neighbouring
space to the catalytic C86K in loop L7 as well as H76, D80, Q116, E118, H119 and
L121, but these are due to a significant change in chemical environment from C86K
being conjugated G76 of Ub rather than from a binding interaction. Taken together,
results suggest that UbcH7-Ub takes on a closed conformation in solution.

A

B

C
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Figure 4.9 NMR shows that UbcH7-Ub takes on a closed conformation. (A) 1H-15N HSQC NMR spectra of free 12C15N2H-labelled UbcH7 (red contours),
free 12C15N2H-labelled Ub (yellow contours) and 12C15N2H-labelled UbcH7-Ub conjugate (black contours). (B) Measured Ub CSPs upon UbcH7-Ub
conjugation. CSPs were of moderate magnitude and localised to loop L1 (T9), the hydrophobic patch (G47-L50) and C-terminal tail (V70 and R72-G76). (C)
Measured UbcH7 CSPs upon UbcH7-Ub conjugation. CSPs were of moderate magnitude and localised to the crossover helix spanning residues K100-N113 as
well as to regions surrounding the catalytic C86K such as loop L7. Significant CSPs were mapped to the surfaces of both Ub and UbcH7 (PDB ID 4Q5E) in
PyMOL. CSPs seen in both UbcH7-Ub are hallmarks of the closed state. Horizontal dashed lines indicate the average CSP ± 1 standard deviation. Data was
collected at 25°C in 25 mM HEPES, 50 mM NaCl, 500 µM TCEP, pH 7.0 buffer.

145

4.3.12 UbcH7 binds to RING1 and Ub binds to the RING1/IBR pocket
In order to determine the surfaces used for interaction between pUb-R0RBR and
UbcH7-Ub, NMR titration experiments were conducted using selectively labelled pUbR0RBR with UbcH7-Ub as well as constructs of R0RBR with the individual UbcH7 or
Ub moieties in order to obtain well-defined surfaces (Table 4.2). In all NMR
experiments involving pUb-R0RBR, pUb was 12C14N2H-labelled and the complex was
co-eluted on a Superdex 75 size-exclusion column. CSP analysis of TROSY 1H-15N
HSQC NMR data showed that the addition of deuterated UbcH7-Ub to 13C15N2H-labelled
pUb-R0RBR resulted in significant line broadening and that resonance CSPs were of
moderate magnitude exhibiting slow-exchange indicative of a large complex being
formed. Resonance CSPs spanned regions of the RING1, IBR and REP linker (Figure
4.10). To specify the individual binding surface on R0RBR for UbcH7, unlabelled
UbcH7 was titrated into 13C15N2H-labelled R0RBR. Results showed that UbcH7 caused
resonance signals to become undetectable or show small CSPs around the canonical E2E3 binding site on RING1 loop L1 (C241-T242), RING1 helix H1 (L266, V269, R271L272) and RING1 Zn2+-loop L2 (A291-G292) as well as to a large portion of the REP
linker (Y391-R392, D394-R396 and A398-K408). The pUb-UblR0RBR crystal structure
and 1H-15N heteronuclear NOE data (Figure 3.16) indicate that pUb binding does not
affect placement of the highly-electrostatic autoinhibitory REP linker and rather, it
indicates that the REP still blocks the UbcH7 binding site on RING1. However, the most
pronounced CSPs upon UbcH7 binding are found in this REP region. Since CSPs are
seen in the RING1 as well, this indicates that UbcH7 is capable of moving the REP linker
in order to bind to the canonical RING1 surface. This also indicates that UbcH7 is either
making contacts directly with the REP, or causing it to be displaced completely. To
specify the individual binding surface on R0RBR for Ub, 13C1H-VIL 12C14N2H-labelled
Ub was titrated into 13C15N2H-labelled pUb-R0RBR. Overall, results showed CSPs in the
RING1/IBR pocket including RING1 helix H1 (V269, R271-L272), the straightened
RING1 helix H3 (R314, E322), IBR β1 (V330-C332 and R334) and loop L4 (F364,
R366, C368), and in the linker (A379-F381 and A383-T386). However, several of the
RING1 helix H3 resonances were broadened by prior pUb binding and were therefore
difficult to visualize in the NMR spectra. 1H -15N cross-saturation data was collected for
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all experiments using 13C1H-VIL 12C14N2H-labelled Ub with 13C15N2H-labelled pUbR0RBR in order to specify a surface on R0RBR for Ub binding, however data did not
reveal a definitive surface.
Determining surfaces on UbcH7-Ub used for binding to pUb-R0RBR was
straightforward. CSP analysis of TROSY 1H-15N HSQC NMR followed the titration of
unlabelled pUb-R0RBR into 12C15N2H-labelled UbcH7-Ub, where both UbcH7 and Ub
moieties were labelled (Figure 4.11). Significant line broadening was observed
indicative of tight binding, and resonance CSPs were of moderate magnitude.
Importantly, both UbcH7 and Ub resonances experienced slow exchange indicating that
both molecules were making tight contact with pUb-R0RBR rather than having one
molecule bind and the other “float”. CSPs observed in UbcH7 localised to the canonical
E2 surface typically used for E3 interactions including residues in the helix H1 (R6, M8K9, L11 and I14), loop L4 (A59-Y61 and F63-K64) and loop 7 (E93-N94, K96, A98 and
T101-D102). CSPs seen in UbcH7 helix H1 extended over a larger portion of the helix
than is typically seen for binding to E3s, suggesting that there may be additional pUbR0RBR contacts being made to this portion of the helix. CSPs observed in Ub localised
to a large portion of the I44 hydrophobic patch including residues in the β1-L1-β2 region
(F4-V5, T7-G10 and I13-T14), β3 (R42-L43) and β4 (Q49). CSPs also localised to a
large part of the C-terminal tail including V70-L71, L73 and G75-C76. A last notable
cluster of CSPs were noticed at the C-terminal end of helix H1 (E34 and I36). Several
1

H-13C HMQC experiments were collected of experiments using 13C1H-VIL 12C14N2H-

labelled Ub with 13C15N2H-labelled pUb-R0RBR and CSP analysis from those spectra
were used to complete the Ub surface interaction dataset.
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A

B

Figure 4.10 NMR of the pUb-activated R0RBR binding interface with UbcH7-Ub. (A) TROSY 1H-15N
HSQC NMR spectra of 13C15N2H-labelled R0RBR bound to unlabelled pUb in the absence (black contours)
and presence of 1 equivalent UbcH7-Ub where UbcH7 is 12C14N2H-labelled and Ub is 13C1H-VIL
12 14 2
C N H-labelled (purple contours). (B) Measured pUb-R0RBR CSPs upon UbcH7-Ub binding. Grey
bars indicate that the resonance was undetectable. The horizontal dashed line indicates the average CSP ±
1 standard deviation. CSPs were moderate in magnitude and exhibited slow exchange indicating a tight
affinity. pUb-R0RBR was purified as a 1:1 complex on a Superdex 75 size-exclusion column. Data was
collected at 25°C in 25 mM HEPES, 50 mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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Figure 4.11 NMR of the UbcH7-Ub binding interface with pUb-R0RBR. (A) TROSY 1H-15N HSQC NMR spectra of 12C15N2H-labelled UbcH7-Ub in the
absence (black contours) and presence of 1 equivalent 12C14N2H-labelled pUb-R0RBR (red contours). UbcH7 residues are indicated in green lettering and Ub
residues are blue. (B) Measured UbcH7-Ub CSPs upon pUb-R0RBR binding. Grey bars indicate that the resonance was undetectable. The horizontal dashed
line indicates the average CSP ± 1 standard deviation. CSPs were large and exhibited slow exchange for both UbcH7 and Ub resonances indicating a tight
affinity. pUb-R0RBR was purified as a 1:1 complex on a Superdex 75 size-exclusion column. Data was collected at 25°C in 25 mM HEPES, 50 mM NaCl, 500
µM TCEP, pH 7.0 buffer.
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4.3.13 The closed UbcH7-Ub state is released upon binding pUb-R0RBR
Close analysis of TROSY 1H-15N HSQC NMR data collected while titrating
deuterated pUb-R0RBR into 12C15N2H-labelled UbcH7-Ub (Figure 4.11) revealed
important features about UbcH7-Ub conformations when this data was compared to 1H15

N HSQC spectra collected of free 12C15N2H-labelled UbcH7, free 12C15N2H-labelled Ub

and 12C15N2H-labelled UbcH7-Ub (Figure 4.9). Initially, resonances for UbcH7 F22,
V40, N43, N56 and Q106 as well as Ub resonances for G47 and Q49 show CSPs when
UbcH7 becomes conjugated to Ub that are consistent with the closed conformation of
UbcH7-Ub. When deuterated pUb-R0RBR is titrated into this UbcH7-Ub conjugate
however, these residue resonances revert back to similar positions seen in the spectra
collected of free UbcH7 and free Ub (Figure 4.12). This finding suggests that the
surfaces that these residues comprise are no longer interacting with one-another in a
closed state, nor are they interacting with pUb-R0RBR. Rather it suggests that these
residues are experiencing chemical environments similar to those seen in free UbcH7 and
free Ub states, which is only possible if UbcH7-Ub is binding to pUb-R0RBR in an open
conformation. Figure 4.12 also shows that both UbcH7 and Ub resonances within the
conjugate experience slow exchange when binding to pUb-R0RBR indicative that both
moieties are binding to pUb-R0RBR with tight affinity. Apart from G47 and Q49, the
majority of Ub residues that interact with UbcH7 in a closed conformation also interact
with pUb-R0RBR. When bound to pUb-R0RBR, the majority of residues do not revert
back to similar chemical shifts as the free Ub state and rather they experience a new
chemical environment suggesting that these residues are interacting with pUb-R0RBR.
Overall, these results show that the closed UbcH7-Ub conjugate conformation is released
upon interaction with parkin.
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Figure 4.12 The closed UbcH7-Ub state is released upon binding to pUb-R0RBR. (A) Ribbon diagram
representations of the free and conjugated UbcH7-Ub states. (B) TROSY 1H-15N HSQC NMR spectra
were taken of free 12C15N2H-labelled UbcH7 (green contours) and free 12C15N2H-labelled Ub (cyan
contours). UbcH7 residues are labelled green and Ub residues are labelled cyan. These two labelled
moieties were then conjugated together (black contours). UbcH7 resonances for F22, V40, N43, N56 and
Q106 and Ub resonances for G47 and Q49 are perturbed upon conjugate formation and form a surface that
interacts in the closed state. UbcH7-Ub was then titrated with 0.5 equivalents (yellow contours) and 1
equivalent (purple contours) of 12C14N2H-labelled pUb-R0RBR. The same UbcH7 and Ub resonances
revert back to the free state chemical shifts suggesting that UbcH7 and Ub release interaction with oneanother and bind to pUb-R0RBR in a more open conformation. Both UbcH7 and Ub residue resonances
exhibit slow exchange indicating that both molecules interact tightly with pUb-R0RBR.
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4.3.14 pUb-R0RBR:UbcH7-Ub HADDOCK structure
In order to understand how UbcH7-Ub binds to parkin, a model for the pUbR0RBR:UbcH7-Ub complex was determined. UbcH7-Ub was successfully docked to
pUb-R0RBR in two steps by sequentially docking UbcH7 and Ub in HADDOCK using
data from NMR experiments, mutagenesis experiments and 1 unambiguous restraint from
Ub G76 to the catalytic C86K in UbcH7 (Table 4.3). The location and orientation of
UbcH7 with respect to pUb-R0RBR was similar in all 100 water-refined complexes and
the best 20 complexes had a backbone rmsd of 0.47 ± 0.07. Likewise, the location and
orientation of Ub with respect to pUb-R0RBR:UbcH7 was similar in all 100 waterrefined complexes and the best 20 complexes had a backbone rmsd of 0.71 ± 0.10.
The pUb-R0RBR:UbcH7-Ub structure shows that UbcH7-Ub takes on an open
conformation, poised for transthiolation (Figure 4.13). UbcH7 makes canonical E2-E3
contacts and Ub uses an altered version of its hydrophobic patch to position itself in a
large pocket formed by RING1, IBR and linker residues 379-386. The Ub surface used
for interaction is considered an altered form of the hydrophobic patch because loop L4
(residues F45, A46 and G47), comprising a part of the typical hydrophobic patch, makes
no contacts with R0RBR. UbcH7 contacts are seen between helix H1 to R0RBR RING1
loop L1, UbcH7 loop L4 to R0RBR RING1 helix H1, and UbcH7 loop L7 to R0RBR
RING1 Zn2+-loop L2 with additional contacts being made to the REP linker. Ub binding
is governed predominantly by contacts from β1-L1-β2 in Ub to the IBR. Interestingly,
Ub loop L1 residues T7, L8, T9 and G10 are a distinguishing feature from the Ubl
domain in parkin where the corresponding residues in Ubl are F7, N8, S9, and S10. This
variation may suggest an important guiding role for loop L1 in both Ubl and Ub binding
to parkin and account for the fact that the two proteins have overall similar tertiary
structures, yet different modes of interaction. Further contacts stabilizing Ub binding to
the R0RBR pocket are also seen between R0RBR linker residues 379-386 to the loop L1
and C-term of Ub, and between Ub loop L3 to R0RBR RING1 helices H1 and H3. An
important feature for Ub binding is the fact that the RING1/IBR pocket is only formed
when pUb is also bound to R0RBR. This confirms that parkin is activated by pUb
binding to induce a conformational change that results in the opening of this Ub binding
pocket (Kumar et al., 2017; Wauer et al., 2015).
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Figure 4.13 pUb-R0RBR:UbcH7-Ub HADDOCK structure. The surface of R0RBR (grey) is shown
binding to ribbon diagrams of pUb (orange) as well as UbcH7 (green) conjugated to Ub (cyan). UbcH7-Ub
binds in a open conformation poised for transthiolation where UbcH7 uses canonical E2-E3 interactions
and Ub binds to the RING1/IBR pocket. R0RBR residues used for ambiguous HADDOCK restraints are
highlighted green and cyan while UbcH7-Ub restraints are highlighted black. 1 unambiguous restraint was
used between the C-terminal G76 of Ub and C86K of UbcH7. R0RBR uses RING1 loop L1, RING1 helix
H1, RING1 Zn2+-loop L2 and REP to bind UbcH7 helix H1, loop L4 and loop L7 whereas R0RBR uses
RING1 helix H1, RING1 helix H3, IBR and linker residues 379-386 to bind Ub β-sheet β1, loop L1, βsheet β2, loop L3 and the C-terminal tail. The location and orientation of UbcH7 and Ub docks with
respect to R0RBR were similar in all 100 water-refined complexes and the best 20 complexes had a
backbone rmsd of 0.47 ± 0.07 for UbcH7 and 0.71 ± 0.10 for Ub.
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4.3.15 UbcH7-Ub binding alters the RING0/RING2 interface
CSP analysis of the TROSY 1H-15N HSQC NMR data of 13C15N2H-labelled pUbR0RBR with deuterated UbcH7-Ub also revealed significant chemical shift changes
around W403 and the RING0/RING2 interface in addition to the CSPs attributable to
being at the UbcH7-Ub binding interface (Figure 4.14). W403 comprises a portion of the
REP linker and is a pillar residue for packing the REP linker against RING1. It is also
located adjacent to the C-terminal V465 at the RING0/RING2 interface in crystal
structures. The W403A variant has been shown to increase parkin activity (Trempe et al.,
2013) proposed to be a result of the REP linker releasing interaction with RING1 to allow
access of the E2 to bind RING1 (Riley et al., 2013). However, the W403A variant may
also result in the disruption of the RING0/RING2 interface. To test this, we collected a
1

H-15N HSQC NMR spectrum of 12C15N1H-labelled R0RBRW403A and performed CSP

analysis using TROSY 1H-15N HSQC NMR data of 13C15N2H-labelled R0RBR as a
comparison. Many resonances were undetectable around W403A and the rest of the REP
linker as expected, and moderate-sized CSPs extended to the RING2/RING0 interface
much like the CSPs that were seen when UbcH7-Ub bound to pUb-R0RBR. Since all
structures of parkin to-date show that C431 is occluded by RING0 interactions, then it is
possible that the CSPs seen around the RING0/RING2 interface upon UbcH7-Ub binding
were reporting a conformational change to allow exposure of the catalytic C431.
Since UbcH7-Ub binding to pUb-R0RBR showed large CSPs in the parkin REP
linker that connects to the RING2, we wondered whether this was due to direct binding of
UbcH7 to the REP linker or due to complete displacement of the REP linker from
RING1. To test this, we collected 1H-15N HSQC NMR spectra of an isolated 12C15N1Hlabelled Drosophila melanogaster RING2 (residues 410-482) construct that includes the
REP linker. Six equivalents of unlabelled UbcH7 were titrated into this RING2
construct, but no interaction was observed, suggesting the possibility that the CSPs seen
in the REP linker are due to displacement from the RING1 rather than from binding to
UbcH7. A similar 1H-15N HSQC experiment was collected titrating six equivalents of
unlabelled Ub into 12C15N1H-labelled RING2. Since Ub ultimately attaches to C431 in
RING2 through a transthiolation reaction, we wondered if there might be an observable
interaction between the two molecules, however no interaction was detectable.
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Figure 4.14 UbcH7-Ub binding alters the RING0/RING2 interface. (A) CSPs were measured for
TROSY 1H-15N HSQC NMR spectra collected of 13C15N2H-labelled R0RBR bound to unlabelled pUb in
the presence of 1 equivalent 12C14N2H-labelled UbcH7-Ub and were modelled onto the surface diagram of
R0RBR (PDB ID code 5N2W). (B) Significant CSPs from panel A that were at the UbcH7-Ub binding
interface. (C) Significant CSPs from panel A that resulted in a change in environment around W403A and
the RING0/RING2 interface potentially result in exposure of C431. Grey bars indicate that the resonance
was undetectable. Horizontal dashed lines indicate the average CSP ± 1 standard deviation. Data was
collected at 25°C in 25 mM HEPES, 50 mM NaCl, 500 µM TCEP, pH 7.0 buffer.
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4.3.16 ARJP variants impair parkin ubiquitination activity
Ubiquitination assays were performed with ARJP and non-ARJP UblR0RBR
variants in order to assess effects on parkin activity (Figure 4.15) and to obtain
ambiguous restraints for HADDOCK pUb-R0RBR:UbcH7-Ub structure calculations
(Table 4.3). Results showed that UblR0RBR T240R, UblR0RBRR271S, UblR0RBRR314A and
UblR0RBRP335G/C337G all showed significant decreases in activity while UblR0RBR W403A
showed increased activity. UblR0RBRN273S and UblR0RBRR402C showed no significant
change in activity. T240R and R271S variants are located at UbcH7 binding site while
R314A and P335G/C337G variants are located at the proposed Ub binding site. Since
these variants resulted in a reduction in parkin activity, it suggests that these residues are
important for making interactions with the UbcH7-Ub conjugate. W403A is a proposed
activating variant that is suggested to increase parkin activity by freeing inhibitory
intramolecular interactions of the REP linker with RING1 (Trempe et al., 2013; Riley et
al., 2013) or by altering the RING0/RING2 interface as shown by CSP data. This variant
indeed showed a marked increase in ubiquitination activity even in the absence of pUb
suggesting that W403A is affecting parkin structure in a manner to become active.
N273S was proposed to be a variant located at the Ub binding site but did it not have an
effect on parkin activity, therefore this residue must not be important for interaction with
Ub. The R402C variant was used to test the conformation of UbcH7-Ub used for binding
to parkin. If UbcH7-Ub was to bind to parkin in a closed conformation, then this residue
would be important for making interactions with Ub. However, this residue variant did
not result in a reduction in parkin activity and rather it increased activity to a small
extent, suggesting that R402 does not interact with Ub and that UbcH7-Ub does not bind
to parkin in a closed conformation.
T240R, R271S, N273S and R402C are all ARJP mutations. Since T240R and
R271S variants are located at the UbcH7 binding interface and resulted in reduced parkin
activity, it is likely that these variants are associated with ARJP due to their ability to
abolish UbcH7 binding to parkin. N273S and R402C variants resulted in no significant
change in parkin activity, suggesting that they work to disrupt the parkin pathway by
some other means.
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Figure 4.15 Ubiquitination activity of ARJP and non-ARJP parkin variants. (A) Assays were
performed in triplicate using E1 Uba1, E2 UbcH7C17S/C137S, E3 UblR0RBR variants, Ub, UbA0C-800 and
Mg2+/ATP in the presence or absence of pUb at 30°C for 30 minutes. Assays were imaged by SDS-PAGE
and a LI-COR Odyssey Classic imaging system at 800 nM. (B) Gel images were processed with ImageJ
and data was analysed using a two-tailed student t-test where * represents P < 0.05. Mean activity and ±
standard error of the mean (s.e.m.) for n=3 replicates are presented. All time zero measurements, 30
minute time measurements and 30 minute time measurements with pUb were compared to their
corresponding wild type parkin control measurements. T240R and R271S are at the proposed UbcH7
binding site, R314A and P335G/C337G are at the proposed Ub binding site and W403A is a proposed
activating mutation that relieves catalytic C431 occlusion.
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4.4 Discussion
4.4.1 A molecular model for E2-ubiquitin engagement with parkin
Extensive research on the RBR E3 ligase parkin has shown that its autoinhibition
is regulated by the Ubl domain (Kumar et al., 2015), a repressor REP linker blocking the
RING1:E2 binding site and by occlusion of the catalytic C431 through RING0/RING2
interactions (Riley et al., 2013; Trempe et al., 2013; Wauer and Komander, 2013).
Previous studies have shown that pUb binding and parkin S65 phosphorylation events
together are sufficient to relieve autoinhibition (Kondapalli et al., 2012; Shiba-Fukushima
et al., 2012; Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014). Similar to
parkin, the RBR E3 ligases HOIP and HHARI are autoinhibited and are activated by
binding to other proteins suggesting a common requirement for distinct modes of
regulation. HOIP autoinhibition is mediated by its ubiquitin-associated (UBA) domain
(Stieglitz et al., 2013; Lechtenberg et al., 2016) and HHARI autoinhibition is regulated
through its Ariadne domain (Dove et al., 2016; Duda et al., 2013). The binding of pUb to
parkin causes release of the autoinhibitory Ubl domain (Kumar et al., 2015) and the
opening of a RING1/IBR pocket for E2-Ub to bind (Figure 4.6) as confirmed in a
Pediculus humanus pUb-R0RBR crystal structure (Wauer et al., 2015). However, pUb
binding does not explain relief of autoinhibition caused by the REP blocking RING1
from E2 binding or occlusion of the catalytic C431 through RING0/RING2 interactions
because both pUb-bound parkin crystal structures still show these inhibitory
characteristics and similar findings are shown by heteronuclear NOE data (Figure 3.16).
NMR experiments performed here indicate that UbcH7-Ub binding to pUb-R0RBR
causes large CSPs in the REP linker around W403 located adjacent to the RING0/RING2
interface (Figure 4.14). Ubiquitination assays performed with UblR0RBR W403A also
indicate an important role in this region for activating parkin activity. This data together
suggests that UbcH7-Ub binding is sufficient to move the autoinhibitory REP linker and
likely cause relief of catalytic C431 occlusion.
RBR E3 ligases and RING E3 ligases have RING domains that are structurally
similar and bind to E2s in a similar fashion (Budhidarmo et al., 2012) using the E3 RING
loop L1, RING1 helix H1 and RING1 Zn2+-loop L2 with the E2 helix H1, loop L4 and
loop L7, much like what was observed for UbcH7 binding to R0RBR (Figure 4.10 and
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Figure 4.11). However, RBR (and HECT) E3s bind to extended conformations of the
E2-Ub conjugate in order to promote Ub transfer to the catalytic E3 cysteine, while
RING E3s bind to closed conformations in order to promote direct Ub transfer to
substrates. RBR RING1 domains differ from canonical RING E3 domains by having an
elongated RING1 Zn2+-loop L2 (Spratt et al., 2014) and the absence of a basic “linchpin”
residue that typically makes contact with the E2-Ub conjugate in a closed conformation
(Pruneda et al., 2012), and these differences are proposed to direct E2-Ub conformational
arrangements upon binding to E3s. The absence of a “linchpin” and the elongation of
RING1 Zn2+-loop L2 are features of parkin that help explain the ability to disfavour
binding to the closed E2-Ub state much like HHARI inhibits closed E2-Ub binding
conformations (Dove et al., 2016; Dove et al., 2017). In agreement with another study,
we found that UbcH7-Ub predominantly occupies closed states in solution (Figure 4.9)
(Dove et al., 2016), however we also showed that UbcH7-Ub undergoes rearrangement to
bind parkin in an open conformation (Figure 4.12). The pUb-R0RBR:UbcH7-Ub
structure (Figure 4.13) shows UbcH7-Ub binding in a very similar open conformation as
shown in the crystal structure of the RBR E3 ligase HOIP:E2-Ub (Figure 4.16) with only
slight differences in E2 angling and a small difference in the position of β1-L1-β2 in Ub
(Lechtenberg et al., 2016). Specifically, both structures show Ub oriented in an open
conformation positioned closer towards the “backside” surface of UbcH7. Two crystal
structures of RBR E3 ligase HHARI bound to UbcH7-Ub show similar placement of
UbcH7, however the orientation of Ub is open with a specific positioning closer towards
the “closed” surface of UbcH7. In these structures, Ub is making contacts to the UBAlike domain in one structure (Yuan et al., 2017) and not making any contacts in the other
(Dove et al., 2017). The full HOIP:E2-Ub structure shows the catalytic site on the
RING2 domain of a neighbouring HOIP molecule extended and poised for transthiolation
with the E2-Ub conjugate, suggesting that the open conformation we see in our
HADDOCK pUb-R0RBR:UbcH7-Ub structure is the correctly primed binding state for
the E2-Ub conjugate.
Together, research here shows that binding of pUb to parkin opens a RING1/IBR
pocket for E2-Ub to bind (Figure 4.6). UbcH7-Ub is closed in solution (Figure 4.9), and
undergoes conformational rearrangement (Figure 4.12) to bind parkin in an open state
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poised for transthiolation (Figure 4.13). UbcH7-Ub binding is sufficient to move the
REP linker and bind to the RING1 (Figure 4.10). Movement of the REP linker alters the
environment around W403A and the RING0/RING2 interface (Figure 4.14), likely to
expose the catalytic C431 for transthiolation. In the proposed model, Ub G76 within the
conjugate remains 50 Å away from the RING2 catalytic site suggesting that parkin will
eventually undergo a conformational change to bring both sites together for
transthiolation to occur.
4.4.2 Parkin mutations and Parkinson’s disease
Based on work to determine the structure of pUb-R0RBR:UbcH7-Ub,
ubiquitination assays showed that several parkin residues had a critical role for binding to
UbcH7-Ub. UblR0RBRT240R and UblR0RBRR271S ARJP variants showed a decrease in
ubiquitination activity which was the result of a loss of ability for parkin to bind to the
conjugate. This finding provides a direct association between the structure and function
of parkin to the diseased-state. Together, research performed here provides an
understanding of parkin regulation and a framework for the design of small molecules to
modulate parkin activity in hereditary forms of Parkinson’s disease.
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Figure 4.16 Conformations of E2-Ub conjugates bound to RBR E3 ligases. The HADDOCK structure of parkin R0RBR (grey surface) is shown binding to
the ribbon diagrams of pUb (orange) as well as to UbcH7 (lime green) conjugated to Ub (cyan). Crystal structure ribbon diagrams of the RING1 and E2-Ub
conjugates for HOIP:UbcH5b-Ub (navy Ub) (PDB ID code 5EDV), HHARI:UbcH7-Ub (magenta Ub) (PDB ID code 5UDH) and HHARI:UbcH7-Ub (purple
Ub) (PDB ID code 5TTE) were superimposed to pUb-R0RBR:UbcH7-Ub using all atoms in RING1 domains and the super comand in PyMOL. Only the RING1
domain of each RBR E3 is shown for clarity. UbcH7 binding and orientation to parkin R0RBR from the HADDOCK structure (lime green) is very similar to
other E2 enzymes (dark green) binding to RBR E3 ligases. The orientation of UbcH7-Ub bound to pUb-activated parkin closely resembles the open
conformation of UbcH5b-Ub bound to HOIP. Both of these structures show Ub stabilized by IBR domain interactions and the E2-Ub conjugate poised for
transthiolation. Not shown, the HOIP structure shows a neighbouring catalytic RING2 domain positioned for conjugate transthiolation suggesting that open
conformation with Ub positioned closer towards he “backside” of the E2 is a primed binding state for the conjugate.
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Chapter 5
SUMMARY AND FUTURE DIRECTIONS
5.1 E2-ubiquitin conformations
Since E2-Ub conjugates are extremely dynamic (Pruneda et al., 2011; Page et al.,
2012) and play important roles in ubiquitination, this thesis sought to determine how the
UbcH7-Ub conjugate behaves in solution, while bound to the shigellosis-associated
kinase OspG and while bound to the Parkinson’s disease-associated E3 ligase parkin.
NMR found that UbcH7-Ub adopts predominantly closed states while free in solution but
that UbcH7-Ub undergoes rearrangement to bind to OspG and parkin in open
conformations as confirmed by the OspG:UbcH7-Ub crystal structure and the docked
pUb-bound parkin:UbcH7-Ub NMR model. Since these results suggest that UbcH7-Ub
must undergo a conformational rearrangement, future work will likely explore what
features govern E2-Ub conformations and whether it is a characteristic of the E2 or E3
that does-so. Work in this area will allow us to predict which conformations different
E3:E2-Ub pairings will adopt while leading to a better understanding of ubiquitination
mechanisms.
5.2 OspG and shigellosis
Common to many bacterial pathogens like the shigellosis-inducing Shigella, the
host ubiquitination pathway is often hijacked by bacterial effector proteins like OspG.
We used NMR and ITC to show that the E2-Ub conjugate is a biological target of OspG.
Since OspG is a kinase lacking a typical kinase activation loop, it has been proposed that
OspG may require binding to a host factor for activation. Indeed, studies have already
shown that both Ub and E2-Ub conjugates can activate OspG autophosphorylation or
phosphorylation of artificial histone substrates (Zhou et al., 2013; Grishin et al., 2014;
Pruneda et al., 2014). With this said, future work on OspG will likely focus on
determining biological substrate phosphorylation targets, and on determining how these
phosphorylation signals help Shigella invasion. Like other Shigella effectors, OspG is
secreted in a precisely-timed manner as a way to control effector activity. Since OspG is
not directly involved in the first stages of translocon pore formation or bacterial invasion,
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it is likely secreted in later stages of host cell manipulation to exert its effect on
dampening host inflammatory responses (Kim et al., 2005; Zhou et al., 2013). As more
and more Shigella effector proteins are studied, it will be interesting to find in which
order OspG is secreted relative to other effectors. Since OspG is now amongst one of the
more well-studied Shigella effector proteins, future work will likely focus on expanding
our knowledge about the function and timing of other effectors. As a final note, we were
able to determine the crystal structure of OspG bound to UbcH7-Ub lending to significant
molecular insights for how therapeutics and competitive drug inhibitors can be designed
to halt OspG activation and the prevalence of shigellosis.

5.3 Parkin and ARJP
Crystal structures determined here of full-length human parkin and full-length
human parkinS65D revealed the autoinhibited state which is regulated through many
interdomain interactions including the presence of the autoinhibitory Ubl domain.
Structural work on other RBR E3 ligases such as HOIP and HHARI have extended the
observation of autoinhibition as a common mode of regulation for RBR E3 ligases
(Stieglitz et al., 2013; Lechtenberg et al., 2016; Dove et al., 2016; Duda et al., 2013). It
will be interesting to see whether the inhibitory features seen in these structures like the
bent RING1 helix H3 become hallmark indicators of autoinhibition in other RBR E3
ligases once more structures are deposited. Research here also showed that
phosphorylation of the Ubl domain at S65 leads to rearrangement of a hinge composed of
basic residues between RING0/RING1 and that this hinge rearrangement optimises pUb
binding to parkin as seen by ITC and the docked pUb-R0RBR NMR model. It will be
interesting to determine how PINK1 accesses the Ubl at S65 in future work. PINK1
requires the Ubl I44 surface for interaction (Rasool et al., 2018), however this same
surface is seen interacting with parkin RING1 in the autoinhibited state.
The crystal structure of full-length human parkin bound to pUb as well as the
NMR model of pUb-R0RBR:UbcH7-Ub determined here both show the activated state of
parkin. The structures show pUb bound to the RING0/RING1 hinge which results in
straightening of RING1 helix H3 and global movement of the IBR domain. Important
competitive binding studies performed by NMR showed the first instance of pUb binding
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to parkin that causes release of the autoinhibitory Ubl domain to create a pocket for E2Ub engagement. Another structure of activated RBR E3 HOIP shows an allosteric Ub
molecule bound to the same position on RING1 as our parkin structures, and this
structure also shows that the allosteric Ub molecule causes straightening of the HOIP
RING1 helix H3 (Lechtenberg et al., 2016). This may suggest a universal role for an
allosteric pUb molecule to activate other RBR E3 ligases and this is likely to be an area
of study in the future. Moreover, in order to predict future pUb-binding partners, work
will likely be done to try to find common structural elements in other proteins such as the
parkin RING0/RING1 hinge basic triad composed of K151, H302 and R305 residues.
Another unresolved question revolves around determining what happens to the pUbl
domain once it is displaced from parkin. Unphosphorylated Ubl has been found to aid
parkin in substrate recognition (Fallon et al., 2006; Trempe et al., 2009) and proteasome
association (Sakata et al., 2003). Future work will likely examine whether pUbl is still
involved in these tethering events, whether it interacts with a different domain on parkin,
or whether it is simply displaced with a loss of interaction capabilities.
NMR work performed here showed the first occurrence of a change in
environment around the catalytic C431 in RING2 driven by E2-Ub binding. Next steps
will be to determine whether E2-Ub binding causes release of the RING2 and to
determine how the RING2 comes into close proximity to the E2-Ub conjugate for
transthiolation to occur. It is well known that HECT E3s have a flexible linker between
the E2-Ub-recruiting domain and the catalytic domain which is able to bring both
domains into close proximity for transthiolation. It will be interesting to determine
whether the RBR E3 stretch of residues that connects to the RING2 uses a similar
mechanism of flexibility.
Finally, ubiquitination assays performed here suggest a link between disease and a
loss of parkin activity due to the inability for E2-Ub to bind to parkin. The continuation
of research on parkin structure and function using parkin ARJP variants will further our
understandings of how disease is caused and how we can develop therapeutics for
managing the progression.
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5.4 Significance of work
Prior to research here, knowledge about UbcH7-Ub conformations in solution,
while bound to the shigellosis-associated kinase OspG and bound to the Parkinson’s
disease-associated E3 ligase parkin was non-existent. The tertiary structures of both
OspG and full-length human parkin were also not known. Parkin was thought to be
constitutively active and no knowledge existed that indicated that Ub could be
phosphorylated by PINK1, let alone that pUb binding could lead to parkin activation.
Furthermore, knowledge for how OspG:E2-Ub and parkin:E2-Ub interactions contribute
to disease was also not known. That being said, our group has made significant
contributions to the discovery of both OspG and parkin structure-function relationships.
Knowledge about OspG functioning, as well as the structure, autoinhibition and
activation of parkin has made extremely large steps in the past few years, and our
research has contributed extensive structural and mechanistic insights into these
understandings. In all, structural and mechanistic insights researched here will have a
significant impact on the understanding of disease and the development of drug
therapeutics in the future.

168

5.5 References
Dove, K.K., Stieglitz, B., Duncan, E.D., Rittinger, K., and Klevit, R.E. (2016). Molecular
insights into RBR E3 ligase ubiquitin transfer mechanisms. EMBO Rep. 17, 1221–1235.
Duda, D.M., Olszewski, J.L., Schuermann, J.P., Kurinov, I., Miller, D.J., Nourse, A.,
Alpi, A.F., and Schulman, B.A. (2013). Structure of HHARI, a RING-IBR-RING
ubiquitin ligase: autoinhibition of an Ariadne-family E3 and insights into ligation
mechanism. Struct. Lond. Engl. 1993 21, 1030–1041.
Fallon, L., Bélanger, C.M.L., Corera, A.T., Kontogiannea, M., Regan-Klapisz, E.,
Moreau, F., Voortman, J., Haber, M., Rouleau, G., Thorarinsdottir, T., et al. (2006). A
regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor
trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 8, 834–842.
Grishin, A.M., Condos, T.E.C., Barber, K.R., Campbell-Valois, F.-X., Parsot, C., Shaw,
G.S., and Cygler, M. (2014). Structural Basis for the Inhibition of Host Protein
Ubiquitination by Shigella Effector Kinase OspG. Structure 22, 878–888.
Lechtenberg, B.C., Rajput, A., Sanishvili, R., Dobaczewska, M.K., Ware, C.F., Mace,
P.D., and Riedl, S.J. (2016). Structure of a HOIP/E2~ubiquitin complex reveals RBR E3
ligase mechanism and regulation. Nature 529, 546–550.
Page, R.C., Pruneda, J.N., Amick, J., Klevit, R.E., and Misra, S. (2012). Structural
insights into the conformation and oligomerization of E2~ubiquitin conjugates.
Biochemistry (Mosc.) 51, 4175–4187.
Pruneda, J.N., Stoll, K.E., Bolton, L.J., Brzovic, P.S., and Klevit, R.E. (2011). Ubiquitin
in Motion: Structural Studies of the Ubiquitin-Conjugating Enzyme∼Ubiquitin
Conjugate. Biochemistry (Mosc.) 50, 1624–1633.
Pruneda, J.N., Smith, F.D., Daurie, A., Swaney, D.L., Villén, J., Scott, J.D., Stadnyk,
A.W., Le Trong, I., Stenkamp, R.E., Klevit, R.E., et al. (2014). E2∼Ub conjugates
regulate the kinase activity of Shigella effector OspG during pathogenesis. EMBO J. 33,
437–449.
Rasool, S., Soya, N., Truong, L., Croteau, N., Lukacs, G.L., and Trempe, J.-F. (2018).
PINK1 autophosphorylation is required for ubiquitin recognition. EMBO Rep.
Sakata, E., Yamaguchi, Y., Kurimoto, E., Kikuchi, J., Yokoyama, S., Yamada, S.,
Kawahara, H., Yokosawa, H., Hattori, N., Mizuno, Y., et al. (2003). Parkin binds the
Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4,
301–306.
Stieglitz, B., Rana, R.R., Koliopoulos, M.G., Morris-Davies, A.C., Schaeffer, V.,
Christodoulou, E., Howell, S., Brown, N.R., Dikic, I., and Rittinger, K. (2013). Structural
basis for ligase-specific conjugation of linear ubiquitin chains by HOIP. Nature 503, 422–
426.

169

Trempe, J.-F., Chen, C.X.-Q., Grenier, K., Camacho, E.M., Kozlov, G., McPherson, P.S.,
Gehring, K., and Fon, E.A. (2009). SH3 domains from a subset of BAR proteins define a
Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol. Cell 36, 1034–
1047.
Zhou, Y., Dong, N., Hu, L., and Shao, F. (2013). The Shigella Type Three Secretion
System Effector OspG Directly and Specifically Binds to Host Ubiquitin for Activation.
PLoS ONE 8, e57558.

170

CURRICULUM VITAE
Tara Condos
Department of Biochemistry
The University of Western Ontario, London, ON, N6A 5C1
University Educational Background
Western University Doctor of Philosophy in Science, Biochemistry
University of Dundee Research Fellowship, Biochemistry
University of Ottawa Honours Major Biochemistry, Minor Business

2012-18
Jun-Aug 2015
2008-12

Selected Scholarships and Awards
NSERC Alexander Graham Bell CGS – Doctoral $70,000
Top-ranked doctoral applicant according to academics, research
potential and leadership

2016-18

Western Doctoral Excellence Award $10,000
Outstanding academic achievement of Western’s best and brightest scholars

2016-18

Ontario Graduate Scholarship $15,000 (declined second offer)
Merit-based according to academics, research and extra-curriculars

2015-17

Western Graduate Research Scholarship $22,500
Student making good progress in research with minimum 78% average

2012-17

Young Investigator’s Award $450
For substantial contributions to the field of biological magnetic
resonance, ICMRBS Kyoto, Japan

Aug 2016

Drs. Madge and Charles Macklin Fellowship for Publication $4,500
Jun 2016
Most significant doctoral first-author publication in a peer-reviewed journal
Boehringer-Ingelheim Travel Grant $4,500
Travel and accommodation for University of Dundee fellowship
Schulich Scholarship for Medical Research $4,000
Ontario Graduate Scholarship holder, based on academic
achievement and research merit

Jun-Aug 2015
2015

CIS Academic All-Canadian
Western varsity athlete with 80% average

2012-13

Women’s Soccer Scholarship $3,250
uOttawa varsity soccer student-athlete with good academic standing

2008-12

171

Research Experience
PhD Research, Western University
2012-18
Supervisor: Dr. Gary Shaw
Project Title: Conformational Arrangements of UbcH7-Ubiquitin with OspG and Parkin
PhD Research Fellowship, University of Dundee
Jun-Aug 2015
Supervisor: Dr. Helen Walden
Project Title: Using X-ray Crystallography to Understand Parkin Function
Undergraduate Summer Research, Western University
May-Aug 2011 and 2012
Supervisor: Dr. Gary Shaw
Project Title: Using NMR to Characterise OspG and E2-Ubiquitin Binding
Teaching Experience
Western Biochemistry Research Mentor for Undergraduate Projects
Western University Biochemistry Lab BCH3380 Teaching Assistant
Western University Molecular Biology BCH4420 Teaching Assistant

2014-2018
2013-2017
2014-2015

Publications
T. E. C. Condos, K. Dunkerley, E. Freeman, K. R. Barber, H. Walden and G. S. Shaw.
‘Structure of phosphoubiquitin-activated parkin bound to E2-ubiquitin reveals the primed
state for catalysis’, publication in preparation (2018).
A. Kumar, V. K. Chaugule, T. E. C. Condos, K. R. Barber, C. Johnson, R. Toth, R.
Sundaramoorthy, A. Knebel, G. Shaw and H. Walden. ‘Structure of human parkin in
complex with phosphoubiquitin reveals a unifying mechanism of RBR E3 ligase
activity’, Nature Structural and Molecular Biology 24 (2017), 475-483.
A. Kumar*, J. D. Aguirre*, T. E. C. Condos*, R. J. Martinez-Torres*, V. K. Chaugule, R.
Toth, R. Sundaramoorthy, P. Mercier, A. Knebel, D. E. Spratt, K. R. Barber, G. S. Shaw,
and H. Walden. ‘Disruption of the autoinhibited state primes the E3 ligase parkin for
activation and catalysis’, EMBO 34:20 (2015), 2506–2521.
*Authors contributed equally and work was featured on the cover of EMBO journal
A. M. Grishin, T. E. C. Condos, K. R. Barber, F. X. Campbell-Valois, C. Parsot, G. S.
Shaw, and M. Cygler, 'Structural Basis for the Inhibition of Host Protein Ubiquitination
by Shigella Effector Kinase OspG', Structure, 22:6 (2014), 878-88.

172

Selected Presentations and Abstracts
SDCI Biology Guest Lecturer
“Research in Biochemistry: Parkin and Parkinson’s Disease”
Oral Presentation
Strathroy District Collegiate Institute, Strathroy, Ontario, Canada

Oct 2017

MOOT NMR
Sep 2017
“Conformational Arrangement of the E2-Ubiquitin Conjugate for Parkin Loading”
Poster Presentation
Western University, London, Ontario, Canada
Collaboration of Practitioners and Researchers Seminar
“Linking Parkin Function to Parkinson’s Disease”
Oral Presentation
Western University, London, Ontario, Canada

Feb 2017

Western Biochemistry Graduate Seminar
Jan 2013-16
"Conformational Arrangements of UbcH7-Ubiquitin with OspG and Parkin"
1 oral presentation, 2 poster presentations
Western University, London, Ontario, Canada
International Conference on Magnetic Resonance in Biological Systems
Aug 2016
“Conformational Arrangement of the E2-Ubiquitin Conjugate for Parkin Loading”
Poster Presentation
Kyoto International Conference Center, Kyoto, Japan
Inspiring Young Women in STEM Conference
“A Day in the Life of a Graduate Student”
Poster Presentation
Western University, London, Ontario, Canada

Mar 2016

MOOT NMR
“Parkin is Activated by Displacement of its Ubiquitin-Like Domain”
Poster Presentation
McMaster University, Hamilton, Ontario, Canada

Oct 2015

London Health Research Day
"Parkin Activation by Phosphorylated-Ubiquitin”
Poster Presentation
London Convention Centre, London, Ontario, Canada

Apr 2015

International Union of Crystallography Congress
"Bacterial Effector Kinases"
Acknowledgment and presentation given by co-author Andrey Grishin
Montreal, Quebec, Canada

Aug 2014

